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Abstract   
The activity of many tastant compounds is poorly understood at a cellular level 
due to limited understanding of the mechanisms of taste. The multiple cellular 
effects and complex pharmacology of tastants make challenging the 
characterisation of their biological activities through conventional approaches. In 
addition, taste research often employs animal models that are difficult to 
manipulate at a molecular level and have associated ethical concerns. The 
potential of employing Dictyostelium discoideum as an animal replacement model 
for the study of poorly characterised natural and synthetic tastants was 
investigated in this thesis. Initially, an assay was developed using D. discoideum 
to monitor the effects of tastants at a cellular level employing the pungent alkaloid 
capsaicin. In this assay, live cell imaging was employed to monitor cell behaviour 
for 15 minutes including pre (5 minutes) and post (10 minutes) addition of 
capsaicin and computer-aided cell tracking was used to monitor behavioural 
changes. This study suggests that capsaicin may modulate D. discoideum 
behaviour through a novel mechanism involving Guanine Nucleotide Exchange 
Factors proteins (Rac-GEF). The method was then applied to the analysis of eight 
known and five blinded bitter compounds with diverse chemical structures. Data 
obtained were compared to the rat in vivo Brief Access Taste Aversion (BATA) 
assay and human taste panels. This analysis showed a positive linear correlation 
between the three models, suggesting that D. discoideum may provide a new 
model for the investigation of bitter tastants. The same approach was also 
employed to investigate changes in D. discoideum cell behaviour after exposure 
to the natural polyphenol curcumin and a range of structurally related derivatives. 
These compounds were also tested on cell growth and development to obtain a 
more in-depth understanding of their chronic cellular effects. Indeed, results have 
demonstrated that curcumin and related compounds have distinct effects on 
acute cell behaviour, growth and development. A mutant screen was then carried 
out to identify potential molecular targets of curcumin and structurally related 
molecules. This screen identified the Protein Phosphatase 2A regulatory subunit 
and the Presenilin B protein which controlled resistance to curcumin and a 
synthetic analogue, respectively. These studies demonstrate that D. discoideum 
may be employed as an animal reduction model to investigate the cellular effects 
of poorly characterised complex tastants and propose novel targets and 
mechanisms of action. 
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Chapter I  
Introduction 
1.1 Research context 
Elements of the physiology and biology of taste will be examined in this 
introduction to provide the basis for considering the use of the simple eukaryotic 
organism Dictyostelium discoideum as a potential model for the replacement and 
reduction of animals for the investigation of tastant compounds.  Prevailing 
models employed in taste research will then be described, before examining D. 
discoideum as an established biomedical model organism. Ultimately, the use of 
D. discoideum as a potential model for the assessment of the cellular effects and 
molecular targets of tastants will be discussed. 
1.2 Taste perception 
Tastants are taste-eliciting molecules that are dissolved in ingested liquids or 
saliva. A tastant represents the correct ligand for receptor proteins or ion 
channels located on the plasma membrane of taste receptor cells. Initially, the 
ingested tastant comes in contact with the oral tissues and, subsequently, 
receptors situated on the taste cells on the tongue are selectively activated by 
the tastant and trigger downstream signalling pathways (Roper, 2013). This 
signalling cascade leads to the release of neurotransmitters by taste cells to 
activate primary sensory afferent nerve fibres, and then the signal is processed 
by the central nervous system (CNS) (Figure 1). There is evidence implicating a 
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number of neurotransmitters involved in taste transduction including adenosine 
triphosphate (ATP), 5-hydroxytryptamine (5-HT), gamma-aminobutyric acid 
(GABA), noradrenaline and acetylcholine (Roper, 2013). However, they do not all 
meet the criteria to be accepted as afferent neurotransmitters (must be present 
in the presynaptic cell, released in response to presynaptic membrane 
depolarisation, able to activate postsynaptic receptors on afferent nerve fibres, 
and is degraded or transported from the extracellular space); ATP is the only 
candidate that meets all the requirements (Kinnamon and Finger, 2013).  
The primary sensory apparatus is represented by the taste buds, which contain 
taste receptor cells (Bradbury, 2004). Each taste bud contains ~100 taste cells 
that possess some neuronal properties. Taste receptors are expressed on the 
apical membrane of microvilli. Anatomically, taste buds are arranged in the form 
of fungiform papillae in the anterior part of the tongue, whereas in the posterior 
part they form a trench-like structure known as foliate papillae. Finally, the dorsal 
area of the tongue contains the circumvallate papillae with a moat-like pattern.  
1.3 Current knowledge of the primary human taste qualities  
The current understanding of human taste (gustation) perception is based on five 
primary tastes, sweet for carbohydrates, a major source of calories (Kochem, 
2017), sour for spoiled and acidic foods (Ugawa, 2003), salty for minerals (Roper, 
2015), umami for proteins and amino acids (Ninomiya, 2016), and bitter for 
potentially harmful compounds which can induce aversive responses (Mennella 
et al., 2013). In addition, the gustatory system also includes pungent (sensed 
through chemesthesis) (Roper, 2014) and astringent (major source are tannins) 
tastes (Jiang et al., 2014; Loper et al., 2015; Schobel et al., 2014). Taste 
perception is thought to play an evolutionary role in nutrition and avoidance of 
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hazardous food chemicals (Breslin, 2013). Indeed, current understanding of how 
taste works is moving towards a more complete and realistic representation of 
the human taste perception, including the identification of a wider range of tastes 
(e.g. pungent, astringent, fat taste and metallicness), which increases the 
complexity of a previously oversimplified system (Chandrashekar et al., 2006).  
1.4 Human taste qualities  
1.4.1 Sweet 
Sweet taste detection enables the discrimination of foods rich in calories. The 
receptors responsible for the detection of sweet substances are the G-Protein-
Coupled Receptors (GPCRs) (Figure 1); in particular, the human taste type 1  
receptors 2 and 3 (hT1R2 + hT1R3 heterodimer) (Assadi-Porter et al., 2010; Li et 
al., 2002), which are situated in the apical membrane of the taste buds. When a 
sweet tasting ligand binds the receptor, this activates a G-protein which in turn 
triggers the activation of phospholipase C (PLC-ß2). PLC generates inositol 
triphosphate (IP3) and diacylglycerol (DAG). This signalling cascade results in 
the activation of the transient receptor potential cation channel subfamily M 
member 5 (TRPM5) leading to cell depolarisation which causes the influx of 
calcium (Ca2+) that triggers the release of the neurotransmitter ATP (Sclafani and 
Ackroff, 2015). Thus, this mechanism provides a basic understanding of sweet 
taste transduction. 
1.4.2 Salty  
The detection of salty compounds is required to control the body salt equilibrium 
(Bradbury, 2004). Salt perception is based on sodium chloride (NaCl) receptors, 
thought to be epithelial-type sodium (Na+) channels (ENaC) present on the apical 
membrane of the taste buds (Kim et al., 2014). Na+ ions enter the receptor cells 
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via Na-channels, which causes membrane depolarisation, generating Ca2+ influx 
through voltage-sensitive Ca2+ channels which leads to neurotransmitter ATP 
release (Figure 1).  
1.4.3 Sour 
The sour taste allows acid detection and is triggered by protons (H+) present in 
acidic foods (Figure 1). Therefore, sour taste is essential to avoid the ingestion of 
acids in excess, as well as to maintain physiological electrolytic and pH levels in 
humans (Melis and Tomassini Barbarossa, 2017). The current view of sour taste 
transduction is that it is generated by intracellular acidification, which stimulates 
acid-sensitive membrane proteins (Roper, 2007). However, the molecular 
mechanisms underlying the transduction of sour taste are not fully characterised. 
1.4.4 Umami 
The taste of umami is triggered by the amino acid L-glutamate, a cleavage 
product of all proteins, conferring the ability to taste protein-rich foods (Lindemann 
et al., 2002). Umami taste was first identified and characterised in 1909, and it 
was initially thought that the metabotropic glutamate receptor 4 (mGluR4) was 
involved in the detection of the umami taste (Chaudhari and Roper, 2010; 
Stanska and Krzeski, 2016). However, recent studies have demonstrated that the 
T1R1 and T1R3 (heterodimer) (Li et al., 2002) receptors mediate umami taste 
(Figure 1). In fact, similarly to the sweet taste signal transduction, the binding of 
L-glutamate to the T1R1 and T1R3 receptor activates G-proteins that lead to the 
increase of the intracellular Ca2+concentration, causing the release of the 
neurotransmitter ATP (Nelson et al., 2002). In addition, there are ionotropic 
receptors in the brain, including the N-methyl-D-aspartate (NMDA) receptors, 
which are activated by neurotransmitter L-glutamate (Vandenbeuch et al., 2010). 
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1.4.5 Bitter 
Bitter taste perception is essential for the detection of harmful compounds and 
enables humans to avoid ingesting potentially deadly toxins (Greene et al., 2011; 
Margolskee, 2002). The currently accepted model of bitter taste perception and 
signal transduction of bitter tastants is through a specific sub-group of GPCRs, 
Taste-Sensing Type 2 Receptors (TAS2Rs), which are expressed in the apical 
membrane of the receptor cells present in a taste bud (Mennella et al., 2013) 
(Figure 1). Signalling of bitter compounds is achieved via the α-subunit of 
gustducin (Gulbransen et al., 2008). This G protein subunit triggers a 
phosphodiesterase which hydrolyses cAMP, and this reduction leads to the 
increase of intracellular Ca2+. In addition, the βγ-subunit of gustducin mediates 
taste signal by activating phospholipase C which generates inositol triphosphate 
(IP3) and diacylglycerol (DAG). As a result, these messengers activate and open 
gated ion channels or may generate the release of calcium ions from intracellular 
stores.  This signalling cascade triggers the release of the neurotransmitter ATP, 
which generates the taste perception in the brain (Margolskee, 2002).  
Interestingly, the number of bitter tastants that can be recognised by mammals is 
greater than the number of taste-sensing type 2 receptors (~ 25 TAS2Rs) (An 
and Liggett, 2017; Meyerhof et al., 2010; Meyerhof et al., 2005), suggesting the 
presence of multiple molecular pathways involved in the transduction of the bitter 
taste stimulus. Indeed, there are many bitter molecules which also have a wide 
range of molecular structures. For example, the Bitter DB database holds around 
700 bitter tastants, with widely diverse chemical structures and biochemical 
characteristics (Wiener et al., 2012). These compounds include fatty acids, 
peptides, amino acids, amines, amides, carbamides, esters, lactones, phenols, 
terpenoids, alkaloids, glycosides, flavonoids, steroids and metal ions (Meyerhof 
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et al., 2010). Therefore, it is still a complicated task to predict the bitterness of 
novel chemical entities.  
 
Figure 1. Accepted mechanisms by which the primary taste qualities are transduced 
(adapted from(Chaudhari and Roper, 2010; Mennella et al., 2013). In taste receptor cells, sweet 
(T1R2 + T1R3), umami (T1R1 + T1R3) and bitter (TAS2R) ligands bind to GPCRs to activate a 
phosphoinositide pathway that elevates cytoplasmic Ca2+ and depolarises the membrane via a 
cation channel, TRPM5. The combined action of elevated Ca2+ and membrane depolarisation 
leads to the release of the neurotransmitter ATP. Organic acids (HAc) pass through the plasma 
membrane where they dissociate causing an increase in cytoplasm acidity. It is hypothesised that 
intracellular H+ is able to block a proton-sensitive K+ channel causing the depolarisation of the 
membrane. Calcium channels increase cytoplasmic Ca2+ which trigger the neurotransmitter ATP 
release. The salty taste of Na+ is detected by direct diffusion of Na+ ions through membrane ion 
channels, (e.g. ENaC), which depolarise the membrane, leading to neurotransmitter ATP release. 
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Pungent taste is transduced via TRPV1, which responds to pungent tastants such as capsaicin. 
Astringent taste transduction is not fully understood. 
 
It is increasingly accepted that there are other molecular pathways involved in the 
transduction of bitter taste. One example is represented by the generation of 
gustducin knockout mice, which does not fully inhibit the sensitivity to bitter 
compounds, suggesting a redundant mechanism for bitter signal transduction 
(Wong et al., 1996). The one hypothesised mechanism for gustducin-
independent bitter tasting is through ion channel (K+) interaction with particular 
bitter ligands (denatonium), which is similar to the ion channel interaction for the 
recognition of sour and salty stimuli (Gulbransen et al., 2008; Spielman, 1998). 
Hence, the molecular mechanisms underlying bitter taste transduction are not 
fully characterised. 
1.4.6 Pungent 
Hot/pungent taste provides another taste type, independent of the five core 
tastes. This is detected and transduced via the Transient Receptor Potential 
Cation Channel Subfamily V Member 1 (TRPV1), which responds to chemical 
stimuli such as capsaicin and several irritants (chemesthesis) (Kawakami et al., 
2015) (Figure 1). It has not been yet elucidated whether TRPV1 is present in the 
taste buds and directly transduces taste. However, it is known that it is expressed 
in non-gustatory sensory afferent fibres and keratinocytes of the oronasal cavity. 
In many sensory fibres and epithelial cells lining of these cavities, Transient 
Receptor Potential Ankyrin 1 (TRPA1) is also co-expressed with TRPV1 and 
transduces a wide variety of stimuli triggered by noxious chemicals in 
combination with TRPV1. TRP channels also include TRPM8, TRPV3, and 
TRPV4, which have less significant roles in chemesthesis and unknown functions 
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in taste (Roper, 2014). Although capsaicin is able to elicit a response in sensitive 
neurons containing TRPV1 receptors, a recent study has shown that this 
molecule is also able to induce a feedback in non-sensitive neurons at high 
concentration (Yang et al., 2014). Hence, other mechanisms are involved in the 
sensation of pungent compounds.  
Interestingly, a study has also shown that the bitter taste of quinine sulphate and 
the burning sensations of capsaicin can be perceived similarly or even confused 
(Lim and Green, 2007). Hence, there may be a link between pungent and bitter 
taste signal transduction, which has been suggested to derive from a common 
function as sensory signals of potentially harmful substances.  
1.4.7 Astringent 
Astringent is an additional taste quality, which is described as a dry or rough 
sensation (Figure 1). This perception is caused by some chemicals (e.g., tannins 
or calcium oxalate), which produce a contraction of the mucous membrane of the 
mouth. Foods that produce an astringent taste include tea, red wine, rhubarb, 
some unripe fruits like persimmons and bananas. A recent study has shown that 
black tea infusion contains flavanol-3-glycosides besides some catechins, which 
contribute to the taste of black tea. The results form sensory studies 
demonstrated that the flavanol-3-glycosides confer the astringent taste sensation 
and also increase the bitter taste of tea infusions by amplifying the bitterness of 
caffeine (Scharbert and Hofmann, 2005). However, it is still unclear whether 
astringent taste is transduced by mechanoreceptors, chemoreceptors, or a 
combination of both. Moreover, the receptor(s) that recognise astringents and 
downstream signalling have not been identified (Jiang et al., 2014). 
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1.4.8 Transient potential receptor and taste transduction 
Transient receptor potential channels (TRPs), situated downstream from the 
taste receptors (i.e., TAS2R, T1R1, T1R2 and T1R3), are expressed in taste 
buds, nerve fibres and keratinocytes in the oronasal cavity (Roper, 2014), and 
play a pivotal role in taste transduction. In particular, the TRPM5 is essential for 
transduction of bitter, sweet and umami tastes. TRPM5 operates downstream of 
taste receptors in the taste transduction pathway, converting taste-elicited 
intracellular Ca2+ release into membrane depolarisation to generate taste 
transmitter secretion (Mennella et al., 2013; Roper, 2014). Furthermore, TRPM5 
channel activity is strongly regulated by voltage, phosphoinositides and 
temperature, and is blocked by acidic pH (Liman, 2007).  
1.5 Drug development process 
The development of a new medicine from the initial concept to the finalised 
product and commercialisation is a time-consuming and expensive process, 
which currently takes up to 15 years and cost over £1 billion (DiMasi et al., 2016). 
The first step in developing a novel drug is to identify and validate its target(s), 
which include proteins, genes and RNA involved in the etiopathogenesis of the 
condition. The second step focuses on the assessment of efficacy and safety of 
candidate drug compounds. While much of this can be achieved using in vitro 
techniques, the use of animal models is considered a heritage of the early 
pharmacological approaches and it is still considered the gold standard for drug 
development in preclinical studies (Hughes et al., 2011; McGonigle and Ruggeri, 
2014). One example is the use of transgenic animals where a genetic 
manipulation to ablate a gene responsible for a disease can lead to embryonic 
lethality and therefore is challenging to accomplish (Hughes et al., 2011). Recent 
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studies have shown that the implementation of a multi-system approach, which 
includes different disciplines such as bioinformatics,  proteomics, RNAi, genetic 
manipulation, modelling, mass spectrometry, and live cell microscopy can lead to 
an increase in target identification and validation (Hughes et al., 2011). Another 
crucial factor to account for when developing new drug formulations is the 
assessment of its palatability. Mice and rats are used for the investigation of the 
bitterness (acceptability/aversiveness) of medicines. Even though in vivo animal 
models are the closest to humans concerning the taste apparatus, they differ in 
the ability to detect and react to the administration of bitter compounds. Humans 
share some similarities in taste preferences with mice and rats in relation to 
acceptance and avoidance responses to a tastant compound and oromotor 
reflexes to a chemical stimulus (Spector 2002). However, there are still 
exceptions in the response to different bitter compounds such as 
phenylthiocarbamide (PTC) and phenyl-β-D-glucopyranoside which are known to 
be bitter to humans, but mice do not respond to them (Mueller et al., 2005). 
Moreover, these types of study involve ethical issues related to animal suffering 
(Holmes et al., 2009). 
1.5.1 Medicines from plants 
Another critical aspect of drug screening is the fact that many drugs commercially 
available have natural origins, hence can elicit an aversive taste response. 
Indeed, around 60% of the pharmaceutically active molecules introduced in the 
past 35 years are derived from plant sources, therefore playing a central role in 
the treatment of many conditions (Newman and Cragg, 2007). In addition, 
medicinal plants have been used for thousands of years to treat many ailments. 
For instance, cardiac glycosides to treat heart failure (Radford et al., 1986), 
taxanes (Jimenez et al., 2011) and vinca alkaloids (Moudi et al., 2013) to treat 
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cancer, and hyoscine to treat motion sickness (Spinks and Wasiak, 2011). Plants 
have co-evolved with animals and pests, producing chemicals to repel predators 
or against disease and infection. Many drugs are not taste-friendly, possibly due 
to our evolutionary ability to recognise and avoid toxins present in food. However, 
this does not always occur as many unpleasant tasting molecules are not toxic 
(Mennella et al., 2013). Furthermore, a recent study reported that there is a strong 
correlation between the taste of medicines and their curative properties (Gilca 
and Barbulescu, 2015).  
1.5.2 The importance of understanding the taste of drugs 
Taste is one of the critical factors in the development of orally administered drugs 
regarding patient compliance and acceptability, thus influencing the commercial 
success of a new drug, particularly in the paediatric sector (Anand et al., 2007). 
In fact, many pharmaceutically active ingredients have an unpleasant taste, 
causing aversive reactions in children and many adults, resulting in some cases 
in severe reactions such as nausea and vomiting (Holmes et al., 2009). For 
example, the unpleasant taste of oral antibiotics is considered the primary 
hindrance to patient compliance. However, antibiotics are the first line of 
treatment for a wide range of paediatric conditions (Baguley et al., 2012).  It is 
currently estimated that the absence of more taste-friendly medicines puts 40% 
of children at risk of preventable adverse effects (i.e. suboptimal dosing) 
worldwide (Mennella et al., 2013). Therefore, the assessment and prediction of 
the taste of medicines is an essential requirement in the drug development 
process. Hence, it is crucial to understand the biology of taste and its molecular 
mechanisms. 
Oral administration is the primary route of drug delivery, as it is the most 
convenient and economical solution, as well as being the safest in terms of 
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infection risks and side effects. Despite the benefits, the oral route is very 
challenging and unpredictable, due to the unpleasant taste of many drugs and 
the requirement for digestive-tract absorption. Higher bioavailability and 
absorption of certain drugs can be achieved through the sublingual route of 
administration. Nevertheless, the taste characteristics of the drugs is still an 
obstacle to sublingual delivery as they can still trigger the taste responses. For 
these reasons, researchers have put significant effort in the development of taste-
masked formulations such as tablet coating, the addition of sweeteners or making 
the formulation insoluble by changing its pH. An additional masking approach is 
the mixing of the formulation with food and beverages, mainly when medicines 
are used to treat children or elderly patients (Gittings et al., 2014).   
1.6 Taste research 
1.6.1 Human taste panels 
The use of a human taste panel for the assessment of the taste characteristics of 
pharmaceutical  formulations represents the most widely accepted method 
(Anand et al., 2007). For these types of study, a panel of healthy volunteers is 
recruited and trained to evaluate the taste of active pharmaceutical ingredients 
(APIs) using the appropriate ranking on which a specific quality of the tastant is 
determined. However, human taste panels have several disadvantages, 
especially when assessing New Chemical Entities (NCEs). Moreover, this type of 
investigations can only be carried out when there is sufficient toxicological data, 
which is extremely rare to have in the initial stages of the drug development 
process (Cram et al., 2009). In addition, taste panels are expensive and time-
consuming, due to the training of adult volunteers required and the overall cost 
for running and setting up a panel. The wide variability of taste perception 
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between individuals is another limitation of taste research studies. Thus, the use 
of human panels is problematic due to ethical reasons, liability issues and toxicity 
risks. In addition, this type of test is based on subjective preferences in adults; 
hence, it is questionable whether the data obtained can be used to predict 
preferences in the paediatric population (Gittings et al., 2014).  
1.6.2 Brief Access Taste Aversion - BATA 
The second most accepted method for the assessment of active pharmaceutical 
ingredients is the in vivo rat Brief Access Taste Aversion assay (BATA).  In the 
BATA assay, mice or rats undergo a period of 16 to 24 hours in which they are 
deprived of water to induce them to drink when exposed to the substances to 
assess. The animals are then placed into a lickometer which records the number 
of licks taken, and this is repeated for all the concentrations tested. Animals are 
exposed to the solutions for limited time periods (5-10 seconds), and 
solutions/concentrations are usually presented in a random order. The less 
aversive the substance, the higher the number of licks. Whereas, when licks are 
almost completely abolished this suggests that the substance is aversive. 
However, this methodology allows only the evaluation of the palatability of drugs 
but not their taste quality (Soto et al., 2015).   
1.6.3 Electrophysiological methods (in vivo) 
In addition to human panels and BATA assays, research also employs 
electrophysiological methods to study taste stimuli. In these experiments, animals 
such as mice, bullfrogs or gerbils are anaesthetised, then electrodes are 
implanted in the chorda tympani nerve bundle and the glossopharyngeal nerve, 
before administering the tastants on the tongue (Anand et al., 2007). 
Electrophysiological recordings allow the assessment of the temporal profiles or 
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dose-response curves of taste stimuli. Although these procedures can determine 
the physiological mechanisms of taste stimuli, the underlying molecular 
mechanisms of taste remain diverse and not fully characterised.  
1.6.4 Electrochemical methods (in silico)  
Electrochemical taste-sensing systems, like the electronic tongue, are able to 
detect a range of substances with varying intensities by mimicking the interaction 
between the taste ligand and the receptor cell (Latha and Lakshmi, 2012). This 
interaction generates changes in current, which are detected by the computer 
and compared with physiological action potentials. Solubility represents the major 
limitation of this model as test drugs must be completely solubilised.  
The assessment of the effects of tastants and investigation of the pathways 
involved in taste transduction is of primary importance. Therefore, implementing 
less complicated models like D. discoideum could be highly advantageous in 
improving the prediction of tastants, as well as reducing the number of animals 
used in this research and the cost of taste research. Indeed, the investigation of 
acute responses to chemicals and genetic manipulations are less challenging in 
this simple eukaryotic organism, thus, providing vital information regarding the 
effects of tastants and unknown mechanisms underlying taste transduction. The 
second section of the introduction will describe D. discoideum as a valuable 
biomedical model and examine its potential use in taste research. 
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1.7 Dictyostelium discoideum as a biomedical model organism 
D. discoideum is a single- and multicellular eukaryotic organism, which belongs 
to the Protozoa Kingdom, and is present in the soil of the forest floor and moist 
leaf litter, and feeds on naturally occurring microflora (i.e. bacteria) (Williams et 
al., 2006). In the vegetative stage, single cells move towards bacteria attracted 
by their folic acid secretion and consume them through phagocytosis (Pan et al., 
2016; Segota et al., 2013). In favourable conditions of a humid and warm 
environment (22 ºC), cells can double in number approximately every 8 h. Upon 
nutrient exhaustion, cells start a developmental program leading to the formation 
of fruiting bodies and the production of spores that are able to survive in hostile 
conditions (Fey et al., 2007). Starving cells produce a chemo-attractant, cyclic 
adenosine monophosphate (cAMP), serving as a signal for around 1 x 105 
neighbouring cells to aggregate, which then develop into a mature fruiting body 
over a 24-hour period, where 20% of the cells form a stalk that supports a spore 
head incorporating 80% of the remaining cells as spores. When conditions 
become favourable, and cells come in contact with nutrients, the spores 
germinate into amoebae, completing the life cycle (Figure 2).  
D. discodeum has been extensively utilised to investigate a range of fundamental 
biological processes such as cell migration, chemotaxis, signal transduction, 
phagocytosis and signalling during morphogenesis and cell differentiation (Insall 
and Andrew, 2007; King and Insall, 2009; Nichols et al., 2015; Stephens et al., 
2008). The fully sequenced genome contains 34 Mb of DNA packed in 6 
chromosomes (84-fold smaller than the human genome) (Eichinger et al., 2005). 
Genome sequencing has led to the identification of 22% D. discoideum genes 
that encode for proteins that are homologues of those present in humans (~60%), 
making this organism a valuable model for the investigation of drug targets and 
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molecular pathways involved in human disease (Eichinger et al., 2005; Williams 
et al., 2006). Therefore, it is possible to characterise the primary role of these 
proteins to understand their related disease function in this simple organism 
(Annesley and Fisher, 2009; Eichinger et al., 2005). D. discoideum brings several 
advantages in comparison to mammalian cell cultures and animal models such 
as the ease of genetic manipulation, behavioural and developmental 
investigations and laboratory maintenance (Annesley et al., 2014; Eichinger et 
al., 2005; Escalante and Vicente, 2000; King and Insall, 2009; Manstein et al., 
1989; Montagnes et al., 2012). New developments have seen the rise of 
techniques capable of generating libraries of mutants that can be used to screen 
for compounds to identify their molecular targets. Therefore, this model can be 
employed as an innovative platform for molecular pharmacology research, to 
accelerate the compound validation prior to animal studies (Williams, 2005).  
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Figure 2. D. discoideum life cycle. D. discoideum develops from a single vegetative amoeba 
(0hrs) through to the generation of the mature fruiting body (24hrs). Aggregation is caused by the 
chemotaxis of cells toward cAMP waves to give rise to a multicellular aggregate. Aggregation 
results in the creation of a mound, then a tipped mound and, as development proceeds, the tip 
elongate and forms a finger. Ultimately, the finger collapses to form a slug or continues to form a 
fruiting body. During the final stage of development, the cells differentiate into vacuolated stalk 
cells that sustain a spore head containing spores which can tolerate a broader range of 
environmental conditions. The full developmental process from starvation of vegetative cells to 
the formation of a mature fruiting body is accomplished over a 24-hour period (Fey et al., 2007).  
 
Recent studies using D. discoideum as a simple model system for bitter taste 
research have shown the utility of using this approach for the reduction of animals 
in testing bitter and emetic compounds (Robery et al., 2011). Furthermore, using 
D. discoideum, researchers were able to study the effects and identify the 
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molecular targets of bitter tastants (e.g. quinine, denatonium, phenylthiourea) and 
this led to the discovery of a novel human receptor implicated in the detection of 
the bitter substance phenylthiourea (Robery et al., 2013). These studies 
demonstrated the potential utility for D. discoideum in the identification of novel 
pharmaceutical compounds with a bitter taste liability. In addition, research 
studies employing D. discoideum  lead to the identification of the molecular 
targets of flavonoids (Waheed et al., 2014), epilepsy therapy including the 
medium-chain triglyceride (MCT) diet (Chang et al., 2012; Eickholt et al., 2005; 
Xu et al., 2007), bipolar disorder treatments (Williams, 2005; Williams et al., 2006; 
Williams et al., 2002), and investigation of the molecular mechanism of 
Alzheimer’s disease (Ludtmann et al., 2014; McMains et al., 2010). In all these 
cases, discoveries in D. discoideum have been successfully translated to humans 
or other mammals (Chang et al., 2013; Chang et al., 2014; Xu et al., 2007).  
Furthermore, D. discoideum does not possess genes encoding homologues to 
TAS2R proteins associated with bitter compounds detection. However, the 
molecular mechanism responsible for the detection of the bitter alkaloid 
phenylthiourea (PTU) has been identified. A library screen was used to identify 
PTU resistant mutants, leading to the identification of GrlJ-, a putative G-protein 
coupled receptor mutant (Robery et al., 2013) (Figure 3). Translation of this 
discovery to human context identified an uncharacterised human gamma-
aminobutyric acid (GABA) type B-receptor isoform, with a relatively weak 
homology to GrlJ. The expression of the human GABA-B receptor restored GrlJ- 
sensitivity to PTU, implicating this human protein as a novel receptor for PTU. In 
addition, GrlJ only partially controls PTU detection but not detection for all bitter 
substances (Robery et al., 2013). 
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Figure 3.  PTU pathway regulation in D. discoideum. Under experimental conditions during 
cell movement, cAMP triggers the cAR receptor, causing the activation of Ras through the 
dissociation of G-protein. This signalling cascade also increases the PI3K activity and therefore 
the production of PIP3, leading to cell movement. PTU can block this pathway through GrlJ 
partially affecting cell behaviour (additional pathways involved) (Robery et al., 2013).  
 
1.7.1 Underlying mechanisms of D. discoideum cell movement 
The cyclic AMP receptor (cAR) is a seven-transmembrane receptor which is 
activated when cells start secreting cAMP due to starvation and initiate 
chemotactic movement towards an aggregation centre (Chung and Firtel, 2002). 
In addition, cARs are uniformly expressed on the cell membrane and modulate 
differentiation and developmental processes (McMains et al., 2008; Verkerke-
Van Wijk et al., 1998). Random movement is a mechanism that initiates when 
cells are in either vegetative or starving states, which leads to profound changes 
in gene transcription (Goury-Sistla et al., 2012). Cells start secreting cAMP and 
responding to it, leading to the generation of random oscillating movement, 
achieved by the directional formation of membrane protrusions, which in turn 
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increases the probability to detect cAMP (Bosgraaf and Van Haastert, 2009; Li et 
al., 2008).   
When cAMP binds to its G-Protein Coupled Receptor cAR1 (Insall et al., 1994), 
this generates the dissociation of the Gα2 and Gβγ sub-units and activate 
downstream signalling (Figure 4).  D. discoideum possesses 14 Gα- subunits, but 
only one Gβ- and one Gγ- subunit, and all play a central role in cell polarisation 
(Chung and Firtel, 2002; Prabhu and Eichinger, 2006). When Gβγ dissociate, 
Ras-guanosine triphosphates (GTPases), like RasC and RasG, are activated 
through the binding with guanosine triphosphate (GTP), which is mediated by 
Ras-guanine exchange factors (GEFs). Subsequently, GTPases become 
inactivated when binding to guanosine diphosphate (GDP) mediated by Ras-
guanine activating proteins (GAPs) which converts GTP to GDP (Jin et al., 2008; 
Kae et al., 2007).  This complex machinery is involved in the movement of 
chemotactically competent cells, which leads to the migration of cells towards a 
cAMP gradient (Chung and Firtel, 2002; Jin et al., 2008; King and Insall, 2009). 
D. discoideum also contains an actin cytoskeleton that allows cells to generate 
movement. The cytoskeleton consists of a network of F-actin filaments, which 
allow pseudopod extension at the leading edge of the cell and retraction of 
uropods at the rear (Bagorda et al., 2006). During random cell movement, the 
polymerisation of F-actin filaments is arbitrary as cells are not driven by external 
stimuli; whereas, in the presence of a chemotactic gradient, cell movement is 
driven by external signals towards the chemoattractant (Choi et al., 2013). For 
instance, chemotactic gradients activate Ras which is a monomeric G protein that 
functions as a molecular switch that activates downstream effectors such as 
PI3K, at the leading edge of the cell membrane (Cheng and Othmer, 2016; 
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Kortholt et al., 2011). These ultimately lead to the polymerisation of F-actin 
filaments.  
The activation of Rho-GTPases (or Rac), which are regulated by RacGAPs and 
RacGEFs, is part of the cellular mechanisms that lead to F-actin polymerisation. 
Moreover, Rac activation is a main determinant of Arp2/3 complex activation, 
which modulated actin polymerisation during pseudopods formation (Pollard and 
Borisy, 2003; Veltman et al., 2012). Arp2/3, together with SCAR (suppressor of 
cAR complex)/WAVE complex are key factors in pseudopod formation.  However, 
D. discoideum cells in which SCAR is ablated, Rac activation is not greatly 
modified, and migration and chemotaxis can still occur through the Arp2/3 
complex.  Furthermore, when the SCAR complex is not present, Wiskott-Aldrich 
syndrome protein (WASP) is recruited in areas in which Rac is active and can 
regulate pseudopod formation (Veltman et al., 2012). RasC and RasG are also 
involved in the cellular chemotactic signalling amplification pathway, which 
includes the phosphatidylinositol-3-kinase (PI3K) pathway (Bolourani et al., 2006; 
Hoeller and Kay, 2007). When cells detect cAMP, this leads to Ras stimulation, 
which activates PI3Ks, generating the conversion of phosphatidylinositol 4,5-
bisphosphate (PIP2) to phosphatidylinositol 3,4,5-triphosphate (PIP3), resulting 
in PIP3 waves followed by F-actin polymerization (Asano et al., 2008; Huang et 
al., 2003; Ueda et al., 2003). PIP3 also binds to myosin I, as well as PhdA 
(pleckstrin homology domain containing proteins), CRAC (cytosolic regulator of 
adenylyl cyclase) and PkB/Akt (protein kinase B), where each protein has a 
specific role in modulating cell chemotaxis (Chen et al., 2012; Funamoto et al., 
2001; Lilly and Devreotes, 1994; Meili et al., 1999). PIP3 production is modulated 
by phosphatase and tensin homologue (PTEN), which dephosphorylates PIP3 
into PIP2 at the uropod, and controls cell polarity spatially and temporally, 
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allowing the formation of PIP3 waves at the leading edge, which sustains the 
amplification and directionality of the chemotactic movement (Iijima and 
Devreotes, 2002; Iijima et al., 2002). In turn, PTEN is modulated by 
phospholipase C, activated by the dissociation of G-proteins, which catalyses the 
conversion of PIP2/DAG and inositol triphosphate (IP3) at the leading edge, 
promoting the translocation of PTEN to the rear end of the cell (Kae et al., 2007). 
Ras, PIK3 and PTEN are activated independently of GPCRs decoupling in case 
of random cell movement (Sasaki et al., 2007), where Ras and PIK3 play a vital 
role in the signalling loop. When PIP3 gradients are removed by the ablation of 
PI3K and PTEN genes, cell motility during random cell movement is partially 
disrupted (Bosgraaf and Van Haastert, 2009; Hoeller and Kay, 2007). 
Furthermore, the target of rapamycin complex 2 (TORC2) is another crucial factor 
in the regulation of D. discoideum chemotaxis, and its activation is modulated by 
RasC, which controls PIP3 and PKB/Akt regulation (Kamimura et al., 2008; King 
and Insall, 2008). In the presence of cAMP gradients, F-actin assembles a 
complex of scaffolding proteins such as Sca1, RasGEF and PP2A and is enriched 
at the leading edge of chemotaxing cells where it modulates F-actin dynamics 
and signal transduction by controlling the activation of RasC and the downstream 
TORC2-Akt/protein kinase B (PKB) pathway (Charest et al., 2010). In addition, 
glycogen synthase kinase-3 (GSK3), a conserved human protein homologue, is 
also involved in regulation of these pathways. In fact, the ablation of the GSK3-A 
gene leads to the disruption of both chemotaxis and cAMP signalling mediated 
by both PIP3 and TORC2, which inhibits PKB/Akt and PKBR1phosphorylation 
(Teo et al., 2010).  
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Figure 4. Schematic representation of D. discoideum chemotactic movement. Upon cAMP 
detection by cAR, G-proteins dissociate, which in turn leads to the activation of Ras. Ras activates 
PI3K, which in turn converts PIP2 to PIP3. PI3K activity results in PIP3 binding to myosin I, 
involved in F-actin recruitment. PhdA is implicated in maintenance of cell polarity and F-actin 
recruitment. PKB/Akt and CRAC signalling transduction pathways are involved in adenylyl 
cyclase A (ACA) activation, which controls cell polarity. In addition, PIP3 is dephosphorylated to 
PIP2 by PTEN, and PIP2 is subsequently split into diacylglycerol (DAG) and inositol triphosphate 
(IP3). This signalling cascade ultimately leads to calcium release through the inositol triphosphate 
receptor (IP3R3). Ras activation is also controlled by the scaffold protein complex consisting of 
Sca1, RasGEF and protein phosphatase 2A (PP2A), which is formed upon F-actin recruitment. 
In addition, activation of Ras leads to the initiation of the TORC2 complex, which in turn triggers 
PKB/Akt and PKBR1 activity.  
  
Finally, D. discoideum possesses many signalling pathways controlling 
chemotaxis and random cell movement, where the inhibition of individual 
pathways does not entirely block chemotaxis. However, chemotactic behaviour 
can be severely hindered when multiple pathways are disrupted. These pathways 
are crucial for the study of cell movement as they are comparable to those 
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present in leukocytes (Veltman et al., 2008) and essential for the investigation of 
the fundamental molecular pathways involved in disease mechanisms and 
chemosensory responses (Carnell and Insall, 2011). Thus, D. discoideum 
represents an excellent model organism to study the behavioural changes and 
molecular pathways controlling cell movement.  
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Chapter II 
Materials and methods 
2.1 Cell culture 
D. discoideum stocks were stored in freezing medium (7% dimethylsulfoxide -
DMSO, horse serum) at -80oC. Every four weeks, frozen stocks were scraped 
onto selective media (SM) agar plates, on which 300μL Raoultella planticola were 
previously spread. Colonies were allowed to form at 22oC over 3-4 days, where 
cells from the growth zone of colonies were then transferred to liquid plates 
containing axenic medium and 100μg/mL penicillin/streptomycin. Liquid plates 
were washed three times per week and maintained in log phase (1-4x106 
cells/mL) in shaking flasks (120rpm). Cell concentrations were determined using 
a Neubauer improved haemocytometer.  
2.2 D. discoideum random cell movement assay 
D. discoideum cells were maintained in axenic medium (Formedium Co. Ltd, 
Norfolk, UK) for at least 48 hours prior to harvesting in mid-log phase growth (2-
5 x 106 cells/mL). Cells (1 x 107) were washed with phosphate buffer (16.5 mM 
KH2PO4, 3.8 mM K2HPO4, pH 6.2), resuspended in 6 mL phosphate buffer and 
pulsed for 5 hours with 30 nM cAMP at 6 minutes intervals at 120 rpm. Cells were 
then resuspended in 4 mL phosphate buffer and diluted 1:9, and 250 μL aliquots 
of cells were transferred into Nunc Lab-Tek chamber (Thermo Fisher, 
Leicestershire, UK), and allowed to adhere for 10-15 min (Figure 5). In each 
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experiment, 250 μL of drug stock solution (to produce the desired final 
concentration) was added at the 225th second of the image recording to assess 
the effects of the compounds on cell movement. To investigate the suitability of 
D. discoideum as a non-animal model for the investigation of bitter substances, 
a standardised assay was developed (Otto et al., 2015). Cell behaviour was 
monitored in cells undergoing random movement by taking images every 15 
seconds over a 15-min period, with 3.75 minutes recorded prior to, and 11.25 
minutes after compound addition. A minimum of three independent experiments 
for each drug concentration were carried out with at least 10 cells quantified per 
experiment. From these series of images, parameter protrusion formation was 
quantified using an image analysis software Fiji (Schindelin et al., 2012), and its 
plugin QuimP 11b (Warwick University, Warwick, England). Prior statistical 
analysis data were analysed and formatted using MATLAB (Mathworks, 
Cambridge, England).  
2.3 Statistical analysis of random cell movement  
Data obtained from membrane protrusions of cells during random movement 
were extracted from videos into GraphPad Prism spreadsheet as time versus the 
number of protrusions formed. Data were normalised by defining 100 as the 
highest value and 0 as the lowest value in each data set and the data expressed 
as a fraction. The mean and standard error was calculated for each set of results 
at all concentrations. To assess whether there was a significant difference in 
protrusion formation, an unpaired, two-tailed t-tests (95% confidence interval) 
was employed, comparing the mean of the last 8 minutes (from minute 4.5 to 
minute 12.5 - after drug addition) against the control conditions for all 
concentrations tested. To determine the IC50 (the concentration required to 
achieve a 50% reduction in cell movement) for each molecule, the mean of the 
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last 8 minutes of pseudopod formation and the standard error were selected and 
plotted against their Log (concentration), and IC50 values with 95% confidence 
intervals were obtained by non-linear regression Log (inhibitor) vs normalized 
response variable slope equation. 
 
Figure 5. Representation of the random cell movement workflow. Cells are harvested from 
confluent plates and shaken for 2-3 days prior the experiment. Cells are then counted, diluted to 
the desired number and pulsed for 5 hours with cAMP in shaking suspension. Subsequently, cells 
are washed twice with KK2 and loaded into the chambers. Cell movement is recorded every 15 
seconds over a 15 minutes period. Videos are then analysed using Fiji image software. Cells are 
outlined using the Fiji plugin Quimp 11b, which can determine cell displacement, motility, 
circularity and pseudopod formation. Data are elaborated using MATLAB and subsequently used 
to generate graphs and statistical analysis using GrapPad Prism. 
2.4 D. discoideum growth assay 
D. discoideum cells were harvested and diluted in axenic medium to 2x104 
cells/ml. Aliquots of cells (500 μL) were transferred to 24 wells plates containing 
consistent concentrations of solvent (DMSO) in addition to investigated 
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compounds. Cells were grown in 24 well plates at 22oC and cell density calculated 
over a seven-day period. 
2.5 Growth inhibition assay.  
Cells were grown in shaking suspensions and harvested in exponential phase 
(1.5-2.5 x 106 cells/ml). Cells were divided into aliquots and shaken for 24 hours 
in the presence of solvent only or compound at a concentration which blocked 
growth by ~50% in a final volume of 2 ml axenic medium. Each condition tested 
was carried out at least in triplicate. 
2.6 Development assays 
1x107 D. discoideum cells were harvested from cells in shaking suspension, 
washed and resuspended in 1mL KK2 (16.2mM KH2PO4, 4mM K2HPO4 – 
pH=6.3). Cells were then evenly distributed onto 1% agar plates containing either 
solvent (DMSO) only to define the control conditions or a compound plus vehicle 
at a specific concentration. Cells were then incubated at 22oC for twenty-four 
hours. 
2.7 Ferric reducing ability of plasma (FRAP) assay.  
The reducing ability of the compounds was assessed by using the ferric reducing 
ability of plasma (FRAP) assay. FRAP solution was prepared by combining 2 ml 
of TPTZ solution (10 mM 2,4,6-tripyridyl-s-triazine in 40 mM HCl), 2 ml of FeCl3 
(10 mM) and 20 mL acetate buffer (300 mM, pH 3.6). The assay was carried out 
by combining 800 μL FRAP solution with 25 μL of positive control (1mM ascorbic 
acid) or curcumin-related compounds (to obtain a final concentration of 31.2 μM), 
and the absorbance measured at 595 nm. Measurements were obtained in 
triplicate.  
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2.8 Protein-ligand docking.  
Protein sequences were obtained from dictybase.org and the tertiary structures 
of the D. discoideum proteins were predicted using Phyre2 (Protein 
Homology/analogy Recognition Engine V 2.0). Docking analysis was performed 
using SwissDock to identify the possible binding sites in psrA and UFCS Chimera 
was used to display the results obtained from SwissDock. Results are expressed 
as ∆G (Gibbs free energy - where a negative value indicates a spontaneous 
interaction). Results obtained with the molecular docking analysis is based on the 
prediction of the most accurate computer modelling, taking as template other 
proteins with a similar tertiary structure. In addition, the prediction of the binding 
site is also based on the calculation of the most favourable interaction between 
the compound and the protein.     
2.9 REMI screen.  
Two libraries of insertional mutants containing 5,000 mutants (psrA) and 11,000 
mutants (psenB) were used to identify D. discoideum mutants resistant to 
curcumin and its analogues. Cells were incubated with different concentrations 
of each compound over fourteen days. The disrupted genes of the mutants 
growing in the presence of each compound were identified using DNA purification 
and Inverse Polymerase Chain Reaction (iPCR).  
2.9.1 Recapitulated mutants 
psrA- (DDB_G0280469) was kindly provided by Dr Lou Kim (Department of 
Biological Sciences, Florida International University), whereas psenB- 
(DDB_G0292310) was readily available from our lab. 
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2.9.2 5k mutant library 
Balint Stewart kindly provided this library (Department of Genetics, 
Evolution and Environment, University College London). The insertional vector 
used was pBSR1. Primers to identify the disrupted genes are T7-iPCR 
(CCCTATAGTGAGTCGTAT TA) and T7-iPCR reverse 
(CTGCACTACCAATCGCAATGG). 
2.9.3 11k mutant library 
Amy Baldwin kindly provided this library (Neuroscience and Mental Health 
Research Institute, Cardiff University). The insertional vector used was pREMI. 
Primers to identify the disrupted genes are AJBiPCR009-reverse (TGTATGCTA 
TACGAAGTTATCC) and AJBiPCR010-forward (GTAGAAGTAGCGACAGAGA 
AG) or AJBiPCR011-reverse (CCATTCGAAACTGCACTACC) and 
AJBiPCR013-forward (TGAATGGTGAAGATAAATATATGC). 
2.10 Extraction of DNA from potential isogenic mutant cells  
Cells were grown in liquid medium on a 10cm dish until confluent, washed from 
the plate and spun down (1000xg) for 3 minutes, and washed twice with KK2. 
DNeasy Blood & Tissue Kit was used to extract the DNA. 
2.11 Polymerase Chain Reaction (PCR) 
Amplification of DNA using polymerase chain reaction (PCR) was achieved under 
the following conditions for standard reactions: 2-5μL DNA, 2μL 2mM dNTPs, 
2μL NH4 BIOTAQ reaction buffer, 1μL MgCl2, 0.2-0.5μL BIOTAQ DNA 
polymerase (5U μL-1), 2μL 5’ primer (10pmol), 2μL 3’ primer (10pmol) and double 
distilled water up to 20μL (total volume). The PCR was carried out using the 
following cyclical conditions for standard PCR reactions: initial denature, 10 
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minutes at 95oC followed by 30 cycles as follows: denature 30 seconds, 95oC, 
anneal 30 seconds, 50-60oC (dependent on primer melting points), extension 4 
minutes, 68oC (or 1-minute 72oC depending on the primer). The PCR was 
completed with a final extension of 10 minutes at 68oC and samples were then 
stored at 4oC.  
2.12 Restriction digest of genomic DNA 
All restriction digests were prepared according to the following conditions: 5μL 
DNA, 0.2-0.5μL each restriction enzyme (100μL-1), 1μL appropriate buffer 
(according to the manufacturer’s instructions). Samples were incubated at 37oC 
for 20 minutes to 2 hours, depending on the type of restriction enzyme and 
FastDigest enzymes were used in shorter incubations.  
2.13 Agarose gel electrophoresis 
To separate and visualise DNA, 1% agarose gels containing ethidium bromide 
and 1x TBE buffer were used. 5-10μL DNA was added to 1-2μL 5xDNA loading 
dye (10 mM Tris-HCl (pH 7.6) 0.03% bromophenol blue, 0.03% xylene cyanol FF, 
60% glycerol 60 mM EDTA). 100bp plus or 1kb DNA ladders (Thermo Fisher 
Scientific) were used as a molecular marker to determine DNA fragment size on 
the agarose gels. Gels were run in an electrophoresis tank for 30 minutes at 110V 
and visualised with UV light using a GeneFlash gel documentation system 
(Syngene Bio Imaging).  
2.14 Compounds 
The following chemicals were obtained from Sigma Aldrich Co. Ltd (Dorset, UK): 
Capsaicin (8-Methyl-N-vanillyl-trans-6-nonenamide; M2028), Azelastine 
hydrochloride (4-((4-chlorophenyl)methyl)-2-(1-methylazepan-4-yl)phthalazin-1-
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one hydrochloride; A7611), Chlorhexidine digluconate (1,1′-Hexamethylenebis(5-
(p-chlorophenyl) biguanide; C9394), Caffeine anhydrous (1,3,7-
Trimethylxanthine; W222402), Quinine hydrochloride dihydrate (Q1125), 
Acetaminophen (Paracetamol, 4′-Hydroxyacetanilide; A7085), Ibuprofen sodium 
salt (α-Methyl-4-(isobutyl) phenyl acetic acid; I1892), Potassium Nitrate (KNO3; 
P8394), Adenosine 3′,5′-cyclic monophosphate (3′,5′-Cyclic AMP; A9501 - 
200mM stock solution), Glucose (D-(+)-Glucose; G8270), Sucrose (D(+)-
Saccharose; S1888) and Glutamate (L-Glutamic acid monosodium salt 
monohydrate; 49621). Curcumin (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-
heptadiene-3,5-dione; C1386), Demethoxycurcumin (E,E)-1-(4-Hydroxy-3-
methoxyphenyl)-7-(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; D7696), 
Bisdemethoxycurcumin (1E,6E)-1,7-bis(4-hydroxyphenyl)hepta-1,6-diene-3,5-
dione; B6938), EF-24 (3E,5E)-3,5-bis[(2-fluorophenyl)methylene]-4-piperidinone; 
E8409), FLLL31 (E,E)-1,7-Bis(3,4-dimethoxyphenyl)-4,4-dimethyl-1,6-
heptadiene-3,5-dione; F9057), Tetrahydrocurcumin (1,7-Bis(4-hydroxy-3-
methoxyphenyl)-3,5-heptanedione; 50202) were also obtained from Sigma 
Aldrich Co. Ltd (Dorset, UK). Curcumin Pyrazole ((E)-3,5-bis[β-(4-hydroxy-3-
methoxyphenyl)-ethenyl]-1H-pyrazole-SL-318) was obtained from Syninnova, 
and Enaminestore supplied UBS109 (3,5-Bis(2-pyridinylmethylidene)-1-methyl-
4-piperidone-Z46034963). Compounds labelled ‘GSK’ were provided by the 
industrial collaborator GlaxoSmithKline and, due to intellectual property 
protection, full names and structures have been withheld. All compounds were 
dissolved in DMSO. 
2.15 Reagents  
2-Propanol, bacteriological agar, sodium dodecyl sulphate (SDS), Luria-broth 
(LB) tablets, magnesium chloride, Nonidet-P40 (NP40). Agarose, 
Marco Cocorocchio 
 
45 
 
deoxynucleotide triphosphates (dNTPs) (Bioline, London, UK); Ethidium bromide 
(Bio-Rad Laboratories, Hemel Hampstead, UK); axenic (Ax) medium, SM 
medium, LoFlo medium (ForMedium, Hunstanton, UK); ethanol, dipotassium 
hydrogen phosphate (K2HPO4), chloroform, isopropyl β-D-1-
thiogalactopyranoside (IPTG), methanol, paraformaldehyde (PFA), potassium 
dihydrogen phosphate (KH2PO4), sodium hydroxide (VWR International Ltd., 
Lutterworth, UK). 
2.16 Antibiotics 
Ampicillin (Sigma Aldrich Co. Ltd, Dorset, UK); Blasticidin, penicillin/streptomycin 
(Pen/Strep) solution x100 (PAA Laboratories Ltd. Yeovil); Hygromycin, Geneticin 
(G418) (Invitrogen, part of ThermoFisher Scientific, Loughborough, UK). 
2.17 Molecular weight standards 
GeneRuler 100 bp and 1 kb DNA Ladder (0.1 μg/μL); (ThermoFisher Scientific, 
Loughborough, UK). 
2.18 Restriction enzyme 
The RSAI restriction enzyme was obtained from ThermoFisher Scientific 
(Loughborough, UK). 
2.19 Other enzymes 
RNase A, DNase (Sigma Aldrich Co. Ltd, Dorset, UK); BIOTaq polymerase 
(Bioline, London, UK). 
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2.20 Kits 
MiniElute PCR purification kit (Qiagen Ltd, Crawley, West Sussex, UK); TOPO® 
TA Cloning kit (ThermoFisher Scientific, Loughborough, UK); DNeasy Blood & 
Tissue Kit (Qiagen Ltd, Crawley, West Sussex, UK). 
2.21 Bacterial strains 
TOP10 chemically-competent E.coli, chemically-competent JM107 E.coli 
(Invitrogen, part of ThermoFisher Scientific, Loughborough, UK); 10β-competent 
cells (New England Biolabs (UK) Ltd., Hitchin, UK); Raoultella planticola (lab-
made stock).  
2.22 Primers 
Custom-made oligonucleotides were purchased from MWG-Biotech AG 
(Eurofins) (Germany) or Sigma Aldrich Co. Ltd (Dorset, UK).  
2.23 Equipment 
505Di peristaltic pump (Watson Marlow); centrifuge (Biofuge 13, Jencons); 
microcentrifuge (ThermoFisher Scientific, Loughborough, UK); Olympus IX71 
microscope (U-RFP-T laser, 482nm emission, QImaging RetegaExi Fast1394 
digital camera (Olympus, Southend-on-sea, UK); Neubauer improved 
haemocytometer; Centrifuge (Biofuge 13, Jencons) 47mm black nitrocellulose 
filters (Millipore, Oxfordshire, England); LabTek 8-well chambered coverglass 
(ThermoFisher Scientific, Loughborough, UK). 
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2.24 Software 
Microscopy and quantification of chemotaxis assays were analysed using 
ImagePro Plus (Media Cybernetics). Random cell movement and global 
stimulation microscopy experiments were quantified in Fiji software, using the 
QuimP 11b plugin (Warwick University, Warwick, UK) and MATLAB software 
(Mathworks, Cambridge, UK). The graphical and statistical analysis was 
performed using GraphPad Prism 5 (GraphPad Software Inc). Protein-ligand 
docking was visualised using UCSF ChimeraX. 
2.25 Websites 
Dictyostelium gene and protein information:  
http://dictybase.org/ 
http://www.uniprot.org/ 
2.26 BLAST  
http://www.ncbi.nlm.nih.gov/BLAST/ 
http://dictybase.org/tools/blast 
2.27 Protein prediction and docking 
Phyre2: http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index 
SwissDock: http://www.swissdock.ch/docking 
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Chapter III 
Rationale of the investigation and strategy employed 
This study focuses on three significant milestones: 
1. The use of D. discoideum as a model to investigate how taste perception 
works at the molecular level and to assess the effects of tastants; 
2. Investigate this model to predict the aversiveness of active ingredients 
present in medicines and the correlation with results obtained in 
mammalian models; 
3. Employ D. discoideum to assess the active components of tastant 
chemicals responsible for their biological activities and to identify their 
molecular targets. 
The first stage was the assessment of the effects of capsaicin on cellular 
movement, which helped in the development of the compound screening 
methodology. In the second part of the project, the aforementioned methodology 
was employed to assess a wide range of bitter-tasting compounds, which 
included a set of known bitter therapeutic agents and a group of blinded 
compounds. Analysis of compounds with known bitter taste in humans and 
activity in the rat BATA assay enabled the comparison of the results obtained in 
D. discoideum with these models (Cocorocchio et al., 2015). The third stage was 
carried out to better understand the fundamental structural characteristics of a 
range of structurally related compounds to the bitter polyphenol curcumin on cell 
movement, growth and development.  
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3.1 Development of a model for the assessment of tastants  
The first step in developing D. discoideum as a model for the investigation of 
tastants involved the assessment of behavioural changes in the amoeba as a 
readout to characterise the effects of the pungent molecule capsaicin. In our 
study, capsaicin was able to inhibit D. discoideum cell behaviour, even though 
the amoeba does not have a TRPV1 receptor homologue, suggesting that it may 
function through a TRPV1-independent mechanism (Otto et al., 2016). The acute 
response to capsaicin of previously identified mutants that showed growth 
resistance to capsaicin has also been characterised. These mutants contain 
disrupted RacGEF proteins (gxcP- and gxcKK), which are Guanine exchange 
factor for Rac GTPases. Studies have shown that in D. discoideum actin 
organisation, chemotaxis and endocytosis are processes all regulated by Rho 
GTPases, which are comparable to those mechanisms presents in higher 
organisms (Rivero and Xiong, 2016; Vlahou and Rivero, 2006).  These proteins 
activate monomeric GTPases provoking the release of guanosine 
diphosphate (GDP) to allow the binding of guanosine triphosphate (GTP) (Bos et 
al., 2007). GTPases act as molecular switches in cell signalling pathways and 
have several downstream targets, which are involved in several cellular 
processes such as cell differentiation and proliferation, cytoskeletal organisation, 
vesicle trafficking and nuclear transport. It has been shown that D. discoideum 
possesses many of these processes that are important for its chemotaxis, 
migration, organisation of the cytoskeleton and the pseudopod formation. Thus, 
D. discoideum may provide a valuable model for the characterisation of novel 
mechanisms of action modulated by capsaicin.  
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3.1.1 Capsaicin 
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) (Fig. 6) is an alkaloid 
present in plants that belong to the Capsicum genus and is the active ingredient 
in chilli peppers. Capsaicin and its analogues are natural molecules called 
capsaicinoids, which give the characteristic pungent flavour to chillies (Sharma 
et al., 2013).These chemicals are produced as a natural defence by the plant 
against predators and parasites. Capsaicin is a highly volatile, pungent, 
hydrophobic, colourless and odourless, white, crystalline powder in its pure form. 
The effects of capsaicin on the human body are a burning sensation, increase in 
blood flow, the rise in salivation and gastric secretion as well as increased 
intestinal contractile activity (Sharma et al., 2013). Research studies have shown 
that capsaicin possesses anti-cancer (Garufi et al., 2016; Park et al., 2014; 
Ramachandran and Srivastava, 2017), cardioprotective (Fragasso et al., 2004; 
Sharma et al., 2013), pain relief and anti-obesity properties (Anand and Bley, 
2011; Mason et al., 2004; Narang et al., 2017).  
Figure 6.  Structure of capsaicin. 
 
The transient receptor potential vanilloid subfamily member 1 (TRPV1) cation 
channel, present in nociceptive neurons in the oral cavity, is responsible for the 
taste transduction of capsaicin in mammals, and is also present in skin, eyes, and 
gastrointestinal mucosa and in non-neuronal cells including muscle, 
keratinocytes, and endothelium (Sharma et al., 2013). The initial painful 
sensation after capsaicin ingestion arises from the selective activation of TRPV1, 
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mainly expressed in sensory neurons (Yang et al., 2014). However, a recent 
study has demonstrated that a low concentration (sub-micromolar) of capsaicin 
blocked capsaicin-sensitive (CS) neurons, while a high concentration of capsaicin 
(> 10 µM) blocked transient current (IA) in both CS and capsaicin-insensitive (CIS) 
neurons (Yang et al., 2014). Therefore, this suggests the existence of two 
mechanisms through which capsaicin may function; a TRPV1-dependent and a 
TRPV1-independent mechanism.  
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3.1.2 Employing Dictyostelium as an Advantageous 3Rs Model for 
Pharmacogenetic Research  
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 Chapter 9 
 Employing  Dictyostelium as an Advantageous 3Rs 
Model for Pharmacogenetic Research 
 Grant  P.  Otto ,  Marco  Cocorocchio ,  Laura  Munoz ,  Richard  A.  Tyson , 
 Till  Bretschneider , and  Robin  S. B.  Williams 
 Abstract 
 Increasing concern regarding the use of animals in research has triggered a growing need for non-animal 
research models in a range of fi elds. The development of 3Rs (replacement, refi nement, and reduction) 
approaches in research, to reduce the reliance on the use of animal tissue and whole-animal experiments, 
has recently included the use of  Dictyostelium . In addition to not feeling pain and thus being relatively free 
of ethical constraints,  Dictyostelium provides a range of distinct methodological advantages for researchers 
that has led to a number of breakthroughs. These methodologies include using cell behavior (cell move-
ment and shape) as a rapid indicator of sensitivity to poorly characterized medicines, natural products, and 
other chemicals to help understand the molecular mechanism of action of compounds. Here, we outline a 
general approach to employing  Dictyostelium as a 3Rs research model, using cell behavior as a readout to 
better understand how compounds, such as the active ingredient in chilli peppers, capsaicin, function at a 
cellular level. This chapter helps scientists unfamiliar with  Dictyostelium to rapidly employ it as an advanta-
geous model system for research, to reduce the use of animals in research, and to make paradigm shift 
advances in our understanding of biological chemistry. 
 Key words  Dictyostelium ,  Mechanism of action ,  Pharmacogenetics ,  Random cell movement 
1  Introduction 
 Dictyostelium  discoideum is a soil amoeba that consumes bacteria, 
but when starved it initiates  multicellular development , a morpho-
genetic process that involves  chemotaxis , intercellular signaling, 
and cell type  differentiation ; these are also the attributes of its life 
cycle that are most studied. However,  Dictyostelium has becoming 
increasingly useful as a simple model organism to dissect the 
molecular  mechanism of action of poorly characterized chemicals 
with therapeutic benefi ts, including new drugs and natural products. 
It is easy and cheap to grow and maintain, its small 34 Mb  genome 
has been sequenced, and it is simple to manipulate genetically to 
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either ablate or overexpress a gene of interest, all attributes that 
make it ideal as a pharmacogenetic model [ 1 ]. 
 Drug discovery and development is a costly, lengthy process of 
identifying chemicals that are not only specifi c and effective, but 
are also well tolerated by patients. Many drugs have nausea as a 
side effect, which can lead to vomiting (emesis), and this adversely 
impacts patient compliance. Thus, investigating the emetic liability 
of new drugs is important, but it is expensive and has animal wel-
fare implications because it typically involves vomiting or food 
avoidance experiments in sentient animals like dogs and ferrets. We 
have used  Dictyostelium to study the emetic liability of compounds 
previously reported to be emetic or aversive in in vivo animal stud-
ies [ 2 ], and identifi ed a  G-protein -coupled receptor and its likely 
mammalian counterpart as the  molecular target of the bitter com-
pound phenylthiourea [ 3 ]. We have also used  Dictyostelium to 
study the molecular mechanism of the action of the dietary fl avo-
noid naringenin, a component of citrus fruits that has antiprolifera-
tive and chemopreventive actions  in vitro and in animal models of 
carcinogenesis. Our studies in  Dictyostelium identifi ed a Ca 2+ -
permeable nonselective cation channel, TRPP2 or polycystin- 2, as 
the target of naringenin [ 4 ]. This channel is implicated in the 
development of autosomal dominant polycystic kidney disease 
(ADPKD) [ 5 ,  6 ], and accounts for about 15 % of the mutations in 
ADPKD sufferers. The channel is the target of naringenin in mam-
malian kidney cells too, and represents a potential novel treatment 
for the 85 % of ADPKD patients where TRPP2 is present and can 
be activated by naringenin. 
 These studies used a simple, rapid assay based on random cell 
movement of chemotactically-competent amoebae as a phenotypic 
readout, but growth and development have also been used to dis-
sect the cellular uptake mechanism for the bipolar disorder drug 
valproic acid [ 7 ]. Here we describe the random cell movement 
assay in  Dictyostelium  cells treated with the pungent alkaloid  capsa-
icin , which is responsible for the spicy taste of chilli peppers of the 
 Capsicum genus, and is of biomedical interest because of its poten-
tial therapeutic effects for the treatment of a variety of human con-
ditions, including pain relief, weight  reduction , anti-carcinogenic 
properties, and cardiovascular, gastric, urological, and dermato-
logical conditions (reviewed in [ 8 ]). The gustatory effects of cap-
saicin in mammals are through its action as an agonist of a cation 
channel, transient receptor potential vanilloid subfamily member 1 
(TRPV1), which is present in nociceptive neurons in the oral cav-
ity, skin, eyes, and gastrointestinal mucosa, but is also present in 
non-neuronal cells including muscle, keratinocytes, and endothe-
lium (reviewed in [ 9 ]). Prolonged exposure to capsaicin causes 
TRPV1 receptor desensitization [ 10 ]; yet extended effects on cel-
lular signaling suggest that capsaicin can act independently of 
TRPV1. Evidence of these effects includes its cocarcinogenic effect 
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in TRPV1 knockout mice [ 10 ], that it alters sucrose preference in 
TRPV1 knockout mice [ 11 ], and that capsaicin inhibition of colla-
gen-induced  aggregation of platelets is unaffected by a TRPV1 
antagonist [ 12 ]. Additionally, capsaicin has a signifi cant acute 
effect on  Dictyostelium cell behavior, including loss of velocity, cell 
shape, and angular movement [ 2 ], even though clear homologues 
of human, mouse, or worm TRPV1 proteins have not been identi-
fi ed in the  Dictyostelium  genome . This result suggests that capsa-
icin is exerting these behavioral effects in  Dictyostelium by a 
TRPV1-independent mechanism, making this organism a useful 
model to identify the molecular identity of this alternate pathway. 
2  Materials 
 A small-volume peristaltic pump (e.g., Watson Marlow 505Di, 
Cornwall, UK) is required to deliver  cAMP to the cells to make 
them  chemotaxis -competent. 
  1.  Dictyostelium  cells ( see  Note 1 ) are grown axenically in  HL5 
medium (Formedium) in sterilized glass conical fl asks with 
aeration on a temperature-controlled platform shaker (21 °C, 
120 rpm). Medium is supplemented with streptomycin and 
penicillin (100× stock of 5000 U/ml, Gibco) and either blas-
ticidin S (10 μg/ml; Apollo Scientifi c) or G418 (10 μg/ml; 
Invitrogen). 
  2.  KK2 buffer: 20 mM Potassium phosphate buffer, pH 6.1. 
  3.  cAMP : A 200 mM stock solution is prepared in water; adjust 
to pH 6.3 with NaOH. Store in aliquots at −20 °C. 
  1.  A 50 mM stock solution of  capsaicin is prepared in the solvent 
dimethyl sulfoxide (DMSO). Store in aliquots at −20 °C. 
  1.  Lab-tek 8-well chambered coverglasses (Thermo Scientifi c 
Nunc). 
  2.  Olympus IX71 inverted microscope with 40× objective. 
  3.  QImaging RetigaExi Fast 1394 digital camera. 
 The following four software programs are used to capture images, 
outline individual cells, quantify cell behavior parameters, and per-
form statistical analysis.
  1.  Images are captured using ImagePro software (Media 
Cybernetics, Buckinghamshire, UK). 
  2.  The QuimP11 plug-ins for the Fiji distribution of ImageJ are 
used to outline individual cells and to quantify cell behavior 
parameters (available for download at  http://go.warwick.ac.
uk/quimp ). 
2.1  Equipment
2.2  Cell Culturing 
and Preparation
2.3  Preparation 
of  Capsaicin 
2.4  Microscopy
2.5  Time-Lapse 
Video Analysis
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  3.  Two custom scripts in MATLAB (MathWorks, USA) are used 
to fi rst read the output generated by Fiji cell segmentation 
and then combine the individual cell values for each parame-
ter (displacement,  motility , circularity, and protrusion forma-
tion) (described in [ 13 ]). The fi nal MATLAB output is an 
Excel fi le containing all the information of cell segmentation 
for each video analyzed (individual values, mean and standard 
deviation). 
  4.  Graphpad Prism v5.02 (GraphPad Software Inc, San Diego, 
USA) is used to perform statistical analysis (data normaliza-
tion, one-way ANOVA with Bonferroni posttest) and to plot 
the data for the generation of graphs. 
3  Methods 
  1.  Dictyostelium  strains are grown for at least 2 days on a shaking 
platform at 22 °C. 
  2.  Cells are harvested during exponential growth (between 1 and 
5 × 10 6 cells/ml) by centrifugation at 500 ×  g for 3 min, and 
washed twice with KK2 buffer. 
  3.  Cells (2 × 10 7 ) are resuspended in 6 ml KK2 buffer in a 50 ml 
conical fl ask, and pulsed with 20 nM  cAMP every 6 min for 5 
h at 22 °C (giving a fi nal cAMP concentration of 1 μM). 
  4.  These cells are chemotactically-competent, and can be used to 
monitor acute changes in cell behavior. 
  1.  Starved, chemotactically-competent cells are diluted tenfold 
with KK2, and 250 μl of this dilution is added to individual 
wells of 8-well Lab-tek chambers. Allow 15 min for the cells to 
adhere before imaging. 
  2.  Cell behavior is visualized using a 40× objective on an inverted 
bright-fi eld microscope, and images are captured every 15 s 
with an attached CCD camera. 
  3.  As an internal control for each experiment, images are cap-
tured every 15 s for 5 min before the addition of the com-
pound to be analyzed (a 2× stock is prepared in 250 μl KK2 
and added gently to the well), or vehicle alone for control 
experiments ( see  Note 2 ). 
  4.  The camera shutter is closed for compound/vehicle addition, 
to provide one black image to indicate compound addition in 
the resultant movie. 
  5.  Images are then captured for a further 10 min every 15 s to 
record cell behavior. 
3.1  Preparation of 
Cells and Compounds
3.2  Imaging Cell 
Behavior
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  1.  Cell outlines are established by hand on the fi rst image of each 
series, and cells tracked through the series using Fiji. Two 
custom scripts in MATLAB are used to fi rst read the output 
generated by Fiji and then combine the individual cell values 
for each of the four cell behavior parameters: cell shape (cir-
cularity),  motility , protrusion number, and displacement. 
  2.  The MATLAB output is transferred to Graphpad Prism for 
statistical analysis and graph production. The data for each 
compound concentration may be normalized to the highest 
value which is defi ned as 100 %. Data can be presented as an 
average cell response (in velocity, displacement, cell shape, or 
protrusion formation) during the time period assessed (e.g., 
15 min) ( see Fig.  1a, b ), with a dose-dependent effect on all 
cell behavior parameters. Alternatively, a change in cell behav-
ior can be visualized by plotting cell response over a period 
after addition of compound (Fig.  1c, d ). In regard to  capsaicin , 
cells treated with 2–3 μM changed shape and produced fewer 
protrusions, with the result that both displacement and  motil-
ity were reduced.
3.3  Analysis 
of Random Cell 
Movement
 Fig. 1  The effect of  capsaicin on random cell movement parameters in parental  Dictyostelium  cells . Adherent 
Ax2 cells in Lab-Tek chambers were imaged every 15 s for 5 min before the addition of capsaicin (2.0 μM, 2.5 
μM, or 3.0 μM), followed by a further 10-min imaging in the presence of the compound. The effect of capsaicin 
on four parameters of cell behavior was analyzed. There was a dose-dependent effect on the degree of round-
ing up or circularity of the cells ( a ), the number of protrusions formed ( b ), displacement ( c ), and  motility ( d ). 
Note that displacement and motility are the averages for the fi nal 288 s of imaging, and statistical analysis was 
between control and each capsaicin concentration. * p < 0.05, ** p < 0.01, *** p < 0.001. Measurements were 
derived from an average of 30 cells analyzed from triplicate experiments. Error bars represent ±S.E.M. 
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  3.  A two-tailed paired student t-test is performed to compare 
between the 5 min preceding addition of compound and the 
fi nal 5 min of image capture for all four parameters. 
  4.  A one-way analysis of variance (ANOVA) with subsequent 
Bonferroni test is conducted to determine whether there is any 
statistical difference in cell behavior between different concen-
trations of compound or between wild-type and mutant cells at 
the same compound concentration. 
  5.  Several factors should be taken into consideration regarding 
the selection of concentrations of a given compound to be ana-
lyzed ( see  Note 3 ). 
  1.  To identify the molecular basis of the action of a chemical, a 
library of  mutants is screened for resistance to the effects of the 
compound on growth, development, or cell behavior, as 
described elsewhere [ 3 ,  4 ,  7 ] ( see  Note 4 ). 
  2.  Mutants identifi ed in one type of screen (e.g., growth) can 
then be analyzed for resistance to a compound in other assays 
(e.g., development or behavior), thus providing additional 
information on the molecular pathway affected by each com-
pound. Alternatively, a range of published  mutants are widely 
available if a candidate approach is taken ( see  Note 1 ). 
  3.  A recent library screen to characterize the molecular mecha-
nism of the  bitter tastant phenylthiourea [ 3 ] identifi ed two 
 RacGEF mutants that were partially resistant to the action of 
 capsaicin on cell behavior:  gxcP  −  (dictybase ID: DDB_
G0285859) and  gxcKK  −  (dictybase ID: DDB_G0293340) 
( see Fig.  2 ).
4  Notes 
  1.  Strains: Many  Dictyostelium  strains are available from the 
searchable  Dictyostelium strain database run by Dictybase 
( www.dictybase.org ;  see ref. [ 14 ]) and can be obtained for a 
nominal fee and the cost of shipping. 
  2.  Vehicle for drugs/compounds: Commonly used vehicles 
include DMSO, DMF, ethanol, methanol, and acetic acid. We 
have conducted experiments to determine the highest concen-
trations that can be used that do not signifi cantly disrupt cell 
behavior in the random cell movement assay (e.g., up to 1 % 
DMSO, 3 % EtOH). 
  3.  The choice of concentrations to be analyzed is based on those 
used in published studies on whole animals or tissue culture 
cells, and two- to fi vefold lower and higher concentrations can 
also be tested. If there is no published data for a chemical, then 
3.4  Identifying 
the Molecular Identity 
of Chemical Detection 
Pathways
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a concentration range for related compounds is used, as long 
as it is within the solubility range of the chemical and does not 
have acute effects on cell viability (e.g., cell lysis). This can be 
simply tested by visual inspection under a microscope. 
  4.  Where possible, it is advantageous to use appropriate controls 
during these experiments. For example, when screening a 
library of  mutants for resistance to a compound, the wild-type 
parental strain containing the antibiotic resistance cassette but 
without gene ablation should be used. When studying indi-
vidual mutants, at a minimum the immediate parental strain 
should be employed because variability in compound sensitiv-
ity is found between laboratory wild-type strains. 
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 Fig. 2  Behavior of  Dictyostelium  gxcP  −  and  gxcKK  −  cells in random cell movement assays. Both  gxcP  −  and 
 gxcKK  −  display partial resistance to 2 and 2.5 μM  capsaicin , both in the number of protrusions formed ( a ,  b , 
respectively) and the circularity of cells ( c ,  d , respectively). Measurements were derived from 50 cells analyzed 
from a minimum of triplicate experiments. Error bars represent ±S.E.M. 
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Figure 1. N=30 cells analysed per condition from 3 independent technical repeats. 
Figure 2. N=50 cells analysed per condition from ≥ 3 independent technical repeats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marco Cocorocchio 
 
54 
 
3.2 Application of the methodology for the investigation of a 
range of structurally diverse bitter tastants 
Early studies have shown that several bitter tasting compounds such as 
denatonium, phenylthiourea and naringenin were capable to affect distinct stages 
of D. discoideum life cycle (e.g. chemotaxis, random cell movement, growth and 
development) (Robery et al., 2011; Robery et al., 2013; Waheed et al., 2014). 
Therefore, to better understand the acute effects of bitter tasting substances on 
D. discoideum cell behaviour, changes in random cell movement were monitored 
before and after the exposure to a range of known and unknown bitter 
compounds with widely diverse molecular structures. The list of compounds was 
tailored to understand if the model system could predict the bitterness of those 
substances and, ultimately, obtain a ranking order comparable to the in vivo rat 
BATA assay and human sensory panel models (Rudnitskaya et al., 2013). The 
set of substances of both organic and inorganic origins included:  azelastine 
hydrochloride, caffeine, chlorhexidine digluconate, potassium nitrate (KNO3), 
paracetamol (acetaminophen), quinine, sumatriptan succinate as well as five 
blinded substances provided by the industrial partner GlaxoSmithKline 
(Cocorocchio et al., 2015) (Figure 7). Our results have shown a positive 
correlation between D. discoideum and the in vivo rat BATA test, suggesting that 
this approach may be used as an early screening platform for the assessment of 
bitter compounds and that the response to aversive chemicals is evolutionarily 
conserved (Cocorocchio et al., 2015).  
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Figure 7.  Structure of known (1-8) and blinded (9-13) bitter tasting substances tested in D. 
discoideum cell behaviour. 
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3.2.1 Azelastine hydrochloride (AZL) 
Azelastine is a selective, non-sedating H1-receptor antagonist, structurally similar 
to other anti-histaminic molecules and prevents the release of inflammatory 
mediators from mast cells (Baba et al., 2016). This bitter-tasting compound is 
pharmacologically classified as a second-generation antihistamine, with relative 
lack of central nervous system activity and is utilised for the treatment of allergic 
conditions, such as rhinitis and conjunctivitis (El-Shaheny and Yamada, 2014). 
Particularly, in vitro studies have shown that azelastine possesses higher affinity 
for H1 receptors as compared to chlorpheniramine, a first-generation H1-receptor 
antagonist (Slack et al., 2011). Finally, in vivo studies in a guinea pig model have 
demonstrated that both histamine-related and histamine-independent 
bronchoconstriction were inhibited by azelastine (Williams et al., 2010). 
3.2.2 Chlorhexidine (CHX) 
Chlorhexidine is a broad spectrum antimicrobial agent with a bitter taste (E Frank 
et al., 1995). It is frequently used in dental-care to inhibit bacterial growth and in 
periodontal disease prophylaxis. It is classified as an antibacterial, but it can also 
interfere with the proteolytic activity of some periodontal pathogens and therefore 
reduces caries progression in humans (Garcia et al., 2009; Trufello et al., 2014). 
This inhibitory effect is associated with its cation-chelating properties on matrix 
metalloproteinases (MMPs) (Gendron et al., 1999). 
3.2.3 Quinine 
Quinine is the active ingredient of the cinchona bark and is a naturally occurring 
bitter alkaloid, which possesses diverse medicinal properties and is also used as 
a flavouring ingredient (Sanchez et al., 2014). Although it is employed as an 
antimalarial (Achan et al., 2011) and babesiosis’s treatment (Dorman et al., 
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2000), quinine is poorly tolerated and has low patient compliance. Quinine is also 
used in some muscular disorders, especially nocturnal leg cramps and myotonia 
congenita (Mandal et al., 1995; Pusponegoro et al., 1991). However, the 
mechanisms of action responsible for its antimalarial and muscular disorder 
effects have not been fully understood. In addition, research studies have shown 
that quinine can activate multiple hTAS2Rs (Upadhyaya et al., 2016).   
3.2.4 Caffeine 
Caffeine is a bitter, white, crystalline, xanthine alkaloid and a stimulant drug 
(Nehlig et al., 1992). In humans, caffeine acts as a central nervous system (CNS) 
stimulant, temporarily warding off drowsiness and restoring alertness (Cappelletti 
et al., 2015). It is the most widely consumed psychoactive compound (Sajadi-
Ernazarova and Hamilton, 2017). Studies have found that caffeine is also able to 
stimulate 4 hTAS2Rs in HEK293T cells (Ueda et al., 2003). In addition, it acts as 
a nonselective antagonist of adenosine receptors reducing the effects of 
adenosine, because of its structural similarity to adenosine (Ribeiro and 
Sebastiao, 2010). In physiological conditions, adenosine acts as an inhibitory 
neurotransmitter that suppresses neuronal activity in the CNS (Fisone et al., 
2004). Caffeine is metabolised in the liver by the cytochrome P450 oxidase 
enzyme system, in particular by the CYP1A2 isozyme, into paraxanthine, 
theobromine, and theophylline (Zanger et al., 2008). 
3.2.5 Ibuprofen 
Ibuprofen also possesses a bitter taste and is classified as a non-steroidal anti-
inflammatory drug (NSAID). It is widely used for relieving pain, helping with fever, 
and reducing inflammation (Van Esch et al., 1995). Nonsteroidal anti-
inflammatory drugs such as ibuprofen work through the inhibition of the 
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cyclooxygenase enzyme (COX) which converts arachidonic acid to prostaglandin 
H2 (PGH2). Subsequently, PGH2 is converted into different prostaglandins (which 
are mediators of pain, inflammation, and fever) and thromboxane A2 (which 
stimulates platelet aggregation, leading to the formation of blood clots) (Karlsson 
and Fowler, 2014). 
3.2.6 Paracetamol 
Paracetamol is one of the most widely utilised antipyretic and analgesic drugs 
worldwide. The bitter taste of this drug is believed to originate from its hydroxyl 
group (Hejaz et al., 2012). Pharmacologically, paracetamol possesses weak 
inhibitory effects on COX-1 and 2 and is metabolised to AM404 (N-arachidonoyl-
aminophenol). AM404 is able to inhibit the reuptake of the endogenous 
cannabinoid/vanilloid anandamide by neurons. Anandamide re-uptake lowers 
synaptic levels of anandamide, resulting in an increased activation of nociceptors 
in the body, such as the TRPV1 or vanilloid receptors (Bertolini et al., 2006). By 
blocking anandamide reuptake, levels in the synapse remain high and are able 
to desensitise the TRPV1 receptor much like capsaicin (Kis et al., 2005). 
3.2.7 Potassium nitrate 
KNO3 is an ionic salt of potassium and nitrate ions. It naturally occurs as a 
mineral, is a solid source of nitrogen and possesses a bitter taste (Alfano et al., 
1999). It has a wide range of applications, such as the manufacture of fertilisers, 
rockets (as propellant) and fireworks and is also used as a desensitising agent in 
some toothpaste for sensitive teeth (Hong and Lim, 2016; Sharma et al., 2012). 
Potassium nitrate is also one of the main constituents of gunpowder (black 
powder) and has been utilised as a food preservative since the 5th century C.E. 
A recent study has also shown that the oral administration of potassium nitrate 
Marco Cocorocchio 
 
59 
 
improved the response to a hypoxic challenge by increasing the number of 
perfused vessels (Kolb et al., 2017). 
3.2.8 Sumatriptan succinate 
Sumatriptan is a synthetic drug that belongs to the triptan class, with a strong 
bitter taste, used for the treatment of migraines (Munjal et al., 2017). Structurally, 
it is an analogue of the naturally occurring neuro-active alkaloids 
dimethyltryptamine (DMT), bufotenine, and 5-methoxy-dimethyltryptamine, with 
an N-methyl sulfonamide group at position C-5 on the indole ring (Razzaque et 
al., 1999). Sumatriptan is structurally similar to 5-Hydroxytryptamine and is a 5-
HT (type 5-HT1D and 5-HT1B) receptor-agonist (Razzaque et al., 1999). Acting as 
an agonist of these receptors, sumatriptan reduces the vascular inflammation 
associated with migraines in the cranial and basilar arteries (Evans et al., 2012). 
These effects are achieved through vasoconstriction of those dilated arteries 
(Gulati et al., 2013). In addition, it has been shown that sumatriptan can decrease 
the activity of the trigeminal nerves, through its agonistic activity on TRPV1 
receptors present in the trigeminal nociceptive system, which is responsible for 
sumatriptan's efficacy in treating cluster headaches (Evans et al., 2012). 
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3.2.9 Bitter tastant responses in the amoeba Dictyostelium correlate with 
rat and human taste assays 
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Whilst reduced compliance is particularly acute in children, it 
is also a well-recognized factor in treatment regimens in adults 
(Clapham et al., 2012; Mennella et al., 2013). 
In the development of new pharmaceuticals, unpleasant 
taste liability may not be apparent until initial clinical trials 
are undertaken (Clapham et al., 2012). If a strongly aversive 
taste is identified there may be a need to repeat studies with a 
taste matched placebo or to undertake taste masking of the ac-
tive pharmaceutical ingredient (API) (where this is possible). 
In some cases it may be necessary to identify a different salt 
version of the API or even to change the API for another can-
didate, with clear implications for progression to the market 
and delay of patient access to a new therapeutic. It is also pos-
sible, at this stage, that the studies could be unblinded because 
1  Introduction
The ability to detect bitter substances is considered to have 
evolved to enable the recognition of toxic substances, which 
often present with a strong bitter taste (Mennella et al., 2013). 
Thus, there are clear survival advantages to the rejection of bit-
ter tasting foods and the induction of learned aversion in the 
wild (Glendinning, 1994). However, when such effects are in-
duced by therapeutic agents, many of which have a bitter taste, 
they can have a negative impact on compliance with treatment, 
leading to sub-optimal therapy. For example, around 40% of 
children worldwide are likely to not follow prescriptions due to 
the bitter taste of a medicine, leading to suboptimal dosing and 
preventable potential therapeutic failure (Mennella et al., 2013). 
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and umami (Drewnowski and Gomez-Carneros, 2000; Wood-
ing et al., 2010; DeSimone et al., 2012; Bachmanov and Beau-
champ, 2007; Kawai et al., 2009; Uneyama et al., 2009) on 
Dictyostelium cell behavior. We found that only bitter tastants 
rapidly and strongly affected cell behavior, and developed an 
approach to quantify these changes. We then investigated a 
range of compounds with diverse chemical structures and bit-
terness (including compounds to which the investigators were 
blind) tailored to test if the model system is able to predict the 
bitterness of those compounds assessed in the in vivo rat BATA 
test and a human sensory panel (Clapham et al., 2012; Rudnits-
kaya, et al., 2013). Analysis of each compound in Dictyostelium 
provides concentration-response curves and IC50 values (the 
concentration of substance producing 50% inhibition), enabling 
comparisons of potency between compounds and comparison 
with rat and human data in addition to objective assessment of 
the potential for Dictyostelium to replace the rat BATA assay in 
identification of bitter taste liability of NCEs. 
2  Animals, materials and methods
Chemicals
The following chemicals were obtained from Sigma Aldrich 
Co. Ltd (Dorset, UK): azelastine hydrochloride (4-((4-chlo-
rophenyl)methyl)-2-(1-methylazepan-4-yl)phthalazin-
1-one hydrochloride; A7611), chlorhexidine digluconate 
(1,1′-hexamethylenebis(5-(p-chlorophenyl) biguanide; C9394), 
caffeine anhydrous (1,3,7-trimethylxanthine; W222402), quinine 
hydrochloride dihydrate (Q1125), acetaminophen (paracetamol, 
4′-hydroxyacetanilide; A7085), ibuprofen sodium salt (α-methyl-
4-(isobutyl) phenyl acetic acid; I1892), potassium nitrate (KNO3; 
P8394), adenosine 3′,5′-cyclic monophosphate (3′,5′-cyclic AMP; 
A9501 - 200mM stock solution), glucose (D(+)-glucose; G8270), 
sucrose (D(+)-saccharose; S1888) and glutamate (L-glutamic ac-
id monosodium salt monohydrate; 49621). Compounds labelled 
“GSK” were provided by our industrial collaborators, Glaxo- 
SmithKline, and due to intellectual property protection, full 
names and structures have been withheld. 
Dictyostelium random cell movement
Dictyostelium cells were maintained in Axenic medium 
(Formedium Co. Ltd, Norfolk, UK) for at least 48 h prior to 
harvesting in mid-log phase growth (2-5 x 106 cells/ml). Cells 
(1 x 107) were washed with phosphate buffer (16.5 mM KH2PO4, 
3.8 mM KH2PO4, pH 6.2), resuspended in 6 ml phosphate 
buffer and pulsed for 5 h with 30 nM cAMP at 6 min intervals at 
120 rpm. Cells were resuspended in 4 ml phosphate buffer and 
diluted 1:9, and 250 µl aliquots of cells were transferred into 
Nunc Lab-Tek chambered cover glass (Thermo Fisher, Leices-
tershire, UK), and allowed to adhere for 10-15 min. In each ex-
periment 250 µl of drug stock solution (to produce the desired 
final concentration) was added at the 225th second of the time 
lapse recording to investigate the effects on cell movement. 
Osmolarity, acidity and vehicle control experiments
To investigate whether the changes in cell behavior were due 
of taste effects. Therefore, it is highly important to identify 
bitter taste effects early in the drug discovery process so that 
competing compounds and/or salt versions of compounds 
without such liability can be selected for development. In ad-
dition to acting on the tongue, bitter substances have also been 
shown to act in the pharynx, gut and airways (Bachmanov and 
Beauchamp, 2007). In airways, bitter tastants increase the 
beat frequency of cilia (Shah et al., 2009) with the potential 
to increase airway clearance and hence reduce the therapeutic 
effect of inhaled drugs. These increasingly complex effects 
and tissue specificity of bitter substances further emphasize 
the importance of identification of such substances early in the 
drug discovery process.
There is no universally applicable chemical approach to iden-
tifying compounds that will trigger a bitter taste response, al-
though alkaloid structures have been associated with bitterness 
(Drewnowski and Gomez-Carneros, 2000). Since taste responses 
are based in the peripheral gustatory system along with a central 
nervous system recognition component, most research in this area 
employs animals or human-based tests. Currently, one technique 
employed to assess the palatability of drugs, including novel 
chemical entities (NCE), is the brief access taste aversion (BATA) 
model using the rat (Rudnitskaya et al., 2013) or mouse (Devan-
tier et al., 2008). Although this assay is not considered harmful to 
the animals and has demonstrable translation to humans for iden-
tification of bitter tastants (Rudnitskaya et al., 2013), it is poten-
tially unpleasant for the animal (due to the aversive nature of some 
of the substances tested), is relatively expensive, time consuming 
and has a limited throughput capacity. Thus, there is a need for a 
non-animal, higher throughput assay that can reliably establish the 
potential of a chemical to trigger a bitter taste.
The social amoeba Dictyostelium discoideum is a simple mod-
el system used for a range of pharmacological projects. It is a 
eukaryote with a haploid genome (Williams et al., 2006), and 
exhibits a bi-phasic life cycle, divided into unicellular and mul-
ticellular stages. In the unicellular stage, starvation induces in-
dividual cells to undergo directional movement (chemotaxis) to 
coalesce and form a multicellular fruiting body. It is at this stage, 
that Dictyostelium has been extensively utilized to investigate a 
range of fundamental biological processes such as cell migra-
tion and signal transduction, as well as a range of pharmaco-
logical studies. These include identifying the molecular targets 
of flavonoids (Waheed et al., 2014), bipolar disorder treatments 
(Williams et al., 2002; Williams, 2005) and epilepsy treatments 
including the MCT ketogenic diet (Xu et al., 2007; Chang et 
al., 2012). In all these cases, discoveries in Dictyostelium have 
been successfully translated to humans or other mammals (Xu 
et al., 2007; Chang et al., 2013, 2014). Finally, Dictyostelium 
was able to identify pungent (e.g., capsaicin) and bitter (quinine, 
denatonium, phenylthiourea) tastants (Robery et al., 2013; Otto 
et al., 2015) and led to the discovery of a novel human receptor 
implicated in detection of the bitter tastant phenylthiourea (Rob-
ery et al., 2013). These wide-ranging studies demonstrated the 
potential utility for Dictyostelium in the identification of novel 
pharmaceutical compounds with a bitter taste liability. 
Here we investigated the effect of representative compounds 
from the five basic taste sensations, i.e., bitter, sweet, sour, salty 
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Male rats weighing 250 to 350 g (age 8-10 weeks) Crl: CD 
(SD) strain (Charles River, UK) were used in the study of the 
five GSK compounds (12 rats per compound) to which the Dic-
tyostelium investigators were blinded. Animals were kept under 
controlled environmental conditions (19-23°C; 45-65% humidi-
ty; 12 h light/dark cycle) with free access to food (Labdiet 5LF2 
EURodent Diet 14%) and animal grade water (reverse osmosis 
filtered and UV treated) between test sessions. BATA tests were 
performed between 09.00 and 13.00. The BATA assay (see De-
vantier et al., 2008; Clapham et al., 2012 for additional details) 
employed an automated apparatus (MS-160 Davis Rig gusta-
tory behavior apparatus, DiLog Instruments, Tallahassee, FL, 
USA) to measure the number of licks in response to water, a 
calibration compound or the test compound. The percentage 
inhibition at various concentrations of the test substance pre-
sented on multiple occasions in random order was used to cal-
culate the IC50 (curve fitting with a four parameter logistic curve 
restrained to zero; SAS) for test substances with 12 rats used per 
group to test each substance. Tests were conducted using a one-
week standardized protocol and analysis of welfare indicators 
showed that the rats were not adversely affected by these tests 
(Clapham et al., 2012). The protocol taken from (Clapham et al., 
2012) is briefly as follows: Day 1. Withdrawal of water; Day 2. 
Shutter open (30 min), 1 bottle, water only. Train drinking. Re-
hydration; Day 3. Standard sequence (30-45 min), water only. 
Acclimatize to protocol. Rehydration; Day 4. Presentation se-
quence one. Controls and concentration response. Rehydration; 
Day 5. Presentation sequence two. Controls and concentration 
response. The same rats can be used over an extended period of 
testing (many months) with no loss of sensitivity of response. 
When required, rats were killed humanely (intraperitoneal over-
dose of pentobarbitone).
3  Results 
3.1  Dictyostelium cell behavior responds 
to acute application of bitter tastants
Initial analysis of the effect of compounds representing the 
five basic taste groups (bitter, salty, sweet, sour and umami) on 
Dictyostelium used cells in the aggregation phase of develop-
ment (showing active polarized movement), with cell images 
recorded before (Fig. 1A) or after treatment (Fig. 1B). To mimic 
salty taste, cells were exposed to increasing salt concentra-
tions (potassium phosphate), from standard buffer conditions 
(24.2 mM potassium) up to a 3.3-fold increase (80 mM), and 
no gross change was observed in Dictyostelium cell shape fol-
lowing treatment. This is consistent with that reported by Rob-
ery et al. (2011), where Dictyostelium does not respond to the 
salty tasting central nervous system depressant lithium chloride 
(Schiffman and Erickson, 1971) under equivalent conditions. To 
mimic sour taste (Da Conceicao Neta et al., 2007), cells were 
transferred to a buffer at pH 5 (from pH 6.3). No gross change 
was observed in Dictyostelium cell shape following treatment. 
Similarly, treatment of cells with umami-related tastant, glu-
tamate (6 mM; Fig. 1B) (Kawai et al., 2009; Uneyama et al., 
2009), and sweet tasting glucose (10 mM; Fig. 1B) (Welcome 
to osmolarity and pH variation, cells were exposed to increas-
ing salt concentrations and different pH values. Phosphate buffer 
was prepared 10X (ten times the standard buffer concentration) 
by using 22 g of KH2PO4 and 7 g of KH2PO4 (total volume 1 l) 
and diluted for the experiments to 3.3X and 5X. For experiments 
regarding pH changes, a buffer solution was prepared using 2.72 
g of K2HPO4 in 800 ml of water and the pH was adjusted with 
1M KOH and made up to 1 l to obtain a final solution with a 
pH of 5. For the buffer with pH 7, 6.81 g of K2HPO4 and 291 
ml of 0.10 M NaOH were made up to 1 l. Solvent only con-
trols (DMSO at 1.5% (220 mM) or ethanol at 4.5% (770 mM)) 
were carried out for all experiments to establish that they did 
not significantly alter cell behavior (see Fig. S1 at http://dx.doi.
org/10.14573/altex.1509011s1). 
Live cell microscopy
To assess the suitability of Dictyostelium as a non-animal model 
for the investigation of bitter substances, a standardized assay 
was developed (Otto et al., 2015). Cell behavior was monitored 
in cells undergoing random movement by taking images every 
15 sec over a 15 min period, with 3 min and 45 sec recorded 
prior to, and 11 min and 15 sec after compound addition. A mini-
mum of three independent experiments for each drug concentra-
tion were used with at least 10 cells quantified per experiment. 
From these series of images, parameter protrusion formation 
was quantified with Fiji (Schindelin et al., 2012) using an image 
analysis software plugin, QuimP 11b software (Warwick Univer-
sity, Warwick, UK). Prior statistical analysis data were analyzed 
and formatted using MATLAB (Mathworks, Cambridge, UK). 
Statistical analysis of cell movement
Data derived from membrane protrusions of cells during ran-
dom movement was extracted from videos into a GraphPad 
Prism (GraphPad Software, Inc., San Diego, CA, USA) spread-
sheet as time versus number of protrusions formed. Data was 
normalized by defining zero as the smallest value in each data 
set and one hundred as the largest value in each data set, and 
the data expressed as a fraction. Mean and standard error was 
calculated for each set of results at all concentrations. To assess 
whether there was a significant change in protrusion forma-
tion, an unpaired, two tailed t-test (95% confidence interval) 
was used, comparing the mean of the last 8 min (from min-
ute 4 min 30 sec to minute 12 min 30 sec) against the control 
conditions for all concentrations tested. To calculate the IC50 
(the concentration required to produce a 50% reduction in cell 
movement) for each compound, the mean of the last 8 min of 
protrusion formation and the standard error were selected and 
plotted against their Log (concentration), and IC50 values with 
95% confidence intervals were obtained by non-linear regres-
sion Log (inhibitor) vs. normalized response-variable slope 
equation.
Rat brief access taste aversion (BATA) assay
All the experiments were reviewed by an ethics committee, au-
thorized by the UK Home Office and performed in accordance 
with the Animals (Scientific Procedures) Act 1986 and the GSK 
Policy on the Care, Welfare and Treatment of Animals.
CoCoroCChio et al.
ALTEX 33(3), 2016228
Fig. 1: Dictyostelium response to salty, sour, umami, sweet 
and bitter tastants
A. Images of Dictyostelium cells taken before the administration of 
the substances that represent each taste. 
B. Responses in cells exposed to salty (3.3-fold higher salt content, 
80 mM), sour (pH reduced from pH 6.3 to pH 5), umami (glutamate 
6 mM), sweet (glucose 10 mM), or bitter (chlorhexidine 0.025 mM) 
tastants respectively. 
Fig. 2: Quantifying Dictyostelium response to bitter tastants
A. Images of individual Dictyostelium cells prior to and 15 minutes 
after addition of solvent only (control) or a bitter tastant (azelastine at 
1 mM) showed that the bitter tastant caused a block in cell behavior 
(membrane protrusions) enabling quantification of compound effect. 
Scale bar is 12 µm. 
B. Time-dependent changes in Dictyostelium cell behavior 
(membrane protrusions) was recorded over a 15 minute period 
for triplicate experiments (± SEM) at increasing concentrations of 
azelastine; addition of different concentrations of azelastine at  
210 seconds (). Data is presented normalized to control conditions. 
Analysis with one-way ANOVA of the reduction of protrusion 
formation caused by azelastine showed a significant difference 
between control condition (vehicle) and 0.25 mM azelastine  
(p < 0.05 ***). 
C. Concentration dependent response is illustrated as the normalized 
reduction of cell behavior (protrusion formation) against the Log 
(concentration) of azelastine, enabling calculation of an IC50 of  
0.18 mM with a 95% confidence interval of 0.16 to 0.19 mM. The 
chemical structure of azelastine is provided as an insert. 
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cle treatment alone. Addition of azelastine (1 µm-1 mM; Fig. 
2C) did not affect cell behavior up to 100 µM, but caused a 
dose-dependent reduction in cell behavior at higher concentra-
tions reaching near maximal effect at 250 µM. To extract com-
parative data from these results, cell responses during the last 
8 minutes of treatment were averaged and plotted against com-
pound concentration (28-32 cells per concentration) (Fig. 2D), 
with non-linear regression used to calculate the IC50 value for 
the compound. To examine if the effect of this compound was 
due to induction of cell death, we also exposed cells to azelas-
tine (0.5 mM) for 10 minutes, washed off the azelastine with 
phosphate buffer and recorded cell behavior after 1 h, to show 
cells restored untreated behavior (see Fig. S2 at http://dx.doi.
org/10.14573/altex.1509011s1).
3.2  Structurally diverse bitter tastants 
affect Dictyostelium cell behavior 
Since bitter substances represent a wide chemical space with a 
range of different potencies in taste models, we then analyzed 
a broad group of chemical structures with different bitterness 
et al., 2015) did not alter cell shape. However, treatment of 
cells with the standard bitter tasting substance, chlorhexidine 
(25 µM), caused a rapid loss of cell behavior leading to cell 
rounding. These results suggest that, under the conditions exam-
ined here, only the representative bitter tastant caused an effect 
on Dictyostelium. 
Since Dictyostelium responded to chlorhexidine and ear-
lier studies showed a response to the bitter tastants phenylthi-
ourea and denatonium (Robery et al., 2013), we then sought 
to develop an approach to quantify cell behavior changes us-
ing another bitter substance, azelastine (Clapham et al., 2012) 
(250 µM; Fig. 2A). By recording time lapse images of cells 
over a 15 minute period, including baseline (prior to substance 
addition) and post addition (see also Fig. S2 at http://dx.doi.
org/10.14573/altex.1509011s1 and Movie at http://dx.doi.
org/10.14573/altex.1509011s2), and using computer-aided im-
age analysis (Tyson et al., 2014), we monitored acute change 
in normalized cell behavior (protrusion formation) following 
tastant exposure (Fig. 2B). In this assay, cells maintained con-
stant behavior over the test period following compound vehi-
Tab. 1: List of bitter substances with different mechanisms/receptor targets examined
A range of concentrations were tested for each compound, spanning concentrations used in human or rat studies.
Name Mechanism /  Effects Conc.  Human Rat Reference 
 Target on range  effect effect   
  Dicty examined  range range   
   (mM) (mM) (mM) 
Chlorhexidine Antimicrobial Y  0.001 - 1 0.13 - 2.3 0.01 - 30 Clapham et al., 2012; Rudnitskaya et al.,  
Digluconate agent      2013; Trufello et al., 2014
Azelastine 2nd-Gen, selective, Y 0.001 - 1 0.74 - 2.4  0.002 - 1 Uneyama et al., 2009; Clapham et al., 2012;  
Hydrochloride histamine H1-     Rudnitskaya et al., 2013;   
 receptor     El-Shaheny and Yamada, 2014 
 antagonist; 
 Rhinitis
Ibuprofen NSAID - COX Y 0.001 - 10  n/a 0.1 - 30 Van et al., 1995; Clapham et al., 2012;  
Sodium inhibitor; Analgesic     Rudnitskaya et al., 2013
Quinine Crystalline alkaloid;   Y 0.001 - 2  0.0028 -   0.01 - 5 Uneyama et al., 2009; Robery et al., 2011 
Hydrochloride Anti-malarial;    0.016 
 Bitterness standard     
Caffeine Stimulant drug;  Y 0.001 - 100 3.1 -16 1 - 100 Boughter, Jr. and Whitney, 1997;  
Anhydrous Bitterness standard     Zanger et al., 2008; Clapham et al., 2012;  
      Rudnitskaya et al., 2013
Potassium Ionic salt Y 0.001 - 500 89 - 500 0.1 - 3 M Clapham et al., 2012;   
Nitrate (K+ NO3−);      Rudnitskaya et al., 2013 
 Toothpaste  
 ingredient   
Paracetamol COX-2 inhibitor;  Y 0.001 - 75 6 - 33 0.1 - 30 Kis et al., 2005; Clapham et al., 2012;  
(Acetaminophen) Analgesic     Rudnitskaya et al., 2013
GSK1C H1 receptor Y 0.001 - 1 n/a n/a n/a 
 antagonist 
GSK0A p38 inhibitor Y 0.001 - 1 n/a n/a n/a
GSK7B p38 inhibitor Y 0.001 - 2 n/a n/a n/a
GSK9A H1 receptor Y 0.001 - 1.65 n/a n/a n/a 
 antagonist 
GSK7L p38 inhibitor Y 0.001 - 5 n/a n/a n/a
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Fig. 3: Sensitivity of Dictyostelium to a range of bitter tastants
A. Using a range of substances with known variation in bitterness, concentration dependent responses were determined for Dictyostelium 
cell behavior (protrusion formation), and illustrated as the normalized reduction in response against the Log (concentration) of each 
compound (shown with errors based on the 95% confidence intervals), enabling calculation of an IC50 value and 95% confidence intervals 
for each compound. The graphic formula for each compound is provided as an insert to highlight the diversity of examined chemicals. 
B. This analysis was repeated using five blinded compounds, provided by the industrial collaborator, again providing IC50 values and  
95% confidence intervals. The core structure of each molecule is shown, with the side chains illustrated as R 1-4 due to intellectual property 
considerations. 
C. The analysis was repeated with two non-bitter substances, sucrose and glucose. 
D. Rank order of potency is provided for all tested compounds, based upon IC50 values.
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pH outside the range 5.5 and 6.6 (Fig. 4A), showing that these 
compounds did not alter cell behavior through pH changes. 
Secondly, exposing cells to increased osmolarity using elevated 
buffer concentration (Fig. 4B) caused no change in cell behavior 
up to 118 mosmol/kg, with affected behavior at 182 mosmol/kg 
(Fig. 4B). For all compounds and concentrations tested, buffer 
osmolarity did not exceed 118 mosmol/kg (Fig. 4B) even at the 
concentration of each compound that blocked cell movement, 
ranking as described in the literature (Clapham et al., 2012). 
Selecting compounds that have established activities in the rat 
in vivo BATA test, we repeated the Dictyostelium cell behavior 
analysis experiments with these compounds (Fig. 3A). These 
compounds were: chlorhexidine digluconate, azelastine, ibu-
profen, quinine, caffeine, potassium nitrate and paracetamol 
(acetaminophen). These compounds include organic and in-
organic structures, with widely varying chemical composition 
(Tab. 1), and with a diverse range of known (and unknown) 
cellular effects. Compounds were tested over 3 to 4 log scale 
units of concentration for effects on Dictyostelium cell behav-
ior, again with cell shape recorded prior to and after addition of 
each compound at each concentration. All compounds caused a 
change in cell behavior (reduced protrusions) at increasing con-
centrations (and see also Fig. S3 at http://dx.doi.org/10.14573/
altex.1509011s1), and non-linear kinetic analysis enabled IC50 
values to be determined with 95% confidence intervals, provid-
ing an activity for each compound in this model. Repetition of 
the behavioral tests using two compounds at two concentra-
tions two months after the first experiments showed comparable 
responses not significantly different from each other (see also 
Fig. S4 at http://dx.doi.org/10.14573/altex.1509011). These ex-
periments show that Dictyostelium can be used to reliably and 
reproducibly distinguish between the effects of a range of com-
pounds associated with a bitter taste. 
Since behavioral tests – even at a cellular level – may give 
rise to user-dependent outcome bias, a range of blinded com-
pounds provided by the industrial partner were also examined 
(Fig. 3B). The structures and taste characteristics of these com-
pounds were unknown to those conducting the Dictyostelium 
studies prior to calculation of the IC50 values. The compounds 
provided could have included any substance (i.e., including 
non-bitter tastants) studied in the rat BATA assay so that values 
from the rat and Dictyostelium could be compared. 
The compounds provided by the industrial partner have differ-
ent core chemical structures and variable functional side groups 
(represented by R1-R4) providing large chemical differences in 
overall structure (Fig. 3B). Again, analysis of the effect of the 
compounds on Dictyostelium cell behavior enabled IC50 values 
to be calculated as previously (Fig. 3B), indicating a range of 
different potencies for these compounds. In contrast, two non-
bitter compounds (glucose and sucrose) were also assessed at 
multiple concentrations without effect (Fig. 3C and see also Fig. 
S5 at http://dx.doi.org/10.14573/altex.1509011s1). Comparison 
of IC50 values from the known bitter compounds (Fig. 3A) and 
the blinded compounds (Fig. 3B) enabled a potency ranking of 
compounds in the Dictyostelium model (Fig. 3D). 
3.3  Physiochemical variables are not responsible 
for Dictyostelium movement inhibition
We next investigated a potential role for the compounds in alter-
ing Dictyostelium behavior through changing pH or osmolarity 
(Fig. 4). Firstly, exposing cells to pH conditions ranging from 
5 to 7, on either side of the control buffer (pH 6.3), caused no 
changes in cell behavior (Fig. 4A). Measurement of the buffer 
pH at the concentration of each compound that blocked cell 
movement indicated that the compounds did not change buffer 
Fig. 4: Physicochemical properties of bitter molecules do  
not block Dictyostelium cell behavior
A. Comparison of cell behavior at pH 5 and at pH 7. Control 
condition represents the pH of the phosphate buffer used to 
resuspend cells for the random movement assay. Results show no 
effect in protrusion inhibition due to pH changes in this range. The 
range of compounds studied had a pH of circa 6.5 when in solution, 
with two exceptions: GSK9A (pH 5.5) and KNO3 (pH 5.9). 
B. Assessing the effects of osmolarity on cell behavior. Cell 
behavior was not inhibited by an osmolarity of 118 mosmol/kg 
(lower dotted line), which is the case of KNO3. The osmolarity 
levels of test conditions for all the other compounds where below 
118 mosmol/kg. At higher osmolarity levels (182 mosmol/kg,  
upper dotted line), cells were arrested in movement. 
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sion (BATA) assay (Fig. 5A), which has been shown to have 
predictive value for identification of bitter tasting substances in 
humans (Clapham et al., 2012; Rudnitskaya et al., 2013). This 
data was defined here for the five blinded GSK compounds, 
and for the other six compounds reported earlier in validation 
studies of the BATA assay using a total of 192 animals employ-
ing identical methodology (Clapham et al., 2012; Rudnitskaya 
et al., 2013). Data from these two sets were compared using a 
radar plot, where the similarities between the IC50 values for 
multiple compounds can be easily identified (Fig. 5A,B). Both 
Dictyostelium and rat models show an overall similar response 
to the known compounds, reflected by the conserved shape 
of the plot. Some compounds, chlorhexidine, ibuprofen and 
KNO3 were more tolerable in the rat model, whereas quinine 
demonstrating that these compounds did not alter cell behavior 
through osmolarity changes. In addition, maximal solvent con-
centrations did not alter cell behavior (Fig. S1). Overall these 
findings support the hypothesis that Dictyostelium cell behavior 
responses are due to properties of the compounds related to their 
ability to induce a bitter taste in mammals. 
3.4  Dictyostelium, rat BATA test and 
human taste panel comparison reveals 
similarities in predicting bitterness
To evaluate whether the IC50 values calculated for each of the 
compounds using Dictyostelium cell behavior inhibition were 
predictive of perceived bitterness, we compared our data to 
results obtained in the established rat brief access taste aver-
Fig. 5: Dictyostelium behavior model shows similarity to rat and human bitter taste models
A. Comparison of IC50 data derived from the Dictyostelium cell behavior model (green) and the rat BATA test model (blue). The radar plot 
provides the IC50 value of each compound on each corner of the polygon in Log scale. The ranking of potency starts with chlorhexidine and 
proceeds clockwise. The closer to the center the IC50 value is, the more potent the compound. The overlapping of the lines generated by 
connecting the values for all compounds of the two models show a similar trend. 
B. The correlation graph (Log IC50 in M) was obtained by comparing the IC50 values of rat (values for GSK compounds from this study;  
other values from Clapham et al., 2012 and Rudnitskaya et al., 2013) and Dictyostelium models, and results show a significant correlation  
(p = 0. 0172*). The value for paracetamol is predicted (from the human data) using the constant difference between human and rat of one Log 
scale. 
C. Human (red) and Dictyostelium data analysis shows that azelastine, caffeine, KNO3 and paracetamol have a similar score prediction in the 
two models, whereas quinine and chlorhexidine have a different output. Data from humans taken from Clapham et al. (2012). 
D. Rat and human comparison shows similar sensitivity with regard to chlorhexidine, azelastine, caffeine and KNO3, and rat model is less 
susceptible to quinine by a Log unit. 
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4  Discussion 
In this paper, we investigated the suitability of employing a 
simple model system, Dictyostelium, in taste perception stud-
ies. Exposing Dictyostelium to substances that evoke the five 
basic tastes in humans showed that it was only affected by the 
bitter tastants. The response of Dictyostelium to bitter tastants 
is to lose the typical amoeboid shape and round up, and in so 
doing, block membrane protrusion formation. There are many 
potential mechanisms behind this effect. Dictyostelium is a 
well-studied model for cell movement (Dang et al., 2013; Ar-
temenko et al., 2014) and has been explored in a range of phar-
macological studies for identifying chemical targets (Robery et 
al., 2013; Waheed et al., 2014; Lockley et al., 2015). Indeed, a 
large number of studies have identified changes in cell behav-
ior (particularly in movement) caused by deletion of individual 
proteins (Chattwood et al., 2014; Fets et al., 2014; Wessels et 
al., 2014). Thus it is likely that pharmacological regulation of 
several proteins by bitter tastants may result in altered cell be-
havior observed in this study. Each of the targets thus controls 
protrusion formation with a dose dependent effect, where pro-
trusions formed is inversely proportional to the concentration 
administered. The broad and varied chemical structures exam-
ined here suggest that the bitter targets are distinct, but modifi-
cation of each target gives rise to an imbalance of cell function 
resulting in a common behavioral phenotype. 
Current opinions of the molecular mechanisms of strongly 
bitter compounds are that these compounds show activity via 
TAS2 receptors (Meyerhof, 2005; Ji et al., 2014), but there is 
little understanding of the molecular mechanisms regarding 
moderate or weakly bitter compounds. It is therefore surpris-
ing that Dictyostelium, lacking proteins related to the large 
family of TAS2 receptors, is sensitive to bitter compounds. 
Furthermore, Dictyostelium also responds to moderately bitter 
compounds. This suggests that, although TAS2 receptors are 
involved in bitter taste perception in mammals, perhaps other 
molecular targets may also be involved in Dictyostelium and 
mammalian systems. An example of this is provided by a re-
cent study investigating novel targets of a standard strong bitter 
tastant, phenylthiourea (PTU), in Dictyostelium, where the bit-
ter tastant inhibited cell movement (Robery et al., 2013), and a 
genetic screen identified a PTU-sensitive receptor with homol-
ogy to a poorly characterized human GABAB protein, where 
the human protein restored the sensitivity to PTU in Dictyoste-
lium (Robery et al., 2013). Another study, again in Dictyoste-
lium, identified an ion channel (PDK2) to be targeted by a bitter 
taste-related compound, naringenin (Glendinning, 1994), a fla-
vonoid found in high levels in citrus fruit (Waheed et al., 2014). 
This study also confirmed the conserved flavonoid-PDK2 inter-
action in mammalian (kidney) cells and proposed a therapeutic 
treatment for genetic mutations in the target through naringenin 
treatment. These combined data suggest that bitter tastants are 
likely to act via a wide range of targets in mammals, in addition 
to the well-characterized TAS2 receptors. Pharmacogenetic 
studies in Dictyostelium (Williams, 2005), including for exam-
ple the analysis of cell behavior in the absence of functional 
(used at comparable levels in several studies (Soto et al., 2015; 
Clapham et al., 2012) was more tolerable in the Dictyostelium 
model. With regard to the blind compounds tested, the rat and 
Dictyostelium models also showed similar responses, with all 
compounds showing a similar potency to within half a Log 
unit. To determine whether the two data sets were comparable, 
we performed a Pearson correlation test, which showed a sig-
nificant level of correlation between the Dictyostelium and rat 
models (p = 0.0132) (Fig. 5B). This analysis demonstrates that 
the Dictyostelium response to a wide range of chemical struc-
tures correlates with the data from the rat BATA test using the 
same range of bitter tastants.
Animal taste perception models may show considerable vari-
ation in response compared to that observed in human taste 
tests. Few published human taste response tests with IC50 val-
ues are available, thus providing scant data for direct compari-
son between Dictyostelium and human responses. However, we 
were able to compare the responses in Dictyostelium with re-
sults obtained previously for six compounds studied in a human 
sensory panel using established taste assessment methodology 
(Fig. 5C) (Rudnitskaya et al., 2013). In these standardized tests, 
human volunteers are asked to score the bitterness of solutions 
with each testing session including a fixed concentration of 
quinine (5 µM) as a calibration to ensure inter-session consist-
ency (Rudnitskaya et al., 2013). Both Dictyostelium and hu-
mans show an overall similar order of response to compounds, 
reflected by the conserved shape of the plot, although the hu-
man response to quinine was stronger and to chlorhexidine was 
weaker than that observed for Dictyostelium. Although the data 
is limited, the Dictyostelium response to a range of chemical 
structures of varying bitter taste correlates with the taste re-
sponses in humans.
To explore the difference between the rat and human taste 
models, we also compared responses between these two models 
using the same radar plot analysis (Fig. 5D). Such a compari-
son also allows us to draw more valid conclusions regarding 
the relationship between Dictyostelium and human assessment. 
This analysis showed that the rat BATA response was consist-
ently less sensitive to the range of bitter tastants examined than 
the human sensory panel, with this change varying between a 
half and one log unit. This analysis shows that the rat BATA 
response to a range of chemical structures of varying bitter taste 
is similar to that observed in humans, although with a lower 
sensitivity to all compounds. This difference in magnitude of re-
sponse is to be expected since the rat response is driven by thirst 
whereas the human response is not. Thus, the rat is somewhat 
more tolerant of bitterness than the human subjects. Importantly 
the offset in IC50 values between the rat and human for these 
compounds is relatively consistent, allowing a good prediction 
of the human response to the particular tastant. Encouragingly, 
it would appear that a similar situation exists for the Dictyoste-
lium response, at least for the majority of the compounds tested, 
suggesting that the amoeba model is likely to be predictive of 
the human response.
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G proteins (Robery et al., 2013), may identify the molecular 
mechanism underlying the responses evoked by the structurally 
diverse bitter tastants in this study.
Can Dictyostelium be developed as an early, non-animal 
model, to inform academic and industrial researchers about 
the potential for adverse taste of a new compound? Our data 
show a significant positive correlation between Dictyostelium 
response and the rat BATA test (Fig. 5A,B), suggesting that 
the model may be useful in this role. The in vivo rat BATA 
test, although widely accepted, has limitations including slow 
throughput, significant economic costs of testing and the use 
of animals (albeit a relatively small number per compound, 
typically 6-12 (Clapham et al., 2012; present study) and 10 
in a more recent study using a novel analytical method aimed 
to improve the robustness of the rat BATA model (Soto et al., 
2015), in a relatively benign regimen). Comparison of the re-
sponses of Dictyostelium and humans suggest a similar pattern 
of response, although fewer compounds were available to com-
pare between the models. We propose that the Dictyostelium 
assay described here could be developed as a validated early 
screening platform for the identification of bitter taste liability 
of novel pharmaceutical agents with the additional benefit of 
reducing animal experimentation. 
In addition to suggesting a potential new non-animal model 
for provisional bitter tastant screening, our data provides an 
interesting insight into this field from an evolutionary perspec-
tive, since rat bitter taste perception is considered an evolution-
ary conserved mechanism used to avoid toxic food chemicals 
(Meyerhof, 2005; Mennella et al., 2013). The ability to recog-
nize and/or respond to bitter tastants is shared amongst phy-
logenetically diverse groups, including mammals (Stern et al., 
2011), amphibians (Go, 2006; Mashiyama et al., 2014), fishes 
(Ishimaru et al., 2005), cephalopods (Darmaillacq et al., 2004), 
decapod crustacea (Aggio et al., 2012), insects and nematodes 
(Hilliard et al., 2004; Gordesky-Gold et al., 2008; Apostolo-
poulou et al., 2014). However, data presented here suggest a 
conserved response from the unicellular Dictyostelium to pri-
mates; the last common ancestor of Dictyostelium and multi-
cellular animals existed about a billion years ago (van Egmond 
and Van Haastert, 2010).
References
Aggio, J. F., Tieu, R., Wei, A. and Derby, C.D. (2012). Oesopha-
geal chemoreceptors of blue crabs, Callinectes sapidus, sense 
chemical deterrents and can block ingestion of food. J Exp 
Biol 215, 1700-1710. http://dx.doi.org/10.1242/jeb.065854
Apostolopoulou, A. A., Mazija, L., Wust, A. and Thum, A. S. 
(2014). The neuronal and molecular basis of quinine-depend-
ent bitter taste signaling in Drosophila larvae. Front Behav 
Neurosci 8, 6. http://dx.doi.org/10.3389/fnbeh.2014.00006
Artemenko, Y., Lampert, T. J. and Devreotes, P. N. (2014). Mov-
ing towards a paradigm: Common mechanisms of chemot-
actic signaling in Dictyostelium and mammalian leukocytes. 
Cell Mol Life Sci 71, 3711-3747. http://dx.doi.org/10.1007/
s00018-014-1638-8
    CoCoroCChio et al.
ALTEX 33(3), 2016 235
Robery, S., Tyson, R., Dinh, C. et al. (2013). A novel human 
receptor involved in bitter tastant detection identified using 
Dictyostelium discoideum. J Cell Sci 126, 5465-5476. http://
dx.doi.org/10.1242/jcs.136440
Rudnitskaya, A., Kirsanov, D., Blinova, Y. et al. (2013). Assess-
ment of bitter taste of pharmaceuticals with multisensor sys-
tem employing 3 way PLS regression. Anal Chim Acta 770, 
45-52. http://dx.doi.org/10.1016/j.aca.2013.02.006
Schiffman, S. S. and Erickson, R. P. (1971). A psychophysical 
model for gustatory quality. Physiol Behav 7, 617-633. http://
dx.doi.org/10.1016/0031-9384(71)90117-X
Schindelin, J., Arganda-Carreras, I., Frise, E. et al. (2012). Fiji: 
An open-source platform for biological-image analysis. Nat 
Methods 9, 676-682. http://dx.doi.org/10.1038/nmeth.2019 
Shah, A. S., Ben-Shahar, Y., Moninger, T. O. et al. (2009). Mo-
tile cilia of human airway epithelia are chemosensory. Science 
325, 1131-1134. http://dx.doi.org/10.1126/science.1173869
Soto, J., Sheng, Y., Standing, J. F. et al. (2015). Development 
of a model for robust analysis of the rodent brief-access taste 
aversion data. Eur J Pharm Biopharm 91, 47-51. http://
dx.doi.org/10.1016/j.ejpb.2015.01.016
Stern, R. M., Koch, K. L. and Andrews, P. L. R. (2011). Nau-
sea – Mechanisms and Management. Oxford, UK: Oxford 
University Press.
Trufello, A. M., Orellana, B. U., Moraga, C. L. et al. (2014). 
Subclinical concentrations of chlorhexidine inhibit gelatinase 
activity of carious dentine in vitro. Aust Dent J 59, 81-86. 
http://dx.doi.org/10.1111/adj.12147
Tyson, R. A., Zatulovskiy, E., Kay, R. R. and Bretschneider, T. 
(2014). How blebs and pseudopods cooperate during chemo-
taxis. Proc Natl Acad Sci U S A 111, 11703-11708. http://
dx.doi.org/10.1073/pnas.1322291111
Uneyama, H., Kawai, M., Sekine-Hayakawa, Y. and Torii, K. 
(2009). Contribution of umami taste substances in human sal-
ivation during meal. J Med Invest 56, Suppl, 197-204. http://
dx.doi.org/10.2152/jmi.56.197
van Egmond, W. N. and Van Haastert, P. J. (2010). Characteri-
zation of the Roco protein family in Dictyostelium discoi-
deum. Eukaryot Cell 9, 751-761. http://dx.doi.org/10.1128/
EC.00366-09
Van, E. A., Van Steensel-Moll, H. A., Steyerberg, E. W. 
et al. (1995). Antipyretic efficacy of ibuprofen and 
acetaminophen in children with febrile seizures. Arch Pedi-
atr Adolesc Med 149, 632-637. http://dx.doi.org/10.1001/
archpedi.1995.02170190042007
Waheed, A., Ludtmann, M. H., Pakes, N. et al. (2014). Nar-
ingenin inhibits the growth of Dictyostelium and MDCK-
derived cysts in a TRPP2 (polycystin-2)-dependent manner. 
Br J Pharmacol 171, 2659-2670. http://dx.doi.org/10.1111/
bph.12443
Welcome, M. O., Mastorakis, N. E. and Pereverzev, V. A. 
(2015). Sweet taste receptor signaling network: Possible 
implication for cognitive functioning. Neurol Res Int 2015, 
606479. http://dx.doi.org/10.1155/2015/606479
Wessels, D., Lusche, D. F., Scherer, A. et al. (2014). Huntingtin 
regulates Ca2+ chemotaxis and K+-facilitated cAMP chemot-
Fets, L., Nichols, J. M. and Kay, R. R. (2014). A PIP5 kinase es-
sential for efficient chemotactic signaling. Curr Biol 24, 415-
421. http://dx.doi.org/10.1016/j.cub.2013.12.052
Glendinning, J. I. (1994). Is the bitter rejection response al-
ways adaptive? Physiol Behav 56, 1217-1227. http://dx.doi.
org/10.1016/0031-9384(94)90369-7
Go, Y. (2006). Proceedings of the SMBE Tri-National Young 
Investigators’ Workshop 2005. Lineage-specific expansions 
and contractions of the bitter taste receptor gene repertoire 
in vertebrates. Mol Biol Evol 23, 964-972. http://dx.doi.
org/10.1093/molbev/msj106
Gordesky-Gold, B., Rivers, N., Ahmed, O. M. and Breslin, P. 
A. (2008). Drosophila melanogaster prefers compounds per-
ceived sweet by humans. Chem Senses 33, 301-309. http://
dx.doi.org/10.1093/chemse/bjm088
Hilliard, M. A., Bergamasco, C., Arbucci, S. et al. (2004). 
Worms taste bitter: ASH neurons, QUI-1, GPA-3 and ODR-3 
mediate quinine avoidance in Caenorhabditis elegans. EMBO 
J 23, 1101-1111. http://dx.doi.org/10.1038/sj.emboj.7600107
Ishimaru, Y., Okada, S., Naito, H. et al. (2005). Two families 
of candidate taste receptors in fishes. Mech Dev 122, 1310-
1321. http://dx.doi.org/10.1016/j.mod.2005.07.005
Ji, M., Su, X., Su, X. et al. (2014). Identification of novel com-
pounds for human bitter taste receptors. Chem Biol Drug Des 
84, 63-74. http://dx.doi.org/10.1111/cbdd.12293
Kawai, M., Uneyama, H. and Miyano, H. (2009). Taste-active 
components in foods, with concentration on Umami com-
pounds. J Health Sci 55, 667-673. http://dx.doi.org/10.1248/
jhs.55.667
Kis, B., Snipes, J. A. and Busija, D. W. (2005). Acetaminophen 
and the cyclooxygenase-3 puzzle: Sorting out facts, fictions, 
and uncertainties. J Pharmacol Exp Ther 315, 1-7. http://
dx.doi.org/10.1124/jpet.105.085431
Lockley, R., Ladds, G. and Bretschneider, T. (2015). Image 
based validation of dynamical models for cell reorienta-
tion. Cytometry A 87, 471-480. http://dx.doi.org/10.1002/
cyto.a.22600
Mashiyama, K., Nozawa, Y., Ohtubo, Y. et al. (2014). Time-
dependent expression of hypertonic effects on bullfrog taste 
nerve responses to salts and bitter substances. Brain Res 
1556, 1-9. http://dx.doi.org/10.1016/j.brainres.2014.02.006
Mennella, J. A., Spector, A. C., Reed, D. R. and Coldwell, S. 
E. (2013). The bad taste of medicines: Overview of basic re-
search on bitter taste. Clin Ther 35, 1225-1246. http://dx.doi.
org/10.1016/j.clinthera.2013.06.007
Meyerhof, W. (2005). Elucidation of mammalian bitter taste. 
Rev Physiol Biochem Pharmacol 154, 37-72. http://dx.doi.
org/10.1007/s10254-005-0041-0
Otto, G., Cocorocchio, M., Munoz, L. et al. (2015). Employing 
Dictyostelium as an advantageous 3Rs model for pharmaco-
genetic research. Meth Mol Biol, in press.
Robery, S., Mukanowa, J., Percie du, S. N. et al. (2011). In-
vestigating the effect of emetic compounds on chemotaxis 
in dictyostelium identifies a non-sentient model for bitter 
and hot tastant research. PLoS One 6, e24439. http://dx.doi.
org/10.1371/journal.pone.0024439
CoCoroCChio et al.
ALTEX 33(3), 2016236
Bioanal Chem 392, 1093-1108. http://dx.doi.org/10.1007/
s00216-008-2291-6
Conflict of interest
The authors declare that they have no conflicts of interest.
Acknowledgements
This work was funded by an NC3Rs UK Crack It Solutions 
grant, and an Industrial Studentship grant from GSK to RSBW 
and PA. Thanks to Mark G. Lennon for advice on statistical 
analysis, and James McEvoy on manuscript comments. Robert 
Ives and David Clapham are employees of GSK. We also wish 
to thank Gianni dal Negro for discussions of initial results and 
the 3Rs implications. 
Correspondence to
Prof. Robin SB Williams 
Centre for Biomedical Sciences
School of Biological Sciences
Royal Holloway University of London
Egham, Surrey, TW20 0EX, UK
Phone: + 44 1784 276162 
Fax: + 44 1784 414224
e-mail: Robin.williams@rhul.ac.uk
axis, in conjunction with the monovalent cation/H+ exchanger 
Nhe1, in a model developmental system: Insights into its pos-
sible role in Huntingtons disease. Dev Biol 394, 24-38. http://
dx.doi.org/10.1016/j.ydbio.2014.08.009
Williams, R. S. B, Cheng, L., Mudge, A. W. and Harwood, 
A. J. (2002). A common mechanism of action for three 
mood-stabilizing drugs. Nature 417, 292-295. http://dx.doi.
org/10.1038/417292a
Williams, R. S. B. (2005). Pharmacogenetics in model systems: 
Defining a common mechanism of action for mood stabilis-
ers. Prog Neuropsychopharmacol Biol Psychiatry 29, 1029-
1037. http://dx.doi.org/10.1016/j.pnpbp.2005.03.020
Williams, R. S. B., Boeckeler, K., Graf, R. et al. (2006). To-
wards a molecular understanding of human diseases using 
Dictyostelium discoideum. Trends Mol Med 2, 415-424. 
http://dx.doi.org/10.1016/j.molmed.2006.07.003
Wooding, S., Gunn, H., Ramos, P. et al. (2010). Genetics and 
bitter taste responses to goitrin, a plant toxin found in veg-
etables. Chem Senses 35, 685-692. http://dx.doi.org/10.1093/
chemse/bjq061
Xu, X., Muller-Taubenberger, A., Adley, K. E. et al. (2007). At-
tenuation of phospholipid signaling provides a novel mecha-
nism for the action of valproic acid. Eukaryot Cell 6, 899-
906. http://dx.doi.org/10.1128/ec.00104-06
Zanger, U. M., Turpeinen, M., Klein, K. and Schwab, M. 
(2008). Functional pharmacogenetics/genomics of human 
cytochromes P450 involved in drug biotransformation. Anal 
ALTEX 33(3), SUPPLEMENTARY DATA 1
 http://dx.doi.org/10.14573/altex.1509011s1
This is an Open Access article distributed under the terms of the Creative 
Commons Attribution 4.0 International license (http://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution and reproduction 
in any medium, provided the original work is appropriately cited. 
Cocorocchio  et al.:
Bitter Tastant Responses in the 
Amoeba Dictyostelium Correlate with 
Rat and Human Taste Assays  
Supplementary Data 
Fig. S1: Solvents do not affect Dictyostelium cell behavior
Addition of maximal concentrations of solvent: DMSO at 1.5%  
(220 mM) or ethanol at 4.5% (770 mM) did not significantly affect 
cell behavior. Data represent the number of protrusions formed 
(mean of at least three experimental repeats) after the compound 
addition (last 8 minutes). Analysis with one-way ANOVA showed  
no significant difference between control conditions and treatment 
with either solvent. 
Fig. S2: Bitter tastant effects are reversible
After the addition of the bitter tastant (azelastine 0.5 mM), there is 
a strong inhibition of protrusion formation, with a full recovery of 
behavior following removal of the tastant (1 h post tastant addition, 
one-way ANOVA, p < 0.001 ***).
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Fig. S3: Raw data of Dictyostelium response to standard bitter compounds
Time-dependent changes in Dictyostelium cell behavior (membrane protrusion) were recorded over a 15 minute period for triplicate 
experiments (± SEM) at increasing concentrations of seven different compounds to assess their ability to inhibit cell behavior.  
The addition of different concentrations of each compound at 210 seconds caused a reduction in protrusion formation. Data is presented  
as normalized to control conditions. Analysis with one-way ANOVA showed significant changes after the treatment with: azelastine  
0.25 mM (p < 0.001 ***); caffeine 5 mM (p < 0.05 *); chlorhexidine 0.025 mM (p < 0.01 **); ibuprofen 0.050 mM (p < 0.01 **);  
paracetamol 50 mM (p < 0.01 **); potassium nitrate 50 mM (p < 0.001 ***); quinine 2 mM (p < 0.001 ***); GSK7B 2 mM (p < 0.001 ***); 
GSK9A 1.65 mM (p < 0.05 *); GSK1C 1 mM (p < 0.001 ***); GSK0A 0.5 mM (p < 0.01 **); GSK7L 2.5 mM (p < 0.01 **).
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Fig. S4: Effects of bitter compounds are reproducible
To assess the reproducibility of the assay a set of repeat experiments were carried out one month after the initial experiments.  
(A) Comparison of data obtained from the azelastine shows that IC50 values are the same for both data sets. (B) The effects of caffeine 
show a similar response in both data sets.
Fig. S5: Raw data of Dictyostelium response to non-bitter compounds, glucose and sucrose
Addition of glucose 50 mM and sucrose 50 mM did not affect cell behavior. Data represent the number of protrusions formed (mean of at 
least three experimental repeats) after the compound addition (last 8 min). Analysis with one-way ANOVA showed no significant difference 
between control conditions and treatment with either compound. 
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Supplementary Movie: Bitter tastants 
regulate Dictyostelium cell behavior
Wild type Dictyostelium cells were 
monitored by time-lapse photography to 
record cell behavior every fifteen seconds 
over a fifteen minute period. At 5 minutes 
(black frame) either solvent (Left) or bitter 
substance (Right) (azelastine, 1 mM) was 
added to cells and images were recorded 
for a further 10 minutes. Subsequent 
computer generated outlines enabled 
protrusion formation to be quantified. Bitter 
tastants gave rise to a loss in protrusion. 
View movie at http://dx.doi.org/10.14573/
altex.1509011s2
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Bitter Tastant Responses in the Amoeba Dictyostelium Correlate with Rat 
and Human Taste Assays 
Figure 2. (B) N≥30 cells analysed per condition from ≥3 independent technical repeats. 
Figure 4. 3 independent technical repeats for each compound. 
Figure S1. N=30 cells analysed per condition from 3 independent technical repeats. 
Figure S2. N=30 cells analysed per condition from 3 independent technical repeats. 
Figure S3. N≥30 cells analysed per condition from ≥3 independent technical repeats. 
Figure S5. N=30 cells analysed per condition from 3 independent technical repeats. 
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3.3 Employing D. discoideum for the characterisation of a family 
of structurally related compounds 
After the screening of a wide range of diverse bitter tastants, a more in-depth 
approach was employed for the investigation of the cellular effects and molecular 
targets of curcumin and a family of structurally related compounds (Figure 8). 
Curcumin (diferuloylmethane) is a natural hydrophobic phenol, the main 
component of the turmeric root, and has a bitter, astringent and pungent taste, 
with a distinctive yellow colour. The health benefits of curcumin have been proven 
by several clinical trials (Lopresti et al., 2014; Panahi et al., 2015; Panahi et al., 
2017) and include anti-oxidant, anti-inflammatory, anti-viral and anti-bacterial 
properties as well as anti-cancer, neuroprotective and hypoglycaemic activities 
(Priyadarsini, 2014). In fact, curcumin is able to affect many different signalling 
pathways such as transcription factors, tumour suppressor genes, chemokines, 
cytokines, adhesion molecules, and microRNAs (Gupta et al., 2012; Prasad et 
al., 2014). In addition, natural phenols like curcumin have no severe side effects, 
are inexpensive and readily available (Goel et al., 2008). Therefore, curcumin 
might be an alternative to conventional drugs for the management of many 
diseases upon resolution of problems with solubility and bioavailability. For this 
reason, there has been an increasing interest in the design and testing of 
curcumin-structurally-related analogues of natural or synthetic origins. An 
example of this approach is represented by EF31 and UBS109 which in a recent 
study demonstrates an increased potency in inhibiting methylation of DNA 
methyltransferase 1 (DNMT-1), Nuclear Factor-kappa-B (NF-κB), and heat shock 
protein 90 (HSP90) (Nagaraju et al., 2013). In addition, these analogues have 
better solubility and bioavailability compared to curcumin, making them promising 
lead compounds for the treatment of cancer.  
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Figure 8.  Structures of natural and artificial curcumin derivatives used in a quantitative 
structural analysis in D. discoideum. 
 
The study presented in this section has shown that D. discoideum cellular 
functions like growth, development and cell behaviour are differentially modulated 
by structural modifications of the molecules. These results highlighted the 
importance of active functional groups and that the effects seen in D. discoideum 
are likely to be indipendent of the antioxidant activity of these compounds. 
Moreover, several mutants were identified through a genetic screen, in particular, 
one curcumin-resistant mutant lacking the protein phosphatase 2A regulatory 
subunit (PsrA) and an EF24-resistant mutant is lacking the Presenilin 1 
orthologue (PsenB). These mutants were recapitulated to confirm their resistance 
to curcumin and its synthetic analogue EF24, respectively. In addition, using 
molecular docking analysis, this study has shown that curcumin may directly bind 
to a key regulatory region of PsrA to regulate its function. The identified molecular 
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targets have been associated with the pathogenesis of cancer and Alzheimer’s 
disease (AD) in animal models and patients, making them clinically relevant. 
These results suggest that this model may be useful in the investigation of natural 
compounds with complex molecular structure and multiple cellular targets 
supporting the development of curcumin-based drugs for the treatment of a wide 
range of conditions. These findings reveal novel cellular and molecular 
mechanisms for the function of curcumin and related compounds.  
3.3.1 Curcumin 
Curcumin is a polyphenolic diketone and main curcuminoid of the turmeric root, 
in which are also present two naturally occurring curcumin analogues 
(curcuminoids), demethoxycurcumin (DMC) and bisdemethoxycurcumin 
(BDMC). Ayurvedic medicine has been using curcumin for thousands of years, 
as a treatment for inflammatory diseases and wounds. Many studies reported 
that curcumin possesses pleiotropic activities, as it can modulate multiple 
signalling pathways including enzymes, receptors, growth factors, transcription 
factors, cell-cycle proteins, protein kinases, protein reductases, carrier proteins, 
cell survival proteins, drug resistance proteins, adhesion molecules, inflammatory 
molecules, chemokines, DNA, RNA, and metal ions (Aggarwal and Harikumar, 
2009; Aggarwal and Sung, 2009; Ghosh et al., 2015; Zhou et al., 2011). It has 
been also shown that curcumin possesses antibacterial, anti-inflammatory, anti-
oxidant, pro-apoptotic, anti-cancer, neuroprotective, wound healing, anti-
nociceptive, anti-parasitic, and anti-malarial properties. (Goel et al., 2008; Gupta 
et al., 2012; Oliveira et al., 2015).  
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3.3.2 Demethoxycurcumin (DMC) 
Demethoxycurcumin (DMC) is a β-diketone like curcumin in which one of the 
methoxy groups is replaced by a hydrogen and represents one of the major 
curcuminoids in turmeric, accounting for 15–20%. It has been recently shown that 
demethoxycurcumin is more potent than curcumin in inhibiting proliferation and 
inducing apoptosis in human colorectal carcinoma cells (HCT116) treated for 48 
h. These effects were likely due to the lower rate of degradation of 
demethoxycurcumin (-70%) in comparison to curcumin (~100%) in 48 h, showing 
that the former compound is more stable in vivo (Tamvakopoulos et al., 2007). 
3.3.3 Bisdemethoxycurcumin (BDMC) 
Bisdemethoxycurcumin (BDMC) is also a natural demethoxy derivative of 
curcumin, accounting for 3-5% of the total curcuminoids. It has been reported to 
suppress the proliferation of several cancer cells and has a higher stability in 
physiological media as compared to curcumin (Luo et al., 2015). BDMC is also a 
potent activator of macrophage phagocytosis and, through the interaction with 
vitamin D3, stimulates amyloid-β clearance by macrophages (Cashman et al., 
2008; Fiala et al., 2007; Masoumi et al., 2009). Thus, this compound may be 
employed in the immunoprophylaxis of AD. 
3.3.4 Tetrahydrocurcumin (THC) 
Tetrahydrocurcumin (THC) is a white curcumin metabolite which possesses 
pharmacological activities comparable to curcumin. THC is a product of bacterial 
or intestinal metabolism of curcumin (via the bacterial enzyme NADPH-
dependent curcumin reductase). THC lacks α,β dienes and is  therefore unable 
to form Michael adducts (nucleophilic addition of a carbanion or another 
nucleophile to a α,β-unsaturated carbonyl compound) with intracellular proteins, 
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but is more stable than curcumin in phosphate buffer solutions at various pH 
ranges (Aggarwal et al., 2014). 
3.3.5 FLLL31 
FLLL31 is a newly developed curcumin synthetic analogue which selectively 
binds to Janus kinase 2 (JAK2) and the STAT3 Src homology-2 (SH2) domain, 
suppressing the activation of STAT3 in both in vitro and in vivo studies. FLLL31 
significantly decreases inflammatory cell recruitment and the onset of asthma in 
vitro and in vivo. Therefore it may be useful as an adjuvant therapy for asthma 
patients (Yuan et al., 2014). 
3.3.6 Curcumin Pyrazole 
Curcumin pyrazole is a curcumin derivative N-(3-Nitrophenylpyrazole), which 
shows great potency in arresting α-synuclein fibrillization and, disrupting 
preformed fibrils as well as preventing the formation of A11 conformation in the 
protein that imparts toxic effects in Parkinson’s disease. Therefore, curcumin 
pyrazole may be a useful inhibitor for the treatment of α-synuclein amyloidosis 
and toxicity in Parkinson’s disease and other synucleinopathies (Ahsan et al., 
2015). 
3.3.7 UBS109 
UBS109 is a novel synthetic curcumin analogue which has demethylating 
properties and, due to the importance of methylation in pancreatic cancer, this 
compound can be used as a therapeutic agent. A recent study has shown that 
cancer cell lines MiaPaCa-2 and PANC-1 treated with UBS109 exhibited a more 
potent inhibition in cell proliferation and cytosine methylation compared to 
curcumin. Thus, UBS109 may be further developed for the treatment of 
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pancreatic cancer, alone or in combination with chemotherapeutic agents 
(Nagaraju et al., 2013). 
3.3.8 EF24 
EF24, 3,5-bis(2-fluorobenzylidine)-4-piperidone is a synthetic chalcone curcumin 
derivative, which participates in nucleophilic addition in the cellular environment 
due to the presence of α,β-unsaturated carbonyl functionality (Michael acceptor), 
able to undergo 1,4-additions with thiols. Many synthetic and naturally occurring 
Michael acceptors are known to exhibit anti-inflammatory activity via the 
inactivation of NF-κB by mediated by their interaction with cysteine residues in 
either IκB kinase (IKK) or the DNA binding domain of NF-κB. It has been shown 
that EF24 directly disrupt the catalytic activity of IkappaB kinase (IKK) which is 
essential for the phosphorylation of NF-kB inhibitory protein IkappaB. By 
inhibiting IKKβ, EF24 also reduces the phosphorylation-dependent proteasomal 
degradation of IkappaB which ultimately results in inhibition of the activation and 
nuclear translocation of NF-kB for its transcriptional activity (Vilekar et al., 2015). 
3.3.9 Characterisation of the proteins regulated by curcuminoids 
In this study, a Restriction Enzyme Mediated Insertional (REMI) mutagenesis 
screen was carried out to identify possible targets of curcumin and its derivatives 
in D. discoideum. These screens led to the identification of two gene products, 
psrA which is regualated by curcumin and Presenilin B targeted by the synthetic 
analogue EF24.  
3.3.9.1 Protein Phosphatase 2A regulatory subunit 
One of the main serine/threonine phosphatases present in cells is the protein 
phosphatase 2A (PP2A). This protein consists of a catalytic subunit (C), a 
structural subunit (A), and a regulatory/variable subunit (B). PP2A plays a pivotal 
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role in the regulation of cellular homeostasis and in particular the modulation of 
major cell signalling pathways through its phosphatase activity. Moreover, PP2A 
is involved in a wide range of cellular processes such as DNA replication, 
transcription, translation, cell cycle, development and programmed cell death 
(Magnusdottir et al., 2009; Seshacharyulu et al., 2013). PP2A is known to 
regulate the activity of more than 30 different kinases, including AKT, PKC, p70 
S6 kinase, cAMP-dependent kinases, CAM-kinases and ERK/MAP kinase. It also 
modulates a range of proteins during cell cycle progression and apoptosis, which 
include Cdc25, Cdc6, Wee 1, DNA polymerase-primase, TAU and cyclin G2 
(Seshacharyulu et al., 2013). PP2A represents 1% of total cellular proteins and 
together with PP1 accounts for >90% of all Ser/Thr phosphatase activity (Cho 
and Xu, 2007). In eukaryotes, the PP2A amino acid sequence is highly conserved 
(78-93%) amongst yeast, Drosophila and mammals (Seshacharyulu et al., 2013). 
Alterations in the PP2A holoenzyme assembly, activity and substrate specificity 
can lead to disease states and is responsible for the initiation and maintenance 
of cancer (Kiely and Kiely, 2015; Sangodkar et al., 2016).  
The core dimer of the PP2A holoenzyme consists of a 65 kDa scaffolding subunit 
(A) and a 36 kDa catalytic subunit (C). However, the full activity of the protein, 
subcellular location and substrate target are conferred by the B regulatory 
subunit, which leads to the formation of a heterotrimeric holoenzyme (Cho and 
Xu, 2007; Sangodkar et al., 2016) (Figure 9). Studies have identified 26 different 
B subunit variants in humans, which represent alternative transcript and splice 
variants encoded by 15 different genes, that allow 96 possible combinations of 
the assembled holoenzyme. Both cell and tissue types determine the expression 
levels and the variant of these subunits.  
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Figure 9. PP2A holoenzyme assembly. Core dimer of the PP2A enzime consists of a scaffolding 
subunit (A), a catalitic subunit (C) and number of different regulatory subunits (B) which determine 
tissue and cellular specificity. 
 
In addition, the PP2A holoenzyme is dynamic as it has the ability to swap B 
subunits, allowing PP2A to react rapidly to specific environmental stimuli. The 
variable regulatory B subunits are divided into four subfamilies: B-B53-PR55, B’-
B56-PR61, B’’-B72-PR72 and B’’’-PR93(SG2NA)-PR110. Amongst these 
subunits variants, the PP2A-B56 is the most studied regulatory subunit subfamily, 
with PP2A-B56α, β and ε expressed in the cytoplasm, γ1-3 isoforms in the 
nucleus and δ in both cellular compartments. PP2A also plays an essential role 
in the regulation of growth factor signalling. For instance, if cells are stimulated 
with epidermal growth factor (EGF), insulin or insulin growth factor 1 (IGF-1), this 
leads to the downregulation of the PP2A  activity and upregulation of the MAP 
kinase pathway, which results in an increased cellular proliferation. The PP2A-
B56 subunit has been implicated in the dephosphorylation of Akt (Thr308), which 
is responsible for the negative regulation of the insulin signalling pathway (Kiely 
and Kiely, 2015). 
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However, the biological function of PP2A seems to be controversial as it does not 
only behave as a tumour suppressor but has also anti-apoptotic abilities. 
Presumably, it plays its dual role by enabling both pro- and anti-apoptotic 
signalling pathways depending on the type of holoenzyme formation. An example 
is the interaction between Bcl-2 and PP2A, where PP2A can lead to apoptosis by 
dephosphorylating Bcl-2 on Ser70 in the mitochondria, and can inhibit 
programmed cell  death by dephosphorylating Bcl-2  on Ser87 in cancer cells (not 
seen in healthy tissue) (Kiely and Kiely, 2015; Van Hoof and Goris, 2003). 
Furthermore, p53, one of the major and most studied tumour suppressors, is also 
regulated by PP2A. A recent study has shown that PP2A downregulates p53 by 
dephosphorylation on Ser15 and activates AKT-1 as well as Plk-1 in glioblastoma 
models. This, in turn, increases cell proliferation which can enhance the activity 
of chemotherapeutic drugs that work by damaging DNA, leading to accumulation 
of DNA mutations and therefore genomic instability resulting in cell death (Kiely 
and Kiely, 2015). On the other hand, the inhibition of PP2A in ovarian cancer cells 
stabilises and activates the overexpressed p53, leading to cell cycle arrest and 
programmed cell death, by increasing Bax and p21 expression (Kiely and Kiely, 
2015). In addition, PP2A can modulate cancer signalling pathways such as 
PI3K/Akt, mammalian Target of Rapamycin (mTOR), Focal Adhesion Kinase 
(FAK) and Extracellular Signal-Regulated Kinase (ERK) to enable cancer growth. 
However, the exact mechanisms of action remain to be elucidated (Van Hoof and 
Goris, 2003). 
PP2A is also involved in brain neurodegeneration, where its dysfunction can lead 
to an increase in TAU hyperphosphorylation, which plays a pivotal role in the 
aetiology of Alzheimer’s disease (AD). Remarkably, PP2A mediates about 71% 
of total TAU phosphatase activity in the brain (Sontag and Sontag, 2014). 
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Moreover, studies have shown that reduction in PP2A mRNA, protein expression 
levels and phosphatase activity levels were detected in the brains of Alzheimer’s 
patients (Sangodkar et al., 2016). It has been demonstrated that in vivo 
dysregulation of PP2A leads to deregulation of a range of Ser/Thr kinases 
involved in AD, including GSK3β, cdk5, ERK and JNK. It has also been linked to 
cytoskeleton abnormalities (microtubules and neurofilaments), alteration in the 
amyloid precursor protein (APP) phosphorylation and processing, as well as 
neurogenesis impairment, alteration in synaptic plasticity and induction of 
programmed cell death (Sontag and Sontag, 2014). 
Interestingly, it has been shown that the curcumin-dependent activation of 
Mitogen-Activated Protein Kinases (MAPK) pathways is linked to the inhibition of 
the PP2A and PP5 proteins. Curcumin can induce apoptosis by activating the 
MAPKs as well as c-Jun N-terminal kinase (JNK), and ERK1/2 independently of  
p53. In fact, the inhibition of JNK (with SP600125) or ERK1/2 (with U0126), the 
downregulation of ERK1/2 or expression of dominant negative c-Jun partially 
inhibited the pro-apoptotic effects of curcumin. In addition, overexpression of 
PP2A or PP5 partially reduced the activation of JNK and Erk1/2 phosphorylation 
as well as cell death induced by curcumin (Han et al., 2012). Furthermore, a 
recent proteomics study has shown that curcumin is able to maintain PP2A 
subunit B expression levels in middle cerebral artery occlusion (MCAO) animal 
models. In particular, curcumin treatment prevented injury-induced reductions in 
PP2A subunit B levels, suggesting that curcumin mantains the levels of PP2A 
subunit B in response to cerebral ischemia, which exerts the neuroprotective 
function of curcumin in cerebral ischemic injury (Shah et al., 2015). 
Finally, D. discoideum encodes for psrA, the protein phosphatase 2A regulatory 
subunit B56 orthologue (Murphy et al., 1999). PsrA is able to regulate cell 
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differentiation by downregulating glycogen synthase kinase 3 (GSK3) function 
(Lee et al., 2008). Ablation of psrA showed an inefficient activation of multiple 
Ras species, a reduction in random cell movement and impaired chemotaxis 
toward cAMP and folic acid (Rodriguez Pino et al., 2015). In addition, psrA- cells 
exhibited elevated basal and poststimulus phosphorylation levels of protein 
kinase B (PKB) family member PKBR1 and PKB substrates. Mutants in which 
Ras is constitutively expressed or GSK3 inhibition in psrA- cells leads to 
increased activity of both PKBR1 and PKBA (Rodriguez Pino et al., 2015). 
However, under identical conditions only the PKBR1 activity was intensified in 
wild-type cells, demonstrating that B56- or GSK3-mediated suppressive 
mechanism is insufficient in preserving low PKBA activity, but both mechanisms 
are essential for the inhibition of  PKBR1. Furthermore, RasD or RasC ablation 
and GSK3 inhibition results in a normal PKBR1 modulation, indicating that RasC 
or RasD are critical factors for GSK3-mediated PKBR1 inhibition (Rodriguez Pino 
et al., 2015).  
3.3.9.2 Presenilin protein 
Alzheimer’s disease (AD) is a neurodegenerative condition, affecting around 30 
million people worldwide and accounts for 50%-75% of all cases of dementia 
(Alzheimer's Association, 2017). The disease etiopathology is characterised by 
intraneuronal neurofibrillary tangles composed of hyperphosphorylated TAU, and 
extracellular senile plaques induced by amyloid aggregation in the brain (Lakey-
Beitia et al., 2017b). These processes can lead to chronic brain inflammation of 
the microglia, astrocytes, and neurons, which lead to overexpression of pro-
inflammatory mediators, such as tumour necrosis factor- (TNF) and interleukin 
(IL)-6. Furthermore, Presenilin 1 (PS-1), a protein encoded by the PSEN1 gene 
and a component of the four core proteins in the γ-secretase complex, plays a 
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key role in generation of amyloid beta (Aβ) from Amyloid Precursor Protein (APP) 
(Giri et al., 2017; Schellenberg et al., 1992) (Figure 10). Presenilin is a protein 
with 9 transmembrane domains, possessing an extracellular C-terminus and 
a cytosolic N-terminus (Laudon et al., 2005; Spasic and Annaert, 2008). 
Presenilin is cleaved in ~27-28 kDa N-terminal and ~16-17 kDa C-terminal 
fragments in humans and is present in the cell primarily as a heterodimer of the 
C-terminal and N-terminus fragments (Thinakaran et al., 1996).  
 
Figure 10. Gamma secretase complex. The γ-secretase complex is composed of four 
components: presenilins (PS), nicastrin, anterior pharynx defective 1 (APH-1), and presenilin 
enhancer 2 (PEN-2) (Parks and Curtis). 
 
Studies have shown that the accumulation of amyloid beta is associated with the 
onset of Alzheimer's disease (Selkoe, 1994). Indeed, mutations in the PSEN1 
gene are the most common cause of familial Alzheimer’s disease (FAD) (Giri et 
al., 2017). The Presenilin 1 protein represents the catalytic subunit of the γ-
secretase complex, which is a protease that cleaves a range of type 1 
transmembrane proteins, including the APP and Notch (De Strooper et al., 2012). 
The cleavage of APP induced by γ-secretase generates β-amyloid (Aβ) peptides 
of varying lengths. The non-pathogenic form of  Aβ is represented by Aβ40 
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peptides which  account  for ∼90% of all Aβ production. However, when there is 
an aberrant Presenilin 1 function, this leads to the formation of the Aβ42 peptide, 
which is more hydrophobic and is thought to cause Aβ aggregation and plaque 
deposition in the brain of AD patients (Kelleher and Shen, 2017). It has been 
recently demonstrated that Presenilin 1  phosphorylation induces the pathogenic 
conformational shift in the living mouse brain, making these phosphorylation sites 
potential new targets for AD treatment (Maesako et al., 2017). 
Recent in vitro studies have demonstrated that curcumin inhibits amyloid-
aggregation, the activity of the enzymes β-secretase and acetylcholinesterase, 
and β-amyloid-induced inflammation (Lakey-Beitia et al., 2017b).  Moreover, 
curcumin is also able to block the production of pro-inflammatory cytokines and 
enzymes, like COX-2 and the inducible nitric oxide synthase (NOS), and 
downregulates the expression of chemokines such as the Monocyte 
Chemoattractant Protein-1 (MCP-1) and interferon-inducible protein (Lakey-
Beitia et al., 2017b). In addition, curcumin is able to inhibit amyloid 
oligomerisation, deposition, and TAU phosphorylation in Alzheimer's disease in 
in vivo animal models. In addition, in vivo studies have shown that dietary 
curcumin is able to cross the blood-brain barrier and significantly decrease 
amyloid deposition and plaque burden in AD transgenic mice, as well as 
preventing TAU phosphorylation. It is also capable of reducing inflammation and 
oxidative damage as well as decreasing genomic instability events (Zhang et al., 
2010; Zheng et al., 2017).  Curcumin also inhibits amyloid formation by blocking 
β-secretase (BACE-1) and glycogen synthase kinase-3β-(GSK-3β)-mediated 
phosphorylation of Presenilin 1 and -secretase proteolytic activity (Di Martino et 
al., 2016; Xiong et al., 2011). 
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Presenilin and other -secretase components are evolutionary conserved. 
Interestingly, highly diverged orthologs for each -secretase component have 
been identified in D. discoideum, but the amoeba  does not possess APP, Notch 
and other characterised PS/-secretase substrates (McMains et al., 2010). It has 
also been shown that D. discoideum can process human APP to generate 
amyloid- peptides A40 and A42, and the ablation of -secretase inhibits the 
production of A peptides, leading to the accumulation of APP intermediates 
(McMains et al., 2010). Furthermore, PS is essential for D. discoideum 
phagocytosis and cell-fate. The ablation of presenilins leads to the inhibition of D. 
discoideum development, and this phenotype is rescued by the expression of 
human Presenilin 1. This role is not linked to its proteolytic activity because the 
mutation of both catalytic aspartates does not influence presenilin ability to rescue 
development, as well the ablation of nicastrin, crucial for proteolytic activity, does 
not inhibit cell development (Ludtmann et al., 2014; McMains et al., 2010; 
Smolarkiewicz et al., 2013). These results suggest that presenilin proteins and 
the -secretase complex have roles independent to Notch and form a highly 
conserved process that emerged prior to metazoan radiation, making  D. 
discoideum a potential model system for the investigation of specific pathways 
involved in AD (Ludtmann et al., 2014; McMains et al., 2010). 
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3.3.10 Curcumin and derivatives function through protein phosphatase 2A 
and presenilin orthologues in Dictyostelium discoideum 
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Curcumin and derivatives function through protein phosphatase
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Marco Cocorocchio1, Amy J. Baldwin2, Balint Stewart3, Lou Kim4, Adrian J. Harwood2,
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ABSTRACT
Natural compounds often have complex molecular structures and
unknownmolecular targets. These characteristics make them difficult
to analyse using a classical pharmacological approach. Curcumin,
the main curcuminoid of turmeric, is a complex molecule possessing
wide-ranging biological activities, cellular mechanisms and roles
in potential therapeutic treatment, including Alzheimer’s disease
and cancer. Here, we investigate the physiological effects and
molecular targets of curcumin in Dictyostelium discoideum. We show
that curcumin exerts acute effects on cell behaviour, reduces cell
growth and slows multicellular development. We employed a range of
structurally related compounds to show the distinct role of different
structural groups in curcumin’s effects on cell behaviour, growth
and development, highlighting active moieties in cell function, and
showing that these cellular effects are unrelated to the well-known
antioxidant activity of curcumin. Molecular mechanisms underlying
the effect of curcumin and one synthetic analogue (EF24) were
then investigated to identify a curcumin-resistant mutant lacking the
protein phosphatase 2A regulatory subunit (PsrA) and an EF24-
resistant mutant lacking the presenilin 1 orthologue (PsenB). Using in
silico docking analysis, we then showed that curcumin might function
through direct binding to a key regulatory region of PsrA. These
findings reveal novel cellular and molecular mechanisms for the
function of curcumin and related compounds.
KEY WORDS: Dictyostelium discoideum, Curcumin, Presenilin,
PP2A, Cancer, Alzheimer’s disease
INTRODUCTION
Natural products obtained from plants have been used for thousands
of years as medicines (Butler, 2004; Newman and Cragg, 2007;
Gurib-Fakim, 2006). However, the active compound(s) often have
complicated pharmacology, with multiple cellular targets and effects,
making traditional pharmacological approaches insufficient to
understand their biological activity. These factors preclude standard
approaches to investigate mechanism(s) of action.
Curcumin (diferuloylmethane) is a flavonoid derived from
turmeric, and provides a good example of a natural product with
potential therapeutic activity (Aggarwal and Harikumar, 2009;
Ghosh et al., 2015). Currently, ∼120 clinical trials have sought to
demonstrate its efficacy in the treatment of various diseases (Gupta
et al., 2013), yet an analysis published in 2017 reported that only
17 trials have shown positive outcomes (Heger, 2017). To improve
our understanding of this compound, it is crucial to identify
potential therapeutic targets, and to test related compounds that have
improved chemical characteristics (e.g. solubility) (Oliveira et al.,
2015) that can focus research on relevant therapeutic outcomes.
Curcumin has diverse cellular effects, including the modulation of
transcription and growth factors regulating cell growth and cell
death, and as an anti- or pro-oxidant (Goel et al., 2008; Prasad et al.,
2014; Priyadarsini, 2014; Gupta et al., 2012, 2013; Zhou et al.,
2011). Curcumin has also been extensively investigated for the
treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD),
multiple sclerosis (MS), cardiovascular diseases, cancer, allergy,
asthma, rheumatoid arthritis, diabetes and inflammation (Yang
et al., 2017; Lakey-Beitia et al., 2017; Jurenka, 2009; Srinivasan,
1972; Chougala et al., 2012; Zhang et al., 2013; Tang and
Taghibiglou, 2017; McClure et al., 2017).
The main limitations of the therapeutic use of curcumin are its
poor bioavailability and limited understanding of the cellular effects
in relation to its molecular structure (Gupta et al., 2013). Its structure
consists of two aromatic rings containing o-methoxy phenolic
groups, with a seven-carbon linker consisting of an α,β-unsaturated
β-diketone (Priyadarsini, 2014; Ruby et al., 1995; Selvam et al.,
1995). Thus, modification of these groups, and analysis of distinct
cellular effects and targets, could help with understanding the
potential use of curcumin and its derivatives in medicinal roles.
Dictyostelium discoideum has been used as a tractable model
system for the analysis of compounds with potential therapeutic
function. It is a eukaryote, with a unique lifecycle including single-
celled and multicellular stages, and contains a range of orthologues
to disease-linked proteins (Müller-Taubenberger et al., 2013). It has
also been used to investigate the molecular actions of structurally
and pharmacologically diverse compounds from bitter tastants
(Cocorocchio et al., 2015; Robery et al., 2011, 2013), to flavonoids
(Waheed et al., 2014), to drugs used in the treatment of bipolar
disorder (Williams et al., 1999, 2002) and epilepsy (Chang et al.,
2012; Xu et al., 2007; Elphick et al., 2012; Boeckeler et al., 2006).
Several of these studies have been successfully translated to in vitro
and in vivo animal models (Chang et al., 2015, 2016; Chang et al.,
2013, 2014). InD. discoideum, distinct cellular processes, including
growth, acute cell behaviour and development provide valuable
tools for the analysis of compound function. Numerous studies
usingD. discoideum have employed chemical genetic approaches toReceived 4 October 2017; Accepted 28 November 2017
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identify genes controlling the cellular effects of compounds through
screening mutant libraries to identify potential molecular mechanisms
of compounds (Williams et al., 1999, 2002; Waheed et al., 2014;
Robery et al., 2013). Several recent papers have also developed an
approach to monitor the acute effects of compounds by measuring
changes in cell behaviour (Cocorocchio et al., 2015; Robery et al.,
2011). D. discoideum is also widely used as a model to investigate
development, where cells during starvation aggregate and differentiate
to form multicellular fruiting bodies (Marée and Hogeweg, 2001).
Thus, using D. discoideum provides an advantageous system to
analyse the cellular andmolecular effects of complex natural products.
In this study, we employ D. discoideum to investigate the cellular
and molecular targets of curcumin, for which previous studies have
demonstrated sensitivity (Garige and Walters, 2015; Swatson et al.,
2017). We initially corroborated the effects of curcumin on cell
growth and development and further showed an effect on acute cell
behaviour (Garige and Walters, 2015; Swatson et al., 2017). To
differentiate these cellular effects andmechanisms,we then employed
a range of complex natural and synthetic curcumin derivatives to
highlight key functional groups of curcumin and differentiate these
effects from antioxidant activity. A chemical genetic approach was
then used to investigate the molecular targets of curcumin and a
synthetic derivative. From this approach, two proteins were
identified – the protein phosphatase 2A regulatory subunit PsrA
(Lee et al., 2008), associated with cancer onset (Kiely and Kiely,
2015), and the presenilin 1 orthologue PsenB (Ludtmann et al., 2014),
implicated in AD (De Strooper and Annaert, 2010) – which partially
control the effects of these compounds. In silico modelling of
curcumin binding siteswas thenused topredict a binding site onPsrA.
RESULTS
Curcumin shows distinct effects on acute cell behaviour,
growth and development in D. discoideum
To investigate the cellular effects of curcumin onD. discoideum, we
initially assessed acute cell behaviour changes following compound
exposure (Fig. 1). In these experiments, rapid cell movement was
induced through starvation in the presence of pulsatile cyclic AMP
(cAMP), leading to the expression of a discrete set of genes
(Santhanam et al., 2015). Cell behaviour was recorded using time-
lapse microscopy for a period of 15 min including pre- (5 min) and
post- (10 min) curcumin addition and computer-aided cell tracking
was used to analyse changes in membrane protrusions, normalised
to average protrusions pretreatment (Fig. 1B). From this analysis,
acute cell behaviour was unaffected at concentrations ≤2 µM
but showed a concentration-dependent reduction at increasing
concentrations, with a complete block at 3 µM (****P<0.0001;
Fig. 1B). By plotting average cell behaviour following treatment
against curcumin concentration, a nonlinear regression analysis was
used to calculate an IC50 for the effect of curcumin on acute cell
behaviour as 2.3 µM [95% confidence interval (CI) 2.0-2.6 µM]
(Fig. 1C). These data show an acute effect of curcumin on cell
behaviour in D. discoideum, suggesting the presence of rapidly
modified target(s) involved in cellular behaviour.
We then examined the effect of curcumin treatment on D.
discoideum cell growth. In these assays, growth was assessed in the
presence of increasing concentrations of curcumin over 7 days at
concentrations ranging from 0 to 100 µM (Fig. 1D). By plotting the
rate of exponential growth at each concentration, an IC50 value was
calculated by nonlinear regression curve fitting. Curcumin
completely blocked cell growth at 100 µM with an IC50 of 45.7 µM
(95% CI 41.7-50 µM) (Fig. 1E). These data indicate an effect of
curcumin on D. discoideum cell growth, suggesting cellular target(s)
for the flavonoid involved in this process.
Furthermore, the role of curcumin in regulating multicellular
development was also assessed. When D. discoideum are starved,
this causes cells to aggregate and differentiate to ultimately form
multicellular fruiting bodies over 24 h. The resulting fruiting body
consists of a spore head, containing dormant spores held above
the substratum by dead, vacuolated stalk cells (Williams et al.,
2006). In this process, a further subset of proteins, partially distinct
from those of growth and early development, are employed to
enable development. In these experiments, cells were plated onto
nutrient-deficient solid media, in the absence or presence of
curcumin, at a concentration shown above to block growth, and
Fig. 1. Acute cell behaviour, growth and developmental effects of curcumin on D. discoideum. (A) Curcumin, a diferuloylmethane, was used to assess
multiple roles usingD. discoideum as amodel. (B) Time-dependent changes inD. discoideum cell behaviour (membrane protrusion) were recorded over a 15-min
period (±s.e.m.) at increasing concentrations of curcumin. Data are presented normalised to control conditions, showing a significant difference between
control condition (vehicle) and 3 µM (****P<0.0001) using one-way ANOVA. (C) The concentration-dependent response is illustrated as the normalised reduction
of cell behaviour (protrusion formation) against the Log (concentration) of curcumin, enabling calculation of an IC50 with a 95% CI. (D) D. discoideum cells
were grown with increasing concentration of curcumin, causing a complete block at 100 µM, with (E) normalised concentration-dependent response shown
plotted against Log curcumin (mM) concentration, providing an IC50 with 95% CI. (F) Cells were developed on agar over 22 h in control conditions
(vehicle) and in the presence of 100 µM curcumin. Scale bar: 0.25 mm for both side view images. All experiments were carried out in triplicate.
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fruiting body structure was recorded after 24 h. In the absence of
curcumin, a field of fruiting bodies was formed, with individual
fruiting bodies consisting of spore heads elevated by stalks
(Fig. 1F). In the presence of curcumin (100 µM), cells were able
to form a reduced number of aggregates and were unable to develop
into mature fruiting bodies (Fig. 1F). This suggests an effect of
curcumin on D. discoideum late development, regulating cellular
target(s) involved in differentiation.
Identifying active moieties in curcumin responsible for
distinct effects on acute cell behaviour, growth and
development
To improve our understanding of the distinct effects of curcumin in
D. discoideum, we employed a range of compounds structurally
related to curcumin (both natural and synthetic) to identify structural
components of the curcumin molecule that are necessary for distinct
effects (Fig. 2A). Analysis of the curcumin-related compounds on
acute cell behaviour was carried out as described earlier, with cell
behaviour recorded prior to and following the addition of each
compound, with data describing a loss of membrane protrusions
postaddition (Fig. S1). Secondary plots illustrated dose-dependent
effects and provided an IC50 value specific to each compound
(Fig. S2). From this approach (Fig. 2B), modulation of the phenolic
groups through loss of one (demethoxycurcumin; DMC), or both
(bisdemethoxycurcumin; BDMC), methoxy groups caused a step-
wise reduction in potency in controlling acute cell behaviour (3.5-
and 14-fold change, respectively). Similarly, a major metabolite of
curcumin, tetrahydrocucrumin (THC), lacking the α,β-unsaturated
carbonyl moiety on the seven-carbon linker, leading to loss of
the planar structure of the compound, also showed a reduced potency
(5-fold change). In addition, loss of the diketone group through
formation of the pyrazolic ring (Jadhav et al., 2015) eliminated
the effect on acute cell behaviour. Furthermore, FLLL31 (Yuan et al.,
2014), which has two hydrogens on the central carbon replaced by
methyl groups, and two extra methoxy groups, also showed a
reduction in potency (5-fold). Lastly, two structurally distinct
compounds, EF24 and UBS109, were investigated, with both
compounds considered to be curcumin derivatives (Vilekar et al.,
2015; Yamaguchi et al., 2014), where EF24 showed enhanced
activity (1.8-fold), and UBS109 showed reduced activity (11-fold),
in this model. These data suggest that the diketonemoiety is essential
for triggering curcumin-dependent inhibition of cell behaviour, and
that the presence of the methoxy groups and planar nature of the
molecule (lost in THC), and numerous changes to the basic flavonoid
chemical composition in the structurally distinct compounds,
provided opposite cellular effects on acute cell behaviour.
The assessment of curcumin derivatives on D. discoideum cell
growth provided insight into chemical moieties of curcumin
necessary for this effect. Analysis was carried out as described
earlier, with cell growth recorded over 144 h (Fig. S3), and
secondary plots illustrating dose-dependent effects and providing
IC50 values specific to each compound (Fig. S4). For this cellular
effect (Fig. 2C), modulation of the phenolic groups through loss of
one or both methoxy groups (DMC and BDMC), caused a step-wise
increase in potency in controlling growth (2.5- and 14-fold change,
respectively). Loss of the planar nature of the compound (THC) also
increased potency (1.8-fold change), and the addition of two methyl
and methoxy groups in the synthetic analogue FLLL31 increased
potency (1.5-fold). Loss of the diketone group through the formation
of the pyrazole ring (CuPy) eliminated the effect on acute cell
behaviour (and growth). Both structurally distinct compounds, EF24
andUBS109, showed a significant increase (14- and 26-fold change,
respectively) in potency in this model. These data suggest that the
diketone moiety is essential, and that the phenolic groups play key
roles in curcumin activity in regulating cell growth.
Development assays were also carried out to determine which
structural components of curcumin control potency in delaying
multicellular development in D. discoideum. Here, cells were again
plated on non-nutrient agar containing curcumin derivatives at
concentrations that block growth, and allowed to develop over 24 h,
after which fruiting body morphology was recorded (Fig. 2D). In
these studies, loss of one or both methoxy groups (DMC and
BDMC), loss of the planar structure of the compound (THC), or
substitution of the central hydrogens caused delayed and aberrant
fruiting body morphology (FLLL31). By contrast, loss of the
diketone group through the formation of the pyrazole ring (CuPy)
eliminated the developmental effect, and no effect was seen for both
divergent structures (UBS109 and EF24). These data suggest that
the key moiety of curcumin involved in developmental regulation is
the central diketone group.
Analysis of antioxidant activity of curcumin-related
compounds
Because curcumin has been widely proposed to function as an
antioxidant (Sandur et al., 2007; Gordon et al., 2015), reducing free
radicals, we then assessed this activity for curcumin and related
compounds. Here, we employed the ferric-reducing ability of
plasma (FRAP) assay, monitoring rapid (0 min) and extended
(60 min) antioxidant function (Fig. 3). The strong antioxidant,
ascorbic acid was used as a control. Of the curcumin-related
compounds, THC provided the strongest rapid antioxidant activity,
with CuPy also providing an immediate strong effect. Curcumin
demonstrated time-dependent antioxidant activity, increasing over
the experimental period. Loss of one or two methoxy groups
reduced this effect (DMC and BDMC), and the addition of two
methoxy groups plus two methyl groups (FLLL31), and
modification of the β-diketone moiety or major structural change
(EF24 and UBS109), eliminated antioxidant activity (Fig. 3).
Identification of the molecular targets of curcumin and
analogues using a chemical genetic approach
To investigate distinct molecular targets and mechanisms for these
compounds, we employed a mutant screen using curcumin and
related compounds (Table 1). In these experiments, a library of
D. discoideum insertional mutants was grown at a concentration of
each compound giving an 80-90% reduction in growth over 21 days.
Using this approach, a mutant was isolated, showing resistance
to curcumin, with the mutagenic cassette inserted into the open
reading frame of the protein phosphatase 2A regulatory subunit
gene (psrA; DDB_G0280469) (Rodriguez Pino et al., 2015)
(Fig. 4A). In addition, a mutant was isolated showing resistance
to EF24, with the mutagenic cassette inserted immediately
downstream of the start codon of presenilin B (DDB_G0292310)
(Ludtmann et al., 2014) (Fig. 4A). To confirm that the encoded
proteins regulate sensitivity to the compounds, recapitulated
mutants were used to assess the rate of exponential growth for
each mutant in the presence of the screening compound and a range
of related structures over 24 h (Fig. 4B,C; Figs S5 and S6). In the
presence of curcumin, psrA− showed significant resistance
compared to wild-type cells (P<0.001), in addition to resistance to
EF24 and DMC (P<0.05) (Fig. 4B). Similarly, in the presence of
EF24, psenB− showed significant resistance compared to wild-type
cells (P<0.01), in addition to resistance to UBS109 (P<0.01), but
not curcumin or BDMC (Fig. 4C).
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Because curcumin and EF24 showed effects on both growth and
cell behaviour, we also assessed the resistance of psrA− and psenB−
to the cell behaviour effects of compounds. In these assays, both
mutants were not resistant to curcumin and related compounds
(EF24 and DMC) (Fig. S7). These data highlight the distinct
mechanisms underlying the effects of curcumin and related
compounds on growth and acute cell behaviour.
Ligand-protein docking prediction of curcumin with PsrA
Molecular docking analysis was used to propose an interaction site
for curcumin on PsrA. Here, a tertiary structure of the protein was
based upon the mammalian orthologue, PP2A. This tertiary
structure was then used to calculate the most stable binding site of
curcumin and related compounds, showing the lowest energetic
expenditure. This approach identified a common site, on the
interface between the regulatory subunit B and the scaffold subunit
A (based on crystallography studies of the human PP2A enzyme)
(Cho and Xu, 2007) of the protein, which is predicted to
bind to curcumin (deltaG −7.39), EF24 (deltaG −7.23) and DMC
(deltaG −7.54), but is not targeted by CuPy (deltaG −6.62) (Fig. 5),
consistent with the resistance phenotype shown by the psrA−
mutant.
DISCUSSION
Improving our understanding of the potential therapeutic roles of
curcumin (Heger, 2017; Gupta et al., 2013) might facilitate its use in
medicine. To do this, it is critically important to identify potential
therapeutic targets, and to test related compounds that have improved
Fig. 2. Quantification of the acute cell behaviour, growth and developmental effects of curcumin derivatives on D. discoideum. (A) Structure of natural
and artificial derivatives used in a quantitative structural analysis of curcumin effects inD. discoideum. (B) Concentration-dependent responses were determined
for cell behaviour (protrusion formation) and illustrated as the IC50 for each compound with errors shown as 95% CIs (Figs. S1 and S2). (C) Concentration-
dependent responseswere determined for cell growth and illustrated as the IC50 for each compoundwith errors shown as 95%CIs (Figs. 3 and 4). Data fromB and
C are presented as mean±s.e.m. of triplicate experiments. (D) Cells were developed on agar over 22 h in the absence of compounds (vehicle only), or the
presence of curcumin derivatives at concentrations shown to block growth (100 µM FLLL31, 25 µMDMC, 20 µM BDMC, 100 µM THC, 6 µM EF24, 5 µMUBS109
and 100 µM CuPy). All images are representative of triplicate experiments. Scale bar: 0.25 mm for all side view images.
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chemical characteristics (e.g. solubility) (Oliveira et al., 2015) that can
focus research on relevant therapeutic outcomes. The present study
employed a novel system, the social amoeba D. discoideum, which
enables the dissection of discrete acute, growth and developmental
effects of curcumin. Utilising curcumin-related structures identified
key chemical moieties responsible for the effects of curcumin, and
eliminated an antioxidant mechanism for these effects. The study then
identified two novel targets related to disease conditions that might aid
in the investigation of its role in therapeutic function.
In this study, we initially quantified the potency of curcumin
to regulate distinct aspects of acute cell behaviour, growth and
development inD. discoideum. We show that curcumin provides the
strongest inhibitory effect against acute cell behaviour (with an IC50
of 2.3 µM), with reduced potency against cell growth (with an IC50
of 44 µM) and development (>100 µM) (Fig. 1). These effects
support and extend a previous study (Garige and Walters, 2015),
and provide a platform for a comparative study of related chemicals.
From these combined data, it is likely that curcumin has more than
one molecular target in D. discoideum that play distinct cellular
roles.
We then adopted a quantitative structure activity relationship
approach (QSAR), employing a range of natural and artificial
curcumin-related compounds to assess common and distinct cellular
effects dependent upon the specific chemistry of the compound
(Fig. 2). These studies showed that loss of the diketone group
(in CuPy) blocked activity in all three functional roles (acute
cell behaviour, growth and development), and modification by
substitution of central hydrogens (FLLL31) reduced activity (in
acute cell behaviour and growth), highlighting the key role of this
group in curcumin function. For the remaining compounds, in acute
cell behaviour, curcumin and EF24 showed the most potent activity,
with any change in curcumin structure leading to a reduction of
activity. By contrast, effects of curcumin-related compounds on
growth showed that curcumin is the least potent of all compounds
analysed. In development, a common delay was seen for the
structures most related to curcumin, with no effect from the
divergent artificial analogues (EF24 and UBS109). Independent of
the central role of the diketone group, the remaining curcumin-
related structures analysed here identified key regions of the
chemical structure associated with distinct cell effects. In acute cell
behaviour, the most important moieties were represented by the
methoxy groups and the planar structure adjacent to the diketone
groups, where loss of one or two methoxy groups (DMC and
BDMC) strongly and incrementally reduced potency, and loss of the
central double bonds (in THC) also reduced potency. However, the
two synthetic analogues have a variable potency in blocking cell
behaviour. A similar trend is present in growth inhibition, but
reversed, where the same molecular substitutions that reduced
potency in acute cell behaviour enhanced potency in growth.
Interestingly, curcumin and its closely related analogues delayed
development, but this was not evident for the synthetic analogues.
These data support that curcumin has distinct targets related to acute
cell behaviour, growth and development.
Many of the cellular roles for curcumin have been associated with
the scavenging of reactive oxygen species (ROS) as an antioxidant.
Through the mechanism, antioxidants quench free radicals to inhibit
cellular damage (Nimse and Pal, 2015). In this role, specific
Table 1. Genes encoding putative targets for curcumin and related compound
Chemical Gene ID Gene Product Orthologues Identity
Curcumin DDB_G0281669 LMBR1 family protein Q68DH5 27%
DDB_G0280469 Protein phosphatase 2A regulatory subunit psrA Q15172 46%
DDB_G0293904 NADPH-cytochrome-P450 oxidoreductase ENSP00000393527 33%
DDB_G0288103 Type A von Willebrand factor (VWFA) domain-containing protein
BDMC DDB_G0267524 Translocon-associated protein TRAP gamma subunit Q9UNL2 33%
DDB_G0289907 EGF-like domain-containing protein C-type lectin domain-containing protein
DDB_G0291722 UNC93-like protein MFSD11 O43934-1 31%
DDB_G0272684 Dihydropteridine reductase P09417 41%
EF24 DDB_G0276169 AAA ATPase domain-containing protein Q8NBU5-1 39%
DDB_G0292310 Presenilin B P49768-1 32%
DDB_G0279417 LRRK family protein kinase Roco6
UBS109 DDB_G0287861 Glycine cleavage system H-protein P23434 25%
Insertions in 11 genes that were found to convey resistance to curcumin, BDMC, EF24 and UBS109. For each insertion, Dictybase gene ID, product, orthologues
and % identity to human protein have been indicated.
Fig. 3. Antioxidant activity of curcumin and related structures. Reducing
activity was monitored using the FRAP assay. Initial rapid (0 min) and
sustained (60 min) activity was measured, using ascorbic acid as an
antioxidant standard. Data are presented as mean±s.e.m. of triplicate
experiments.
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regions within the curcumin structure (the diketone moiety and two
phenolic groups) can undergo oxidation by electron transfer and
hydrogen abstraction (Priyadarsini, 2014), and the methoxy groups
of curcumin are necessary for antioxidant effects in a range of
models (Yang et al., 2017). To investigate whether the effects of
curcumin and related compounds on D. discoideum were related to
this effect, a time-dependent assay was used to assess antioxidant
activity (Fig. 6). Surprisingly, THC and CuPy provided the largest
rapid-onset activity, with both these compounds and curcumin
providing strong activity over an extended period. The remaining
compounds showed greatly reduced or no significant antioxidant
function, consistent with a crucial role for the diketone and methoxy
groups in antioxidant function, but not supporting this effect in
the modulation of D. discoideum acute cell behaviour, growth or
development roles. Similar outcomes for curcumin and its
derivatives, shown in anti-inflammatory and antiproliferative
Fig. 4. Loss of psrA and psenB genes provides partial growth resistance to curcumin or its derivatives. (A) Through screening a D. discoideum mutant
library, amutant showing resistance to curcuminwas identified showing an insertion into the protein phosphatase 2A regulatory subunit gene (psrA), and amutant
showing resistance to EF24 was identified showing an insertion into the presenilin B gene (psenB) (blue exons and black introns). (B) Analysis of wild-type (Ax3)
and recapitulated psrA− mutant growth rate confirmed that the psrA− mutant was resistant to curcumin, and additionally to EF24 and DMC, but not BDMC
(Fig. S5). (C) Analysis of wild-type (Ax2) and recapitulated psenB− mutant growth rate showed that PsenB was not resistant to curcumin, but showed confirmed
resistance to EF24, in addition to UBS109 (Fig. S6). Data are presented as mean±s.e.m. of triplicate experiments. *P<0.05; **P<0.01; ***P<0.001;
ns, nonsignificant.
Fig. 5. Molecular docking prediction of PsrA and
curcumin analogues. Tertiary protein structures were
generated with Phyre2, with docking prediction performed
by SwissDock to provide the most stable binding site
(deltaG; Gibbs free energy). Using this approach,
curcumin, DMC and EF24 are predicted to bind to the
same site on PsrA that is not shown for CuPy.
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effects of human-derived cancer cell lines also did not relate to their
ability to modulate ROS (Sandur et al., 2007). Thus, in our study, we
have shown that the antioxidant properties of curcumin and its
derivatives are not related to the cellular effects in D. discoideum
observed here, and these effects are therefore likely to occur through
other mechanisms.
Studies in animal models or animal-derived cells provide
an insight into the potential of natural products as therapies in
humans. However, limiting research to these models precludes
a range of experiments that could provide important step changes
in investigating molecular mechanisms. For example, in D.
discoideum, a range of novel targets for therapies and natural
products have been proposed by using a chemical biology approach
(Cocorocchio et al., 2015; Robery et al., 2011, 2013; Waheed et al.,
2014; Williams et al., 1999, 2002; Chang et al., 2012; Xu et al.,
2007; Elphick et al., 2012; Boeckeler et al., 2006). To apply this
approach to curcumin and its derivatives, we identify one gene
product, PsrA, regulating the function of curcumin, and a second
gene product, presenilin B, regulating the function of the synthetic
analogue EF24.
The D. discoideum psrA gene encodes the orthologue of the
mammalian protein phosphatase 2A (PP2A) regulatory subunit B56
(PPP2R5A). In D. discoideum, this protein has been shown to
regulate cell chemotaxis and differentiation by negatively modulating
glycogen synthase kinase 3 (GSK3) protein function (Rodriguez
Pino et al., 2015; Lee et al., 2008). PP2A is a major Ser/Thr
phosphatase expressed ubiquitously in eukaryotic cells. It is a
heterotrimeric enzyme, consisting of a core dimer formed by the
scaffolding subunit (A) and a catalytic subunit (C) (Sangodkar
et al., 2016). The dimer complexes with one of the several
regulatory subunits. In fact, there are >80 different combinations
of the PP2A holoenzyme, which regulates the activity and cellular
localization of PP2A (Magnusdottir et al., 2009). PP2A regulates
a wide variety of cellular processes, including translation,
transcription, inflammation, differentiation and apoptosis (Van
Hoof and Goris, 2003; Codreanu et al., 2006). PP2A plays a pivotal
role in numerous cellular processes, such as cell proliferation, signal
transduction and apoptosis, and its deregulation is associated with
multiple cancers, AD and increased susceptibility to pathogen
infections (Cho and Xu, 2007). It has been shown that in many
cancers, there is an abnormal function of the PP2A scaffold and
regulatory subunits, supporting its role as a tumour suppressor
(Seshacharyulu et al., 2013; Van Hoof and Goris, 2003). In cancer
treatment, data are conflicting; patients with a range of cancers
improve upon restoring PP2A activity (Kiely and Kiely, 2015), but,
conversely, inhibition of PP2A also leads to programmed cell death
in many tumour cells. Interest in curcumin as an anticancer
treatment is due to a large number of in vitro and in vivo studies
reporting growth arrest of different types of cancer, such as brain,
breast, head and neck, liver, pancreas, colon, prostate, ovary and
skin cancers (Anand et al., 2008; Kunnumakkara et al., 2008; Ghosh
et al., 2015; Klinger andMittal, 2016; DiMartino et al., 2017; Panda
et al., 2017; Singh and Aggarwal, 1995; Bharti et al., 2003). In
addition, curcumin has been demonstrated to exert neuroprotective
effects by maintaining the levels of PP2A subunit B, leading to
tau protein dephosphorylation and/or GSK3β inhibition, which
prevents tau hyperphosphorylation (Shah et al., 2015; Sontag and
Sontag, 2014; Di Martino et al., 2016).
In our study, we demonstrate that loss of PsrA markedly reduces
growth sensitivity to curcumin, EF24 and DMC, suggesting that
these compounds might function to regulate cellular activity
through this protein. We further propose a potential direct binding
of these compounds to PsrA through molecular docking analysis,
in which these molecules bind to PsrA but related (inactive)
compounds do not. Interestingly, the region of interaction identified
in this approach is responsible for interaction with the scaffolding
subunit, which might regulate this function. Thus, binding of
curcumin and derivatives to the PP2A core regulatory dimer might
influence the rate or specificity of binding to the scaffolding subunit
and subsequent cellular function. Therefore, this approach has
provided a novel insight into a mechanism of curcumin in regulating
PP2A activity, with potential impact on therapeutic use.
The D. discoideum presenilin B gene encodes one of two
presenilin proteins, as part of the γ-secretase complex (Ludtmann
et al., 2014). Recent results in D. discoideum have shown that
presenilin proteins play a conserved noncatalytic role which is
independent of proteolytic activity (Otto et al., 2016b). This activity
is conserved between human and D. discoideum proteins, because
the expression of human presenilin 1 in D. discoideum restores
γ-secretase complex function (Ludtmann et al., 2014). In addition, it
has been demonstrated that D. discoideum presenilin/γ-secretase
activity is required for both phagocytosis and cell-fate determination.
Thus, presenilin function and γ-secretase activity are ancient
processes that arose prior to metazoan divergence (McMains
et al., 2010). The human presenilin 1 (PS1) protein, as a key
component of the γ-secretase complex, plays a pivotal role in
amyloid precursor protein (APP) cleavage to generate Aβ, where
aggregates of Aβ provide a hallmark of AD pathology. In addition,
PS1 is a substrate for GSK3β, which is also involved in the
pathology of AD (Otto et al., 2016b). Curcumin has been proposed
to decrease Aβ production by inhibiting GSK3β-mediated PS1
activation (Zhang et al., 2010; Di Martino et al., 2016), and
curcumin downregulates presenilin 1 protein in a dose-dependent
manner to regulate γ-secretase function (Yoshida et al., 2011). As a
result, curcumin might have neuroprotective effects by inhibiting
the generation of Aβ and tau fibrils, but the mechanisms of action
remain unknown. In AD, animal models have shown that curcumin
reduces amyloid levels and protein oxidisation, which are involved
in the cognitive decline process (Baum and Ng, 2004). Furthermore,
in patients with AD, macrophages unable to phagocytose Aβ show
restored/enhanced activity following curcumin treatment (Zhang
et al., 2006). Our study identified and validated a mutant lacking the
presenilin B (PS1 homologue) resistant to curcumin-related EF24
and UBS109, and these compounds could provide interesting
analogues for further study in the treatment of AD.
Numerous targets and effects have been proposed for curcumin
that have led to its investigation for the treatment of several diseases.
Targets include transcription and growth factors, cytokines, and
regulators of cell growth and death (Goel et al., 2008). Furthermore,
curcumin interacts with P-glycoprotein, glutathione, protein kinase
C (PKC; PRKC proteins), ATPase, nuclear factor-κB (NFKB1),
epidermal growth factor receptor (EGFR), phosphatidylinositol 3
kinase (PI3K; PIK3CA), AKT proteins, mTOR and many other
cellular targets (Goel et al., 2008; Prasad et al., 2014; Priyadarsini,
2014; Gupta et al., 2012, 2013; Zhou et al., 2011). In addition,
several studies have examined the heptadienedione moiety, which
possesses two thiol-reactive α,β-unsaturated carbonyl groups (Fuchs
et al., 2009; Ou et al., 2013), that might function to covalently
modify cysteine residues of target proteins to regulate cellular
functions. These results have stimulated many studies to investigate
these targets and effects in a wide range of chronic illnesses such as
AD, PD, MS, cardiovascular diseases, cancer, allergy, asthma,
rheumatoid arthritis, diabetes and inflammation (Yang et al., 2017;
Lakey-Beitia et al., 2017; Jurenka, 2009; Srinivasan, 1972;
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Chougala et al., 2012; Zhang et al., 2013; Tang and Taghibiglou,
2017; McClure et al., 2017). It remains to be examined if the targets
identified in this paper function as upstream modulators or
downstream effectors for these curcumin-regulated effects.
In this study, we demonstrated the use of a chemical biology
approach to highlight active moieties of curcumin with cellular
function using the model system D. discoideum. Based upon
identified effects, we further employed a chemical genetic approach
to identify two possible molecular targets for curcumin and its
derivatives, which have been associated with the pathogenesis of
cancer and AD in animal models and patients. The study therefore
proposes curcumin-related compounds with improved chemical
characteristics, which might provide beneficial therapeutic approaches
for treating a range of diseases that have been proposed to be curcumin
responsive. This approach also highlights a useful model to investigate
natural products with multiple cellular effects, and could aid in the
development of new therapeutics related to natural products.
MATERIALS AND METHODS
Chemicals
The following chemicals were obtained from Sigma-Aldrich (Dorset, UK):
curcumin [(E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione;C1386], demethoxycurcumin [(E,E)-1-(4-hydroxy-3-methoxyphenyl)-7-
(4-hydroxyphenyl)-1,6-heptadiene-3,5-dione; D7696], bisdemethoxycurcumin
[(1E,6E)-1,7-bis(4-hydroxyphenyl)hepta-1,6-diene-3,5-dione; B6938],
EF-24 {(3E,5E)-3,5-bis[(2-fluorophenyl)methylene]-4-piperidinone; E8409},
FLLL31 [(E,E)-1,7-bis(3,4-dimethoxyphenyl)-4,4-dimethyl-1,6-heptadiene-
3,5-dione; F9057], tetrahydrocurcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-
3,5-heptanedione; 50202], adenosine 3′,5′-cyclic monophosphate (3′,5′-cyclic
AMP; A9501, 200 mM stock solution). Curcumin pyrazole {(E)-3,5-bis[β-(4-
hydroxy-3-methoxyphenyl)-ethenyl]-1H-pyrazole; SL-318} was obtained from
Syninnova. Enaminestore supplied UBS109 [3,5-bis(2-pyridinylmethylidene)-
1-methyl-4-piperidone; Z46034963]. All compounds were dissolved in
dimethylsulfoxide (DMSO, vehicle).
D. discoideum growth assay
D. discoideum cells were harvested and diluted in axenic medium to 2×104
cells/ml. Aliquots of cells (500 µl) were transferred to 24-well plates
containing consistent concentrations of solvent (DMSO) in addition to
indicated compounds. Cells were grown in 24-well plates, at 22°C, and cell
density calculated over 7 days. To provide secondary plots, a rate of
exponential growth was calculated (from 72 h to 120 h) at each
concentration, and normalised to control (solvent only) conditions.
D. discoideum random cell movement and cell development
D. discoideum random cell movement assays and developmental
phenotypes assays were carried out as described (Cocorocchio et al.,
2015; Robery et al., 2011). In these experiments, behaviour was monitored
in cells undergoing random cell movement by taking images every 15 s over
a 15-min period, with 5 min recorded prior to, and 10 min after, compound
addition. A minimum of three independent experiments for each drug
concentration were used, with ≥10 cells quantified per experiment.
Protrusions per cell were averaged over the last 5 min of recording, and
normalised to control (solvent only) conditions. In these experiments,
average (untreated) protrusions per cell were ∼5.7 with a maximum of 6.4
and a minimum of 5.4, consistent with previous reports (Cocorocchio et al.,
2015; Otto et al., 2016a).
D. discoideum restriction enzyme-mediated integration screen
To identify mutants in D. discoideum resistant to curcumin and analogues,
two libraries of insertional mutants containing 5000 mutants (psrA−) and
11,000 mutants (psenB−) were used. Cells were incubated with different
concentrations of each compound over 14 days. Mutants growing in the
presence of each compound were identified as previously described (Robery
et al., 2011; Waheed et al., 2014).
Mutant growth inhibition assay
Cells were grown in shaking suspensions and harvested in early exponential
phase (1.5-2.5×106 cells/ml). Cells were then divided into aliquots and
shaken for 24 h in the presence of solvent only or compound, at a
concentration which blocked growth by ∼50% in a final volume of 2 ml
axenic media. Growth (%) was defined for each wild type and derived
mutant (Ax2 and psrA−; or Ax3 and psenB−), with growth normalised to
relevant wild-type cell growth in the absence of compound (solvent only).
Each condition tested was carried out at least in triplicate.
FRAP assay
FRAP solution was prepared by combining 2 ml TPTZ solution (10 mM
2,4,6-tripyridyl-s-triazine in 40 mM HCl), 2 ml FeCl3 (10 mM) and 20 ml
acetate buffer (300 mM, pH 3.6). The assay was carried out by combining
800 µl FRAP solution with 25 µl of the positive control (1 mM ascorbic
acid) or curcumin-related compounds (to give a final concentration of
31.2 µM), and the absorbancewas measured at 595 nm.Measurements were
obtained in triplicate.
Protein-ligand docking
Protein sequences were obtained from dictybase.org. The tertiary structure
of the D. discoideum protein was predicted using Phyre2 (Protein
Homology/Analogy Recognition Engine V 2.0) (Kelley et al., 2015).
Docking analyses were performed using SwissDock to identify the possible
binding sites in PsrA. UFCS Chimera was used to display the results
obtained from SwissDock (Grosdidier et al., 2011). Results are expressed as
deltaG (Gibbs free energy, where a negative value indicates a spontaneous
interaction).
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Supplementary information 
Supplementary Fig. 1. Raw data of D. discoideum acute response to curcumin derivatives. Time-
dependent changes in D. discoideum cell behaviour (membrane protrusion) were recorded over a 15 
minute period for triplicate independent experiments (± SEM) at increasing concentrations of six 
curcumin derivatives to assess their ability to inhibit protrusion formation. The addition of different 
concentration of each compound at 210 seconds caused a reduction in protrusion formation. Data is 
presented as normalised to control (vehicle) conditions. Analysis with Two-tailed t-test showed 
significant changes after the treatment with: DMC 25 µM, FLLL31 25 µM, THC 20 µM,  BDMC 40 µM, 
EF24 2.5 µM and UBS109 35 µM (p < 0.0001 ****). 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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Supplementary Fig. 2. Quantification of the acute effect of curcumin derivatives on D. discoideum. 
Using a range of structurally related compounds, concentration dependent responses were 
determined for D. discoideum cell behaviour (protrusion formation), and illustrated as the 
normalised reduction in response against the Log (concentration) of each compound (shown with 
errors based on the 95% confidence intervals), enabling calculation of an IC50 values and 95% 
confidence intervals for each compound.  
Supplementary Fig. 3. Raw data of D. discoideum chronic response to curcumin derivatives. D. 
discoideum cells were grown with increasing concentration of curcumin derivatives in triplicate 
independent experiments ± SEM. DMC fully blocked growth at 30 µM, FLLL31 and THC at 100 µM, 
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instead BDMC arrested growth at 20 µ, EF24 and UBS109 inhibiteg proliferation at 6 and 5 µM 
respectively.  
Supplementary Fig. 4. Quantification of the chronic effect of curcumin derivatives on D. 
discoideum. Using a range of structurally related compounds, concentration dependent responses 
were determined for D. discoideum cell growth, and illustrated as the normalised reduction in 
growth against the Log (concentration) of each compound (shown with errors based on the 95% 
confidence intervals), enabling calculation of an IC50 values and 95% confidence intervals for each 
compound.  
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Supplementary Fig. 5. Growth inhibition assay - Ax3 and psrA- in presence of curcumin and its 
derivatives. Cells were grown in shaking suspension in presence of different curcumin derivatives. 
Analysis with Two-tailed t-test showed that psrA- mutants are resistant to curcumin as compared to 
AX2 (*** p < 0.001). psrA- mutants were also resistant to EF24 (* p < 0.05), THC (* p < 0.05) and 
DMC (** p < 0.01) in comparison to AX2. psrA- mutants were not resistant to BDMC, UBS109 and 
FLLL31. Data is provided as mean of at least three independent experiments ± SEM. 
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Supplementary Fig. 6. Growth inhibition assay - Ax2 and psenB- in presence of curcumin and its 
derivatives. Cells were grown in shaking suspension in presence of different curcumin derivatives. 
Analysis with Two-tailed t-test showed that psenB- mutants are resistant to EF24 as compared to 
AX2 (*** p < 0.001). Interestingly psenB- mutants were also resistant to UBS109 (** p < 0.01) in 
comparison to AX2. Results showed that the psenB- mutants were not resistant to curcumin, DMC, 
BDMC, THC and FLLL31. Data is provided as mean of at least three independent experiments ± SEM 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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Supplementary Fig. 7. Assessment of the chronic effect of curcumin and its derivatives on D. 
discoideum mutants. psenB and psrA null mutants were exposed to curcumin, DMC and EF24. The 
mean of the normalised protrusion formation was calculated for the first and the last 5 min for each 
cell line. The first set of graphs shows that the psenB- mutant is not resistant to any of the 
compounds. The second set of graphs illustrates that psrA is sensitive to this range of molecules. 
Data is provided as mean of at least three independent experiments ± SEM. 
Disease Models & Mechanisms 10: doi:10.1242/dmm.032375: Supplementary information
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Curcumin and derivatives function through protein phosphatase 2A and 
presenilin orthologues in Dictyostelium discoideum 
Figure 1. (B) N=30 cells analysed per condition from 3 independent technical repeats. (D) N=3 
independent technical repeats. (F) N=3 independent technical repeats.  
Figure 2. (D) N=3 independent technical repeats. 
Figure 3. N=3 independent technical repeats. 
Figure 4. N≥3 independent technical repeats. 
Supplementary Figure 1. N=30 cells analysed per condition from 3 independent technical 
repeats. 
Supplementary Figure 3. N=3 independent technical repeats. 
Supplementary Figure 5. N≥3 independent technical repeats. 
Supplementary Figure 6. N≥3 independent technical repeats. 
Supplementary Figure 7. N=30 cells analysed per condition from 3 independent technical 
repeats. 
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Chapter IV 
Critical evaluation 
The overall objective of this research is to improve the characterisation of 
substances that elicit taste response and have medical relevance. The specific 
project goal has been the development of D. discoideum as a model for the 
evaluation of structurally different tastants, and it is divided into three main 
milestones. 
1) To develop a method for the assessment of the effects of tastants on cell 
behaviour using the pungent alkaloid capsaicin; 
2) To employ the aforementioned method to test a range of known and blinded 
bitter tasting substances on cell behaviour and assess the ability of the 
compounds to inhibit protrusion formation; 
3) To utilise the method to test the effects of the phytotherapeutic tastant 
curcumin and a range of structurally related compounds on D. discoideum 
growth, movement and development as well as identify novel molecular 
targets.  
The concept of the project is controversial since D. discoideum does not possess 
taste receptors, taste buds or a nervous system able to process taste. However, 
the use of D. discoideum to sense tastants is dependent upon the ability to detect 
extracellular chemicals and respond to them in different ways (Aufderheide and 
Janetopoulos, 2016; Bosgraaf and Van Haastert, 2009; Chung and Firtel, 2002). 
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For instance, D. discoideum can detect chemotactic gradients such as cAMP and 
folic acid (Chung and Firtel, 2002; Jin et al., 2008; King and Insall, 2009; Pan et 
al., 2016; Segota et al., 2013) and exposure of cells to these chemoattractants 
causes changes in cell behaviour. These changes can be used to assess the 
activity and function of tastant chemicals (Iijima et al., 2002; King and Insall, 2009; 
Robery et al., 2011). D. discoideum also possesses a range of proteins with 
conserved functions to mammalian orthologues, and the identification of a target 
for tastants in the amoeba may lead to the discovery of targets related to 
mammalian models (Eichinger et al., 2005). Therefore, the use of D. discoideum 
represents a valid approach for the investigation of the effects of tastants. 
Understanding how taste works is essential as several tastants have potential 
therapeutic qualities, but it remains unclear whether the mechanism of taste are 
linked to their medicinal properties. Evidence suggests that the biology of tastants 
is not confined to taste receptors located on the taste cells, as some of these 
chemicals may also trigger changes in other cell types (e.g. airway smooth 
muscle cells) (Zhang et al., 2013a). Furthermore, there are many natural and 
synthetic therapeutic agents which elicit a specific taste and target disease 
mechanisms. For instance, the bitter compound azelastine is an H1-receptor 
antagonist used for the treatment of allergic rhinitis (El-Shaheny and Yamada, 
2014), whereas the bitter alkaloid quinine is used as antimalaria and babesiosis’s 
treatment (Achan et al., 2011; Dorman et al., 2000). Therefore, tastants may have 
both therapeutic and taste properties, and in many cases, it remains unclear if 
these properties are interconnected. Thus, a better understanding of the cellular 
mechanisms of taste transduction could enable the prediction of aversive 
tastants, impacting positively on medical research and drug development 
process. 
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4.1 Development of a model for the assessment of tastants  
4.1.1 Critical evaluation of the methodology used 
Although the methods paper (Otto et al., 2016) presents an innovative approach 
to assess the effects of tastants, a range of changes would improve the 
experimental approach. Indeed, capsaicin had a dose-dependent effect on D. 
discoideum cell behaviour, but three concentrations are insufficient to fully 
characterise a concentration-response curve and to obtain a precise IC50 value. 
To provide an accurate IC50 calculation, a concentration range from no effect to 
complete inhibition of cell movement must be determined, allowing a more 
accurate comparison of the rank order of potency over a range of compounds.  
Although results suggest that the identified mutants lacking RacGEFs proteins 
showed partial resistance to capsaicin, further experiments would support this 
proposal. These experiments could involve a double knockout of both RacGEFs 
(Rivero and Xiong, 2016; Vlahou and Rivero, 2006), that may provide enhanced 
resistance over single knockouts (Meßling et al., 2017). If the resulting cells were 
completely resistant to capsaicin, this would indicate these proteins are either the 
only two targets or a parallel complementary pathway to capsaicin in this model. 
Further analysis may include the assessment of capsaicin on growth and the 
rescue of sensitivity with either D. discoideum or human RacGEF genes. 
The length of time required for the analysis of data derived from video recordings 
of cell movement has been identified as a limitation of this approach.  Typically, 
nine movies could be recorded in one day, enabling the tracking of 10 cells over 
60 frames for each video. From these series of images, cell movement was 
quantified using the image analysis software Fiji (Schindelin et al., 2012), and the 
corrections of automated cell tracking errors, caused by cell-cell interaction, 
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majorly interfere with the analysis process. Therefore, to facilitate the imaging of 
the cell outline and increase the speed of the analysis following exposure to 
tastants, a range of fluorescence techniques were explored. These procedures 
were investigated since it was speculated that using fluorescence microscopy 
could provide an enhanced contrast of the cells against the background, speeding 
up the computer-based analysis (Sanderson et al., 2014). 
Two attempts were made to improve the cell imaging recording in random 
movement assays and  automated cell tracking. The first approach involved 
transforming cells with an empty vector used for overexpressing proteins with the 
green fluorescent protein GFP tag (Levi et al., 2000), allowing the visualisation of 
the cytosol of D. discoideum cells. This approach was expected to provide bright 
cells with a dark background. However, cells demonstrated sensitivity to the 
excitation light during the image capture, resulting in cells rounding and 
photobleaching over the experiment (Hoebe et al., 2007). The second approach 
to improve cell behaviour imaging analysis was carried out by employing the 
fluorescent dye TAMRA (5-Carboxytetramethylrhodamine) (Dougherty et al., 
2015). During these experiments, cells were incubated with TAMRA (20 µM, 5 
minutes), washed twice in phosphate buffer, and resuspended and assessed 
using the cell behaviour analysis (section 3.1.1). TAMRA labelled cells were 
visible using fluorescence microscopy; however, photobleaching issues limited 
the application of this method due to the assay time length.  
Experiments were carried out by manually operating the microscope shutter to 
minimise the exposure of the cells to the fluorescent light and reduce 
photobleaching (Frigault et al., 2009). However, these techniques were 
discontinued as they did not provide benefits over the bright field imaging 
microscopy in terms of improving the precision and reducing the time of the 
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analysis. This method could be further developed as a medium-high throughput 
platform for the screening of tastants, with access to automated equipment for 
fluorescent cell imaging. 
The methodology developed here provides restricted information on underlying 
molecular mechanisms. In fact, chemicals could negatively affect many essential 
cellular processes regulating cell behaviour such as actin polymerisation (Noegel 
and Schleicher, 2000), loss of myosin formation (Kollmar, 2006) and deregulation 
of mitochondrial function (Barth et al., 2007). Thus, further investigation is 
required to better understand the molecular mechanisms of capsaicin in D. 
discoideum. 
4.1.2 Critical evaluation of D. discoideum as a suitable model for the acute 
assessment of tastants 
In the first milestone of the project, a method was developed for the assessment 
of the acute effects of the pungent tastant capsaicin on cell behaviour. Indeed, D. 
discoideum acutely responded to the administration of this hot tastant, and the 
concentrations used in these experiments are comparable to the concentrations 
used in mammalian models. For instance, it has been shown that capsaicin is 
able to block the hyperpolarisation-activated inward currents via TRPV1 in rat 
neurons with an IC50 of 0.7 µM and a maximal inhibition of 10 µM (Kwak, 2012). 
Similarly, capsaicin at 1 µM can activate the TRPV1 receptor in mice dorsal root 
ganglion neurons, increasing the current density in a concentration-dependent 
manner as well as intracellular calcium concentration (Masuoka et al., 2017). 
Thus, the concentrations employed in D. discoideum are comparable to those 
used in mammalian models, providing partial support for the possible translation 
of this mechanism to human studies. 
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In this study, D. discoideum has provided a novel methodology for the 
assessment of the effects of capsaicin using random cell behaviour. Indeed, two 
mutants containing disrupted RacGEF proteins have been identified, leading to 
the discovery of a novel cellular mechanism of the pungent tastant capsaicin. 
RacGEF proteins are involved in a wide range of cellular processes in D. 
discoideum, including actin organisation, chemotaxis and endocytosis (Rivero 
and Xiong, 2016; Vlahou and Rivero, 2006). Interestingly, these proteins fulfil 
similar functions in higher organisms, including humans (Bos et al., 2007; 
Demarco et al., 2012; Pengelly et al., 2016). Therefore, results obtained in this 
study may suggest the existence of alternative molecular pathways through 
which capsaicin regulates cell function.  
The data provided in this paper suggest the existence of additional mechanisms 
through which capsaicin works. Research studies have demonstrated that 
capsaicin functions through the TRPV1 in mammalian cells (Masuoka et al., 
2017; Yang et al., 2014). However, it has been also demonstrated that capsaicin 
can block transient current in capsaicin-insensitive neurons through a TRPV1-
independent mechanism (Yang et al., 2014). Thus, this study identifies that 
capsaicin may also work through a TRPV1-independent mechanism by 
modulating the function of RacGEF proteins. 
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4.2 Investigation of the utility of D. discoideum as a model for 
the identification of bitter tastants  
4.2.1 Critical evaluation of the methodology used 
This study aimed to investigate the potential utility of D. discoideum for the 
identification of structurally diverse bitter compounds. The first step in this study 
was to examine if D. discoideum behavioural responses were specific to any of 
the five primary taste qualities. Therefore, a range of compounds and 
physiochemical conditions such as pH, osmolarity and solubility of the 
compounds were employed to assess whether D. discoideum model could 
discriminate between the compounds which have been identified as bitter, salty, 
sweet, sour and umami tasting. Finally, the results obtained using D. discoideum 
were compared to the rat BATA assessments and human taste panel studies to 
evaluate a correlation amongst these models. 
It has been demonstrated that D. discoideum  does not respond to sweet and 
umami tastants as well as sour and salty conditions (Cocorocchio et al., 2015) 
but further studies could be used to confirm these data. The use of standard 
sweet-tasting compounds such as glucose and sucrose did not cause any 
changes in D. discoideum  cell movement up to 50 mM. Although the standard 
compounds that elicit sweet taste in humans were assessed in this study, the use 
of additional sweet-tasting compounds with diverse structures (e.g. fructose, 
maltose, aspartame, saccharin, acesulfame K) could strengthen this approach.  
A higher concentration of the phosphate buffer was used to mimic the salty taste, 
which also increased the osmolarity of the solution from 36 mosmol/kg (standard 
phosphate buffer) to 118 mosmol/kg. It has been shown that cell behaviour was 
not affected by increased osmolarity (Cocorocchio et al., 2015). Reasonably, the 
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salt concentration could have been assessed by using sodium chloride. However, 
a previously published study has shown that D. discoideum cell movement is not 
affected by increasing sodium chloride concentrations (171 mM – 335 
mosmol/kg) (Waligorska et al., 2007), indirectly confirming recent results 
(Cocorocchio et al., 2015).  
Similarly, to mimic the sour taste, the pH of the solution was reduced to 5 to 
increase the H+ concentration (Ugawa, 2003). Acidic conditions did not affect cell 
movement, suggesting that the amoeba is not susceptible to sour taste. However, 
additional experiments should be conducted to assess the effects of other 
acidifying compounds on D. discoideum  cellular behaviour. These experiments 
may include citric acid (citrus fruit) (Penniston et al., 2008), malic acid (sour 
apples) (Khan et al., 2013), lactic acid (sour milk) (Widyastuti et al., 2014) and 
butyric acid (rancid butter) (Pituch et al., 2013). Thus, these experiments could 
further validate the methodology developed if the results are consistent with 
recent findings (Cocorocchio et al., 2015).  
In this project, D. discoideum random cell movement was used to assess the 
effects of a range of structurally diverse substances with a known bitter taste. The 
method used to carry out this investigation has been refined based on the 
knowledge acquired during the initial development stage. For example, for each 
compound, the concentrations assessed started from no effect and were 
increased until complete inhibition of cell behaviour was achieved, with a 
minimum of three experimental repeats for each concentration and at least 30 
cells analysed at each concentration. In addition, the study was carried out using 
several compounds that were blinded in terms of their structures and tastes. 
These improvements led to a better characterisation of the effects of the 
investigated molecules on cell movement. 
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The calculation of the IC50 values using non-linear regression curve fit equation 
enabled the generation of a rank order of the compounds’ potencies, which in 
turn allowed comparison of the data obtained in D. discoideum with the rat BATA 
test and human taste panels (Cocorocchio et al., 2015). These results are of 
particular  importance as they show the utility of the amoeba to replace or reduce 
animal use as well as demonstrating the translation of findings in D. discoideum 
to humans responses. In addition, these findings suggest that the stronger the 
effect on D. discoideum cell behaviour the more likely the compounds are 
described as bitter in humans and BATA assays (Cocorocchio et al., 2015). 
Future experiments should include more tastants from a broader range of 
chemical space, in a blinded manner, and a panel of at least 30 bitter compounds 
as well as non-bitter tastants, to add more validity to the system and improve the 
confidence in the model for the prediction of bitter tastant effects. Although more 
compounds could have been assessed in D. discoideum, the insufficient data 
available on the concentration-response relationship in the standardised rat 
BATA test and human taste panels represented the main limitation. 
The reproducibility of the methodology has been demonstrated by repeating the 
experiments at different times with the same compound and with different 
concentrations (Cocorocchio et al., 2015). Repetition of the experiments 
demonstrated a comparable concentration response for azelastine and caffeine 
with similar IC50 values. However, all the compounds tested should be repeated 
on different days, to ensure that the results are consistent and to further assess 
the reproducibility of this method, which, together with stability, is critical in case 
pharmaceutical   companies adopt this methodology.  
The methodology used here is based on the analysis of random cell movement 
and how it is affected by the administration of bitter tastants. This methodology 
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was introduced in a previous study showing that when D. discoideum cells are 
exposed to bitter compounds, they lose their typical amoeboid shape and round 
up, and in so doing, membrane protrusion formation is blocked (Robery et al., 
2013). However, this approach has its limitations as it only reflects the changes 
in cell behaviour but does not identify the molecular targets that are affected when 
a substance is administered to the cells. Therefore, a mutant screen would be 
useful to investigate the molecular mechanisms of the compounds tested in D. 
discoideum, possibly leading to the identification of novel pathways through 
which the chemicals tested might work. Further experiments should also include 
the analysis of compounds metabolism to assess whether the molecules are 
converted into more active metabolites. Mass spectrometry could help to identify 
the methsbolites by comparing their molecular weight to that of the parent 
compound (Permentier et al., 2008).  
A previous study has identified a mutant lacking the Grlj protein, responsible for 
the detection of the bitter-tasting alkaloid PTU  (Robery et al., 2013). In fact, cells 
lacking the Grlj receptor show partial resistance to the effects of PTU. Grlj is a G-
protein coupled receptor protein (Prabhu et al., 2007) and homologue of an 
uncharacterised human GABA-B receptor. Additional experiments showed that 
the expression of the human GABA-B in D. discoideum restored the sensitivity of 
the cells to PTU, suggesting a conserved function of the GABA-B protein in the 
amoeba. Since Grlj receptor shares the Gβ subunit (Wu et al., 1995) with other 
GPCRs (e.g. cAMP receptor-like, GABAB and Frizzed-like receptors) (Prabhu 
and Eichinger, 2006) in D. discoideum, future investigation of the effects of bitter-
tasting compounds on cells lacking the functional Gbeta subunit, responsible for 
downstream signalling transduction in cell movement, could indicate whether 
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these receptor proteins are also involved in the transduction of bitter tastants 
signalling.  
4.2.2 Critical analysis of D. discoideum as a suitable model for the 
evaluation of bitter tastants  
The bitter taste of medicines is a critical issue in therapeutic efficacy due to 
aversiveness. Patients, especially children, are affected by the bitterness of 
medicines, which reduces compliance and therefore may lead to the failure of 
therapeutic regimens (Anand et al., 2007; Mennella et al., 2013). Pharmaceutical 
companies are interested in the assessment of the bitterness of candidate drugs 
in the early stages of compound selection and development, as this is one of the 
factors that can limit the clinical utilisation of a therapeutic agent (Walsh et al., 
2014). Bitter taste research is routinely carried out in animals, human assessment 
panels and recently also using the electronic tongue (Anand et al., 2007; Palmer 
et al., 2013; Rudnitskaya et al., 2013; Soto et al., 2015). However, animal studies 
have their limitations regarding the experimental approaches that are available, 
cost and ethical concerns. Furthermore, human panels rely on the subjective 
response to tastants, are expensive to run (Cram et al., 2009; Gittings et al., 
2014) and can only test substances with a known safety profile. In addition, there 
are also ethical concerns with the use of healthy volunteers in taste panel studies 
when assessing cytotoxic drugs, and this is particularly important when studying 
substances for paediatric use (Mennella et al., 2013). Finally, the electronic 
tongue based on electrochemical sensors is able to detect a range of substances 
with varying intensities, (Anand et al., 2007). However, this system cannot 
analyse compounds that are not fully soluble or assess their aversiveness (Anand 
et al., 2007). The development of a tastant assessment system for the 
identification of the acute aversive effects of novel chemical entities may impact 
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on the development of pharmaceuticals and would be of considerable interest to 
medical research and industry.  
The accepted model of bitter taste transduction is solely based on TAS2Rs 
(Meyerhof et al., 2010) and is not sufficient to fully explain bitter taste 
transduction. For instance, the one hypothesised mechanism for gustducin-
independent bitter taste transduction is through ion channel (K+) interaction with 
certain bitter compounds (e.g. denatonium), which is comparable to the ion 
channel interaction for the transduction of sour and salty stimuli (Gulbransen et 
al., 2008; Spielman, 1998; Wong et al., 1996). Thus, further investigation is 
needed to identify possible additional TAS2R-independent molecular 
mechanisms responsible for the transduction of bitter taste. 
The results obtained from these studies are very promising as they suggest that 
D. discoideum has the potential to be used for early screening of bitter and 
pungent taste liability in candidate drugs (Cocorocchio et al., 2015; Otto et al., 
2016). Although it is unlikely that D. discoideum will be used independently of 
animal and human models, it may provide an additional, early screen for the 
prediction of bitter tastants. Thus, providing a broad set of compounds are 
screened, and derived data are comparable to the rat BATA assay, this model 
might be used to decide which NCEs would go on to be studied in BATA assay 
and which would be discontinued.  Furthermore, this assay could also be used 
for the identification and development of strongly bitter compounds to be 
combined with toxic products that are not intended for human use.  
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4.3 Employing D. discoideum for the investigation of structure-
activity relationship of curcumin and congeners  
4.3.1 Critical evaluation of the methodology used 
In the third and final part of the project, the effects of the bitter tastant curcumin  
(Hewlings and Kalman, 2017) and a family of structurally related natural and 
synthetic analogues were examined on D. discoideum, using the methodology 
developed in the first study (Otto et al., 2016). This investigation was extended 
into a quantitative structure-activity-relationship study in which the effects of 
curcumin and its derivatives were assessed in cell growth and development, and 
potential molecular targets for these compounds were investigated (Cocorocchio 
et al., 2018). The concentrations of curcumin and its derivatives employed in this 
study were smaller than the concentrations used in vivo and in vitro studies (Table 
1). 
 
Table 1 Concentrations of natural and artificial curcumin derivatives used in vivo, in vitro 
and in D. discoideum. 
 
Compounds In vivo D. discoideum 
Curcumin 180 – 390 mM (Dadhaniya et al., 2011; Marczylo et al., 
2007) 
0.5 – 100 µM 
DMC 35 mM (Agrawal et al., 2012; Boonrao et al., 2010) 2.5 – 35 µM 
BDMC 39 mM (Agrawal et al., 2012; Boonrao et al., 2010) 1 – 40 µM 
THC 13 mM – 33 mM (Han et al., 2016; Jearapong et al., 2015; 
Yoysungnoen et al., 2015) 
5 – 100 µM 
FLLL31 59 µM – 2.7 mM (Yuan et al., 2014) 5 – 100 µM 
EF24 16 – 803 µM (Bisht et al., 2016; Kasinski et al., 2008) 0.1 – 6 µM 
UBS109 1.7 mM – 13 mM (Nagaraju et al., 2013; Yamaguchi et 
al., 2014) 
0.25 – 35 µM 
CuPy 210 µM (Ahsan et al., 2015) 100 µM 
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All curcumin-related compounds were able to inhibit protrusion formation in a 
concentration-dependent manner. Therefore, a non-linear regression analysis 
was used to calculate the shape and the IC50 values of the concentration-
response curves using data from a concentration range (no effect to complete 
inhibition) with at least three replicates. Moreover, the effects of curcumin and its 
derivatives were investigated on cellular proliferation, where cells were grown in 
still culture at a range of concentrations, from no effect to complete growth 
inhibition (Garige and Walters, 2015). The concentrations used in the growth 
assays were higher as compared to those employed in the random cell movement 
assays. For instance, curcumin concentrations in random cell movement ranged 
from 0 to 5 µM and with an IC50 of 2.3 µM, whereas in the growth assays curcumin 
concentrations ranged from 0 to 100 µM, with an IC50 of 45.7 µM. All 
measurements were carried out at least in triplicate, and the slope of the graph 
during exponential growth of each concentration was used to calculate the IC50. 
This assay may be improved by using automated counting equipment to increase 
the speed, accuracy, precision and potential user bias of the assay (Stone et al., 
2009).  
REMI mutant screens were carried out to investigate the molecular targets of 
curcumin and its derivatives and successfully led to the identification and isolation 
of several mutants resistant to growth inhibitory effects of these compounds 
(Kuspa, 2006). REMI is a consolidated method used to generate mutations by 
random insertion of linearised plasmid DNA into the genome of the organism that 
leads to gene ablation. However, this approach has some limitations. Firstly, 
should the primary target for the compounds be vital, a null mutant would not 
survive and thus not be identified (Journet et al., 2012). Secondly, the random 
mutagenesis may not cover the entire genome and therefore all the genes without 
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a cut site within the open reading frame, necessary for integration of the knockout 
vector, would not be found (Guerin and Larochelle, 2002). Thirdly, this approach 
would be unlikely to identify mutants lacking proteins that are encoded by multiple 
genes (e.g. actin), since ablation of one gene would not affect the remaining 
copies of the targeted protein. Finally, this approach may not be able to identify 
cells that are more sensitive to the tested compounds, as those will be lost during 
the screen. To overcome several of these limitations, REMI mutagenesis can be 
employed to generate large pools of mutants, following compound treatment at a 
concentration below complete inhibition, to enrich the frequency of partially 
resistant mutants. Analysis of this pools using Next Generation Sequencing 
(NGS) would then allow the identification of disrupted genes. Each mutant would 
possess a unique sequence tag (or “barcode”) providing a quantitative measure 
of the relative abundance of that mutant. Therefore, when the pool of mutants is 
subjected to selection conditions, mutants that increase or decrease their 
frequency can be identified by changes in barcode read counts. Nevertheless, 
the mutant screening carried out in this study has proven to be a valuable tool for 
the identification of a number of potentially relevant targets (Cocorocchio et al., 
2018). Athough two curcumin and related compound targets were identified and 
analysed in detail in this study, a range of other targets were also found. These 
mutants included insertions into:  
• LMBR1 family protein (DDB_G0281669);  
• NADPH-cytochrome-P450 oxidoreductase (DDB_G0293904);  
• Type A von Willebrand factor (VWFA) domain-containing protein 
(DDB_G0288103);  
• Translocon-associated protein TRAP gamma subunit (DDB_G0267524);  
• EGF-like domain-containing protein (DDB_G0289907);  
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• UNC93-like protein MFSD11(DDB_G0291722);  
• Dihydropteridine reductase (DDB_G0272684);  
• AAA ATPase domain-containing protein (DDB_G0276169);  
• LRRK family protein kinase Roco6 (DDB_G0279417);  
• Glycine cleavage system H-protein (DDB_G0287861).  
Characterisation of these mutants could also lead to the identification of novel 
mechanisms through which curcumin and structurally related derivatives may 
function (Cocorocchio et al., 2018). The study identified a range of molecular 
targets through which curcumin and its derivatives may function but, due to time 
limitations, these were not validated. 
The REMI screen allowed the identification of two mutants, psrA- and psenB-, 
resistant to both curcumin and the synthetic curcuminoid EF24. Mutants were 
identified using iPCR to isolate flanking DNA sequences of the insertional 
cassette and to determine the DNA sequence; fragments were amplified and then 
sequenced. Subsequently, BLAST searches were performed to identify the 
disrupted gene(s). The recapitulated null mutants, psrA- (Lee et al., 2008) and 
psenB- (Ludtmann et al., 2014), were then assessed using a growth inhibition 
assay. Results from these experiments showed that psrA- is significantly resistant 
to curcumin as well as EF24 and DMC, compared to the parent strain, suggesting 
that these compounds might work through similar pathways. Therefore, the 
studied derivatives could be investigated as an alternative to curcumin to target 
the psrA protein. In addition, results also show that psrA- is resistant to THC, but 
the difference was not statistically significant. Therefore, increasing the number 
of experimental repeats may provide a significant difference, confirming that this 
compound may also work through the same pathway. Moreover, the psenB- 
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mutant showed resistance to EF24 as well as UBS109, suggesting that both may 
work through a similar mechanism of action.  
Development assays were carried out to evaluate whether curcumin and related 
compounds were able to inhibit cell development. Curcumin, DMC, BDMC, THC 
and FLLL31 all blocked the development process, leading to a similar cell 
morphology, characterised by the formation of tipped mounds; whereas, cells 
exposed to EF24, UBS109 and CuPy were able to form fruiting bodies. Based 
upon this common phenotype, it is possible to speculate that these active 
compounds may have a single target involved in development.  For instance, it 
may be possible to identify this target by employing a development screen, plating 
a mutant library as single colonies in the presence of each compound (Kuspa and 
Loomis, 1992).  Mutants able to overcome this developmental block can be 
identified, characterised, and assessed for resistance to the other curcumin-
related compounds. Therefore, additional development assays should be carried 
out exposing the psrA- mutant to curcumin to assess whether this protein is 
involved in the fruiting body formation process.  
Amongst many cellular roles that have been ascribed to curcumin, its ability to 
function as either an antioxidant or a pro-oxidant is one of the most well-known 
properties (Ak and Gülçin, 2008; Thayyullathil et al., 2008). Therefore, 
experiments were carried out to evaluate the antioxidant properties of curcumin 
and its derivatives. Here, the ferric reducing activity of plasma (FRAP) assay was 
used to evaluate the antioxidant power of curcumin and its derivatives. Each 
molecule possesses a different potency measured in absorbance at 595 nm (THC 
103%, ASC 100%, CuPy 75%,  Curcumin 56%, DMC 33%, BDMC 13%, FLLL31 
3%, EF24 1.6% and UBS109 0%). The activity of the compounds in acute cell 
behaviour, growth inhibition and development did not reproduce this order of 
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potency, suggesting that anti-oxidant activity may not control any of these cellular 
roles. It has been demonstrated that the diketone and methoxy groups are 
responsible for the antioxidant activity of curcumin and its derivatives (Anand et 
al., 2008), further validating recent findings (Cocorocchio et al., 2018). However, 
the FRAP assay cannot evaluate the intracellular antioxidant activity of the 
compounds, which may regulate the intracellular production of reactive oxygen 
species. Therefore, additional experiments that measure the ability of the 
molecules to inhibit the production of reactive oxygen species intracellularly 
should be carried out. These experiments include the use of 
Dichlorodihydrofluorescein diacetate, which is an indicator of peroxide and anion 
superoxides (Garige and Walters, 2015), as well as Dihydroethidium (DHE) assay 
for the measurement of intracellular superoxide production  (Zhang and Soldati, 
2013). Molecular docking prediction was used to assess the interaction between 
curcumin and psrA- and showed that curcumin binds psrA- in the region of 
interaction formed between the intra-repeat loops of the scaffolding A-subunit and 
the convex side of the regulatory B56 subunit (Cho and Xu, 2007). Although this 
hypothesis was based on human protein modelling simulation, these results 
could suggest a novel mechanism through which curcumin functions in regulating 
PP2A. To further validate this hypothesis, the precise amino acid sequence of the 
site of interaction with curcumin should be determined using site-directed 
mutagenesis, which should confer resistance to curcumin. 
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4.3.2 Critical evaluation of D. discoideum as a model for the 
characterisation of the cellular effects and targets of curcumin and 
related compounds 
Curcumin has been used for thousands of years as medicine to treat human 
ailments, such as inflammatory diseases and wounds, and there are several 
published papers documenting its wide range of cellular effects (Aggarwal and 
Harikumar, 2009; Butler, 2004; Ghosh et al., 2015; Gurib-Fakim, 2006; Newman 
and Cragg, 2007). Studies have also demonstrated that curcumin has many 
properties including  anti-oxidant, anti-cancer, neuroprotection and anti-
inflammatory  (Chougala et al., 2012; Ghosh et al., 2015; Jurenka, 2009; Lakey-
Beitia et al., 2017a; McClure et al., 2017; Srinivasan, 1972; Tang and 
Taghibiglou, 2017; Yang et al., 2017; Zhang et al., 2013b). Despite all the 
research conducted on this phytopharmaceutical, there is no agreement on 
curcumin’s  mechanism(s) of action (Ghosh et al., 2015). Nevertheless, curcumin 
continues to be widely studied and its therapeutic relevance has been proven by 
several clinical trials (Lopresti et al., 2014; Panahi et al., 2015; Panahi et al., 
2017). Therefore, there is a need to develop new approaches for the investigation 
of its mechanisms of action. In addition, curcumin has some limitations due to its 
poor bioavailability, low solubility and rapid metabolism (Gupta et al., 2013). 
Hence, the identification of novel curcumin analogues could lead to more potent 
and efficacious therapeutic agents. Most importantly, new treatments using 
curcumin and congeners may help to treat a wide range of conditions such as 
cancer, neurodegenerative diseases and inflammation. 
In conclusion, this study identifies distinct molecular targets of curcumin in 
regulating different cellular functions such as cell movement, growth and 
multicellular development in D. discoideum (Cocorocchio et al., 2018). 
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Furthermore, with the methodology employed in this study, results have shown 
the dependency of specific functional groups of the compound for enhanced or 
reduced activity in movement and growth assays.  Results obtained here also 
suggest that curcumin has multiple molecular targets in D. discoideum, which 
play distinct cellular roles. Moreover, a genetic screen was carried out, which led 
to the identification of presenilin and protein phosphatase 2A (PP2A) as potential 
targets of curcumin activities. Computer docking analysis identified a potential 
binding site of curcumin and derivatives on PP2A and described the differing 
efficacies of these molecules based on binding. However, the sites of action of 
curcumin identified here using D. discoideum need to be investigated in 
mammalian cells before assessing the therapeutic potential of curcumin and its 
analogues in vivo.  
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Chapter V 
Conclusions 
This work aimed to develop D. discoideum as an animal reduction model for the 
characterisation of natural and synthetic tastants as their activites at a cellular 
level and mechanisms of taste are not fully understood. The unpleasant taste of 
medicines represents a central aspect in the development of oral drugs, as it can 
affect considerably patient compliance and in turn the progress of NCEs. Hence, 
the investigation of the biology of tastants and the prediction of their taste are 
essential requirements in the drug development process. Taste research mainly 
employs animal models and human assessment panels. However, these studies 
have their limitations concerning cost and ethical issues and, more importantly, 
preclude an improved understanding of the molecular mechanisms of tastant 
function. The results obtained in this study demonstrate that D. discoideum has 
the potential to be used as an early screening platform for bitter tastant research 
since data show significant correlation with animal and human models. Hence, 
this single cell analysis could be integrated into the early compound screening 
conducted by pharmaceutical   companies. This methodology could be useful for 
the elimination of potentially aversive substances but also for the identification 
and development of bitter compounds to increase the safety of toxic products that 
are not intended for human use. This thesis also describes that D. discoideum 
can be used to identify and characterise molecular mechanisms of tastants, 
demonstrated by curcumin and related compounds. For the first time, data show 
distinct molecular targets of the bitter compound curcumin in regulating different 
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cellular functions such as cell movement, growth and multicellular development 
in D. discoideum. Furthermore, it has been demonstrated that specific functional 
groups in the compounds are responsible for increased or reduced potency in 
blocking cell movement and growth. Genetic screening led to the identification of 
protein phosphatase 2A (PP2A) and presenilin as potential targets of curcumin 
activity. Finally, this work further validates D. discoideum as an excellent 
organism for rapid identification of cellular drug targets, providing valuable 
support for the development of novel treatments. 
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